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Abstract 
Longitudinal studies and the development of gene therapy for ovine neuronal 
ceroid lipofuscinoses 
 
by 
Nadia Lesley Mitchell 
 
The neuronal ceroid lipofuscinoses (NCLs, Batten disease) are a group of fatal inherited lysosomal 
storage diseases characterised by progressive neurodegeneration, cortical atrophy, and blindness. 
Currently there are no effective treatments. Naturally occurring animal models exist, including two 
forms in sheep which are representative of the different NCL protein defects. A lesion in a soluble 
lysosomal protein (CLN5) causes NCL in Borderdale sheep, whilst South Hampshire sheep have a 
defective intracellular endoplasmic reticulum membrane-bound protein (CLN6). This subdivision has 
consequences for the planning of therapies. This thesis compares the progressive neuropathological 
changes, and examines the efficacy of viral-mediated in vivo gene therapy, in these two NCL sheep 
models. 
An immunohistochemical study revealed that, despite very different gene products and subcellular 
localisations, the pathogenic cascade was remarkably similar for CLN5 and CLN6 affected sheep. 
Dysregulated glial activation preceded regionally specific neurodegeneration in both disease models 
and both occurred well before clinical onset. Neuropathological changes were more advanced in the 
CLN5 model, which correlated with the earlier onset of clinical symptoms in these sheep, but by end-
stage disease CLN5 and CLN6 brains were similarly affected. Windows for best therapeutic efficacy 
were established and these data highlight the translational utility of the sheep brain for testing 
human gene therapies. 
Lentiviral vectors have been shown to mediate successful gene delivery to the ovine brain yet the 
efficacy of adeno-associated viral (AAV) vectors has not been tested in sheep. Stable, predominantly 
neurotropic, transgene expression was evident one month after intracerebroventricular (ICV) and 
intraparenchymal (IP) delivery of AAV9 to the normal sheep brain. However with a greater spread 
and no evidence of vector or procedural neuroinflammation or toxicity, the ICV approach proved 
most efficacious in sheep. 
 vi 
 
Deficiencies in soluble lysosomal proteins are deemed particularly amenable to in vivo gene therapy 
via the normal lysosomal enzyme trafficking system and the phenomenon of ‘cross-correction’. To 
test this paradigm in sheep, six pre-clinical CLN5 deficient lambs were treated with combinatorial ICV 
and IP injections of either lentiviral or AAV9 vectors expressing ovine CLN5. Both vector platforms 
afforded sustained protection against stereotypical disease in these sheep. Cognitive and 
neurological function was preserved, whilst longitudinal neuroimaging revealed normalisation of 
intracranial volume and structural brain integrity. Quality of life was profoundly improved for the 
treated sheep and, apart from delayed-onset visual deficits, treated sheep well exceeded the typical 
lifespan of untreated animals. 
 
Defects in membrane-bound proteins are generally considered harder therapeutic targets. However 
the current study indicates that gene therapy is also possible for these NCL forms. Whilst five 
similarly injected pre-clinical CLN6 deficient sheep developed stereotypical CLN6 disease, one AAV9-
CLN6 treated animal was clinically indistinguishable from age-matched control animals through the 
24-month follow up period. Post mortem neuropathological studies revealed significant correction of 
neurodegeneration, normal cortical laminar organisation and a reversal in disease-associated glial 
activation.  
 
These encouraging results of sustained therapeutic and functional efficacy in large animal models of 
NCL provide a strong rationale for the clinical translation of viral-mediated gene transfer to human 
patients with CLN5 and CLN6 disease. In fact, the findings of this thesis have encouraged a Phase I/II 
CLN6 clinical trial which has just begun.  
 
 
 
 
 
 
Keywords: Batten disease, neuronal ceroid lipofuscinosis, lysosomal storage disorder, animal models, 
sheep, brain, neurodegeneration, neuroinflammation, neurogenesis, gene therapy, vector, adeno-
associated virus, lentivirus, transduction.  
 vii 
Acknowledgements 
I have found to complete a PhD you need to surround yourself with many different people; firstly 
those who know more than you do! Add to the mix those who encourage you, those who make you 
want to explore and keep learning. For me, this thesis would not have been possible without the 
following such people. 
Foremost I am indebted to my supervisor, Prof. David Palmer, who over the past 15 years has 
opened up a world of opportunities for me. Thank you for introducing me to the Battens community, 
for your constant belief in me and for providing a ‘blend’ of motivation, support, responsibility and 
freedom during this time. We’ve shared (and survived!) some ups and downs through this process 
but I’m thrilled to play a part in fulfilling one of your life-long goals – seeing a therapy come to 
fruition in NCL. How exciting was it to see those treated sheep run free in the paddock at 26 months 
of age?! Your knowledge of NCL is boundless and if I could one day know even half as much as you 
do, then I would be happy. Much love to you and Jeanette always. Oh, and guess what? I finally 
finished ‘Lucky Jim’! 
I whole-heartedly thank my co-supervisor, Assoc. Prof. Graham Barrell, for his enthusiasm, surgical 
expertise and incredible way with words. My writing benefits tremendously from your keen and able 
eye. I am so fortunate to work with some other amazing colleagues at Lincoln University, whom I 
cannot thank enough: Martin Wellby for your boundless knowledge and skills, initiative and 
willingness to be involved in anything and everything; Katharina Russell (DVM, Copenhagen, 
Denmark) for your invaluable veterinary and imaging skills, positive energy and for months of helping 
me shovel sheep poo! To my office-mate Dr. Hannah Lee, thank you for your friendship, open advice, 
many de-stressing swims and runs and for generally keeping me (semi-)sane! I thank Drs Graham Kay 
and Robin MacFarlane for sharing your skills with me over the years, and Jarol Chen for paving the 
PhD pathway, your passion and constant smile are invigorating. In your own way, you have all 
inspired me to want to keep learning and I am so appreciative of your help. The cake is on me! 
I warmly thank our BARN colleagues, particularly Drs. Stephanie Hughes (University of Otago) and 
Imke Tammen (University of Sydney), and Hollie Wicky (University of Otago). These long-standing 
collaborations have been rewarding, your expertise and support have been instrumental in this 
project and I value your friendship. Locally, I acknowledge more recent collaborators at the New 
Zealand Brain Research Institute (Dr. Tracy Melzer) and the Department of Radiology, University of 
Otago, Christchurch (Assoc. Prof. Nigel Anderson) for their neuroimaging contributions and general 
enthusiasm about this project. I look forward to expanding these studies further when I commence 
post-doctoral studies with you. 
 viii 
I gratefully acknowledge the following funding groups: the John W and Carrie McLean Trust for my 
PhD scholarship; CureKids NZ, the Batten Disease Support and Research Association (BDSRA), 
Lysosomal Diseases New Zealand (LDNZ), Batten Disease NZ, and the Faculty of Agriculture and Life 
Sciences, Lincoln University for the financial support for this study and my conference travel grants.  
My deepest gratitude goes to animal technicians and research farm staff, particularly Amy Smaill, 
Robin McAnulty, Chris Logan, James Meyer, Colin Pettigrew and Hélène de Batz. Without their 
dedication, care and hours of weekend work this project simply would not have been possible. To my 
woolly friends, what a sacrifice you have made in the name of research. I have loved the many hours 
spent in the field observing, monitoring and just ‘playing’ sheep. What a totally under-rated species 
you are! Sheep are curious, intelligent, gregarious animals and we could all learn from their 
fellowship. 
To put a human face to NCL, we are incredibly fortunate as research scientists in this field to interact 
with patients, parents, family advocacy groups and clinicians. The NCL families I have met, both in 
New Zealand and internationally, drive me to want to answer many of the outstanding questions we 
still have about this disorder. As a mother, I stand in admiration of your strength and perserverance 
in such adversity. 
I would not be here today without all of my family and friends outside of work. I thank my parents, 
John and Anne, and sister Alika, for their supportive discussions through this time, child-minding and 
for instilling in me a strong ‘work ethic’ and love of education! Thank you Gately grandparents for 
your love and holiday support. In particular, I want to thank the ‘Thursday night walkers’ for your 
constant support and for always renewing my energy. What an inspirational group of strong and 
beautiful women, I value your friendship more than you know.  
Finally, but by no means least, to the three amazing men in my life – you are my world and this PhD 
would not have been possible without your support. Karl, you are the calm to my storm. Always 
willing to help, be it finishing my immunostaining, chasing sheep or ‘last minute’ dashes to pick up 
the boys from school! You’re my best friend, dependable beyond belief and the greatest dad to our 
wee people. Jackson and Ethan, this thesis is for you. Your smiling faces, hugs and funny stories make 
me so happy every day. I want you to know that if you work hard, good things can come your way. 
I’ve loved sharing many ‘sheepy times’ with you all but now it’s time for that Gately-Mitchell ‘holiday’ 
that I promised you! Love love love you. Let’s keep exploring together… 
 



 xii 
List of Tables 
Table 1.1    Genetic classification of the NCLs.......................................................................................... 3 
Table 1.2    Naturally occurring genetic diseases of the ovine CNS ......................................................... 8 
Table 1.3    Clinical neuro-ophthalmic tests to assess loss of vision in NCL ........................................... 21 
Table 1.4    Biological properties of gene therapy viral vectors in current use for the lysosomal 
storage diseases ................................................................................................................. 25 
Table 3.1    Clinical rating criteria for assessing neurological dysfunction in sheep .............................. 41 
Table 3.2    Criteria for assessing cognition and behaviour during maze negotiation ........................... 43 
Table 3.3    Primary antibodies, with associated DAB incubation times ................................................ 46 
Table 4.1    CNS regions and sagittal section levels in which they were investigated ........................... 52 
Table 4.2    Mean brain weight of normal and affected sheep from birth to 24 months of age ........... 53 
Table 6.1    Treatment groups and clinical assessment at post mortem (or trial completion) ............ 107 
Table 7.1    Treatment groups and clinical assessment at post mortem (or trial completion) ............ 131 
Table 7.2    Reported adverse events following viral-mediated CLN6 gene therapy in sheep ............ 134 
Table 7.3    Average intracranial volume changes in treated and untreated sheep over time ........... 146 
Table 7.4    Quantitative assessment of neurodegeneration after viral-mediated CLN6 gene 
transfer to preclinical CLN6 deficient sheep .................................................................... 151 
Table 7.5    Quantitation of microglial activation in the cortex after viral-mediated CLN6 gene 
transfer to preclinical CLN6 deficient sheep .................................................................... 157 
Table 8.1    Summary of clinical and neuropathological changes in CLN5 Borderdale sheep ............. 170 
Table 8.2    Summary of clinical and neuropathological changes in CLN6 South Hampshire sheep ... 171 
 
 
 xiii 
List of Figures 
Figure 1.1    Comparison of average human, sheep and mouse brains and body weights ..................... 7 
Figure 1.2    Disease-causing mutations identified within the CLN6 gene ............................................. 10 
Figure 1.3    Disease-causing mutations identified within the CLN5 gene ............................................. 12 
Figure 1.4    Cortical atrophy in ovine CLN6 compared to normal control animals ............................... 16 
Figure 1.5    Structure of the wild-type HIV-1 and recombinant lentiviral genome .............................. 26 
Figure 1.6    Structure of the wild-type adeno-associated virus (AAV) and recombinant AAV 
genome .............................................................................................................................. 28 
Figure 3.1    An indirect test for the preclinical diagnosis of ovine CLN6 .............................................. 35 
Figure 3.2    Alternative methods for the genetic diagnosis of ovine CLN5 ........................................... 36 
Figure 3.3    Viral vector injection sites in the ovine brain ..................................................................... 39 
Figure 3.4    Configuration of the maze .................................................................................................. 42 
Figure 4.1    Anatomical structure of the normal sheep brain ............................................................... 51 
Figure 4.2    Lateral view of the normal and affected sheep brain ........................................................ 54 
Figure 4.3    Progressive cortical atrophy in CLN5 and CLN6 affected sheep ........................................ 56 
Figure 4.4    Microscopic comparison of the CLN5 and CLN6 affected cortices .................................... 57 
Figure 4.5    Quantitative assessment of the cortical thinning in CLN5 and CLN6 affected sheep 
brains ................................................................................................................................. 58 
Figure 4.6    Comparative astrocytosis during ovine NCL disease progression ...................................... 60 
Figure 4.7    GFAP expression in the CLN5 and CLN6 affected visual and motor cortices ..................... 61 
Figure 4.8    Astrocytic activation in the CLN5 and CLN6 affected sheep brain ..................................... 62 
Figure 4.9    Comparative microgliosis during ovine NCL disease progression ...................................... 64 
Figure 4.10  Microgliosis in the CLN5 and CLN6 affected visual and motor cortices............................. 65 
Figure 4.11  Microglial activation in the CLN5 and CLN6 affected sheep brains ................................... 66 
Figure 4.12  Comparative storage body accumulation during ovine NCL disease progression ............. 68 
Figure 4.13  Accumulation of fluorescent storage bodies in CLN5 and CLN6 affected sheep ............... 69 
Figure 4.14  Extended neurogenesis in the CLN5 and CLN6 affected sheep brain ................................ 72 
Figure 4.15  Expression of endogenous CLN5 and CLN6 proteins in the normal adult sheep brain ..... 73 
Figure 5.1    Comparative AAV9 transduction efficiency via two delivery routes in the sheep brain ... 89 
Figure 5.2    Robust CNS transduction profile of the sheep brain after ICV delivery of AAV9-GFP ....... 91 
Figure 5.3    Robust transduction of the sheep spinal cord after ICV AAV9-GFP administration .......... 92 
Figure 5.4    Localised CNS transduction profile of the sheep brain after IP delivery of AAV9-GFP ...... 94 
Figure 5.5    Dominant neurotropism of AAV9-GFP vector in the healthy adult sheep brain ............... 95 
Figure 5.6    Differential inflammatory responses following ICV and IP injection of AAV9-GFP ............ 97 
Figure 6.1    Confirmation of the affected genotype in the six gene therapy sheep subjects ............. 109 
 xiv 
Figure 6.2    Mean live weight increases following viral-mediated CLN5 gene transfer in sheep ....... 110 
Figure 6.3    Attenuation of stereotypical clinical progression following viral-mediated CLN5 
delivery ............................................................................................................................ 112 
Figure 6.4    Sustained performance in a closed-field maze test after viral-mediated CLN5 delivery . 115 
Figure 6.5    Prolonged visual acuity and maze navigational ability after viral-mediated CLN5 
delivery ............................................................................................................................ 116 
Figure 6.6    Attenuation of intracranial volume loss after viral-mediated CLN5 delivery .................. 118 
Figure 6.7    Preservation of brain structure in LV-CLN5 and AAV9-CLN5 treated sheep .................... 119 
Figure 6.8    Retention of intracranial volume after CLN5 delivery ..................................................... 120 
Figure 6.9    Normalisation of sheep brain structure after viral-mediated CLN5 delivery ................... 121 
Figure 7.1    Confirmation of the affected genotype in the six gene therapy sheep subjects ............. 133 
Figure 7.2    Mean live weight increases following viral-mediated CLN6 gene transfer in sheep ....... 136 
Figure 7.3    Clinical progression of CLN6 deficient sheep following viral-mediated CLN6 gene 
transfer ............................................................................................................................ 139 
Figure 7.4    Electroretinography (ERG) as an indicator of retinal damage ......................................... 141 
Figure 7.5    Performance in a close-field maze test after viral-mediated CLN6 delivery .................... 143 
Figure 7.6    Grading of maze navigational ability after viral-mediated CLN6 delivery........................ 144 
Figure 7.7    Prevention of brain atrophy in 1027/13 after AAV9-mediated CLN6 delivery ................ 145 
Figure 7.8    Normalisation of brain structure in 1027/13 after AAV9-mediated CLN6 delivery ......... 146 
Figure 7.9    Lentiviral and AAV9-mediated CLN6 transfer to the CLN6 affected sheep brain ............ 148 
Figure 7.10  Qualitative assessment of neurodegeneration after lentiviral- and AAV9-mediated 
CLN6 gene transfer to preclinical CLN6 deficient sheep ................................................. 150 
Figure 7.11  Effects of viral-mediated CLN6 gene transfer upon astrocytosis ..................................... 153 
Figure 7.12  Effects of viral-mediated CLN6 gene transfer upon microglial activation ....................... 156 
Figure 7.13  Effects of viral-mediated CLN6 gene transfer upon storage body accumulation ............ 158 
Figure 7.14  Evidence of peripheral storage body accumulation in 1027/13 ...................................... 160 
Figure 7.15  Effect of AAV9-mediated CLN6 gene therapy on the retina ............................................ 161 
Figure 8.1    Schematic representation of intraocular injection routes and some retinal layers  ....... 185 
 
 
 xv 
List of Abbreviations 
Only abbreviations that appear more than once and in more than one chapter are displayed. 
AAV   adeno-associated virus 
AAV9   adeno-associated virus, serotype 9 
BARN   Batten Animal Research Network 
BBB   blood brain barrier 
bp   base pair 
cDNA   complementary DNA 
CDS   coding DNA sequence 
CLN/CLN  NCL causing gene/protein 
CNS   central nervous system 
CRS   clinical rating score 
CSF   cerebrospinal fluid 
CT   Computed tomography 
DAB   3, 3’-diaminobenzadine 
DNA   deoxyribonucleic acid 
DPX    p-xylene-bis(pyridinium bromide) 
EPA   Environmental Protection Agency (NZ) 
ER   endoplasmic reticulum 
ERG   electroretinography 
ERT   enzyme replacement therapy 
GABA   γ-aminobutyric acid 
gDNA   genomic deoxyribonucleic acid 
GFAP   glial fibrillary acidic protein 
GFP   green fluorescent protein 
GSB4   Griffonia simplicifolia isolectin type I-B4  
HIV-1   human immunodeficiency virus 1 
ICV   intracerebroventricular 
INCL   infantile NCL 
IP   intraparenchymal 
kDa    kilodalton(s) 
 xvi 
kB   kilobase 
LFB   Luxol fast blue 
LINCL   late infantile NCL 
LOD   logarithm of the odds 
LSD(s)   lysosomal storage disease(s)  
LV   lentiviral 
MND(U3)  myeloid sarcoma virus (U3 element) 
MPS   mucopolysaccharidosis 
MRI   magnetic resonance imaging 
mRNA   messenger ribonucleic acid 
NCL   neuronal ceroid lipofuscinosis 
NGS   normal goat serum 
PBS   phosphate buffered saline, pH 7.4 
PBST   phosphate buffered saline, pH 7.4, containing 0.3% Triton X-100 
PCR   polymerase chain reaction 
PLR   pupillary light reflex 
PME   progressive myoclonic epilepsy 
PPT1   palmitoyl protein thioesterase 1 
PSA-NCAM  poly-sialated neural cell adhesion molecule 
RNA   ribonucleic acid 
SAP   sphingolipid activator proteins (saposin) 
scAAV   self complementary AAV 
SEM   standard error of the mean 
ssAAV   single stranded AAV 
sub c   subunit c of the mitochondrial ATP synthase 
SVZ   subventricular zone   
TPP1   tripeptidyl peptidase I  
TU   transducing units 
vg   viral genomes 
VSV-G   vesicular stomatitis virus glycoprotein 
 

 2 
1.1.1 Genetic classification 
Historically the NCLs were classified into four forms based on the age of onset of clinical symptoms, 
infantile, late-infantile, juvenile and adult with a plethora of eponyms coined for these (Haltia, 2003). 
However advances in molecular genetics and biochemical technologies, particularly whole exome 
sequencing, have resulted in the identification of 446 mutations in over a dozen NCL genes 
(http://www.ucl.ac.uk/ncl/mutation.shtml) and demonstrated much more genetic heterogeneity 
than was initially thought. Mutations in several NCL genes can cause a similar clinical and 
histopathological phenotype, for example late infantile variant NCL can be caused by mutations in 
CLN5, CLN6, CLN7 or CLN8 (Warrier et al., 2013). Phenotypic heterogeneity has also been reported 
recently, with mutations in the same gene leading to very different disease courses (Kousi et al., 
2012; Warrier et al., 2013). All these considerations prompted the development of a new NCL 
nomenclature with classification based on the defective gene as well as the age of onset (Williams & 
Mole, 2012; Table 1.1). Nevertheless the more recently identified NCL subtypes (CLN11–14) do not 
meet all the classification criteria (clinical, neuropathological and ultrastructural commonality) and 
there is less certainty over their inclusion into the NCL family (Palmer et al., 2013).  
Interestingly too, mutations in some of these recently described NCL genes are also linked to other 
more common neurodegenerative diseases (Table 1.1). A homozygous mutation in the progranulin 
gene, CLN11/GRN, was claimed to cause adult onset NCL in a single-family report (Smith et al., 2012). 
Yet heterozygous mutations in the same gene are a major cause of frontotemporal lobar 
degeneration (Benussi et al., 2008), the second most common type of early-onset dementia. 
Mutations in CLN12/ATP13A2 generally cause a rare juvenile Parkinsonism disorder, Kufor-Rakeb 
syndrome (Ramirez et al., 2006) but have been implicated in a family with juvenile onset NCL with 
learning difficulties (Bras et al., 2012), as well as a causative role in a Tibetan terrier canine model of 
NCL (Wöhlke et al., 2011). Mutations in CLN14/KCTD7 have been described in three diseases; 
infantile-onset NCL, infantile progressive myoclonic epilepsy (PME) and opsoclonus-myoclonus 
ataxia-like syndrome (Van Bogaert et al., 2007; Blumkin et al., 2012; Staropoli et al., 2012). 
Previously defined NCL genes have also been recently shown to intersect genetically and 
pathophysiologically with other neurodegenerative disorders. Compound heterozygous missense and 
splice site variants in TPP1, the gene typically mutated in classic late-infantile CLN2 NCL, cause an 
autosomal recessive spinocerebellar ataxia 7 (SCAR7) (Sun et al., 2013). SCAR7 patients present with 
pyramidal signs and cerebellar ataxia, but none of the ophthalmologic abnormalities or epilepsy seen 
in the CLN2 disease. Moreover, mutations in the CLN6 gene cause two distinct subsets of NCL: 
variant late infantile onset, and adult-onset NCL with PME but no visual dysfunction. Recently CLN6 
mutations have also been documented alongside CLN14/KCTD7 in PME patients with no evidence of 
lysosomal storage (Andrade et al., 2012). 
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Table 1.1    Genetic classification of the NCLs (modified from http://www.ucl.ac.uk/ncl/, Cotman et al., 2013; Kollmann et al., 2013; Warrier et al., 2013)  
NCL gene Genotype-Phenotype correlation* NCL gene 
product 
Cellular localisation Major storage 
component 
Ultrastructural 
features 
CLN1 Classic infantile, late infantile, juvenile, adult PPT1 Lysosomal matrix SAP A and D GROD 
CLN2 Classic late infantile, juvenile, protracted, SCAR7 TPP1 Lysosomal matrix sub c CL 
CLN3 Classic juvenile CLN3 Endo-lysosomal membrane sub c CL, FP 
CLN4/DNAJC5 Adult autosomal dominant (Parry disease) CSPα Cytosolic/ vesicular membrane SAPs A and D CL, GROD, FP 
CLN5 Variant late infantile, juvenile, adult, protracted CLN5 Lysosomal matrix sub c  CL, FP, GROD,  RL 
CLN6 Variant late infantile, protracted, adult Kufs Type A, PME CLN6 ER membrane sub c  CL, FP, GROD, RL 
CLN7 Variant late infantile, juvenile protracted MFSD8 Lysosomal membrane sub c  CL, FP, GROD, RL 
CLN8 Late infantile, protracted, EPMR/Northern epilepsy  CLN8 ER/ER-Golgi membrane sub c CL, FP 
CLN10/ CTSD Congenital, late infantile, juvenile, adult Cathepsin D Lysosomal matrix, extracellular SAP A and D GROD 
CLN11/GRN Adult, Frontal temporal lobe dementia (when heterozygous) Progranulin Extracellular n.d. FP 
CLN12/ATP13A2 Juvenile, Kufor-Rakeb syndrome P-type ATPase Lysosomal membrane n.d. FP, GROD 
CLN13/CTSF Adult Kufs type B Cathepsin F Lysosomal matrix n.d. FP, GROD 
CLN14/KCTD7 Infantile, Infantile PME, OMA KCTD7 Cytosolic/ membrane associated sub c? FP, GROD 
* Typical phenotype caused by complete loss of gene function (bold) whereas “milder” mutations result in a later age of onset, a more protracted disease course 
or in some cases a non-NCL disease phenotype also associated with the gene (italic). 
 
The NCL genes, encoded proteins and their cellular localisations, ultrastructural findings as well as typical clinical onsets and phenotypes are presented. The 
different cellular localisations are highlighted in grey shades, with light grey for soluble lysosomal enzymes/proteins and dark grey for membrane-associated 
proteins. Abbreviations: CL, curvilinear profile; CLN1 etc, ceroid lipofuscinosis, neuronal 1 etc; CSPα, cysteine string protein; DNAJC5, DnaJ (Hsp40) homolog, 
subfamily C, member 5; EPMR, progressive epilepsy with mental retardation; ER, endoplasmic reticulum; FP, fingerprint profile; GROD, granular osmiophilic 
deposits; KCTD7, potassium channel tetramerization domain-containing protein 7; MFSD8, major facilitator superfamily domain containing 8; n.d., not 
determined; OMA, opsoclonus-myoclonus ataxia-like syndrome; PPT1, palmitoyl protein thioesterase I; PME, progressive myoclonic epilepsy; RL, rectilinear 
profile; SAP, sphinglolipid activator protein; SCAR7, autosomal recessive spinocerebellar ataxia type 7; sub c, subunit c of the mitochondrial ATP synthase; TPP1, 
tripeptidyl peptidase I.  
  
3
 
 4 
1.1.2 Gene product classification 
Aside from genetic classification, the NCL gene products fall into two general subclasses – bona fide 
soluble glycosylated lysosomal enzymes (CLN1, CLN2, CLN10, CLN13) and glycoproteins (CLN5), or 
predicted transmembrane proteins of unknown function (see Table 1.1).  
The function of most of the NCL proteins and their natural substrates are unknown, but their 
intracellular localisations provide some hints. The soluble subset of NCL gene products are typically 
known lysosomal enzymes. For example, CLN1 and CLN2 encode soluble lysosomal hydrolases, 
palmitoyl protein thioesterase (PPT1) (Vesa et al., 1995) and tripeptidyl peptidase 1 (TPP1) (Sleat et 
al., 1997) respectively. The lysosomal proteases cathepsin D (CTSD) and cathepsin F (CTSF) are 
encoded by CLN10 (Siintola et al., 2006) and CLN13 (Smith et al., 2013) respectively. A lack of 
cathepsin D activity causes a congenital NCL in children and sheep (Tyynelä et al., 2000; Siintola et al., 
2006) whilst cathepsin F deficiency results in an adult onset NCL. CLN5 encodes a soluble lysosomal 
glycoprotein of unknown function (Sleat et al., 2005, 2006, 2007) (see Section 1.4.2). The CLN11 gene 
encodes progranulin, a secreted protein that is localised within the ER and endosomal-lysosomal 
system (Cenik et al., 2012). Its function is unknown, however it is highly expressed in neurons and 
activated immune cells, therefore has a proposed role in neuronal function and inflammation (Jian et 
al., 2013). 
The second group of NCL associated proteins are putative polytopic membrane proteins, thought to 
functionally reside in the lysosomal membrane or in pre-lysosomal organelles. CLN3 probably 
encodes a lysosomal or endosomal membrane protein (Ezaki et al., 2003; Fossale et al., 2004; Kyttälä 
et al., 2004), whilst the CLN7/MFSD8 gene encodes a putative lysosomal transporter (Siintola et al., 
2007). Overexpression studies suggest that the CLN12 protein, ATP13A2, is also localised to the 
lysosome (Ramirez et al., 2006) and is possibly a transmembrane P-type ATPase transporter of 
cations or glycolipids (Bras et al., 2012). NCL gene products CLN6 and CLN8 are reportedly ER-
resident proteins. CLN6 has been documented to modulate the endocytosis of exogenous proteins 
(Heine et al., 2004; Mole et al., 2004) (see Section 1.3.2) whilst CLN8 recycles between the ER and 
the ER-Golgi intermediate compartments (Lonka et al., 2000, 2004). Two other NCL gene products, 
CLN4 and CLN14, are cytosolic yet appear to associate with vesicular membranes. CLN4/DNAJC5 
encodes a cysteine-string protein alpha chaperone protein with a likely role in neuronal synaptic 
activity (Fernández-Chacón et al., 2004) whilst the CLN14 protein, potassium channel tetramerization 
domain-containing protein 7 (KCTD7), may modulate ion channel activity (Azizieh et al., 2011). 
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1.1.2.1 Interactions between NCL gene products 
Coherent ideas as to why deficiences in separate NCL gene products result in a similar clinical, 
pathological and biochemical phenotype remain elusive. Most characterised NCL proteins are located 
in the endosomal-lysosomal system, being trafficked through or resident in the ER-Golgi system, 
suggesting that they may participate along a single common pathway (Weimer et al., 2002), or in 
intersecting or parallel pathways that, when dysfunctional, result in the shared pathology (Cotman et 
al., 2013). Links have been described for many of the NCL proteins (reviewed by Kollmann et al., 
2013). In particular, the CLN5 protein may have a central role, having been suggested to interact with 
PPT1/CLN1, TPP1/CLN2, CLN3, CLN6 and CLN8 in vitro (Vesa et al., 2002; Lyly et al., 2009; von 
Schantz et al., 2009). Of these, the CLN5-CLN1 interaction is of considerable interest as the co-
expression of CLN1/PPT1 in cell culture can restore the lysosomal trafficking of the most common 
CLN5 mutant Y392X (Lyly et al., 2009). However given these were protein overexpression studies, 
conditions of which could have a detrimental effect on protein structure (e.g. dimerisation, incorrect 
glycosylation, cleavage and folding) or result in protein retention in the ER, described in vitro 
interactions need to be considered carefully for biological significance.  
1.2 Animal models of NCL 
Systematic studies of the pathological changes in the NCLs, both early and with disease progression, 
and proof of therapeutic concept have only been possible in genetically-defined animal models of the 
disease. For these studies, experimental mouse models have proven valuable. A panel of naturally 
occurring and knock-in or knock-out murine mutants for CLN1, CLN2, CLN3, CLN5, CLN6, CLN8, CLN10  
and CLN13 exist (http://www.ucl.ac.uk/ncl/mouse.shtml, Cooper et al., 2006; Shacka, 2012). Mice 
have the advantage of a clearly defined and uniform background, well-known genetics and a short 
reproductive cycle thus providing large numbers of affected progeny. However mice are not ideal for 
the validation and pre-clinical translation of CNS-directed NCL therapeutics, given their brains are 
non-gyrencephalic and much smaller than those of humans (Figure 1.1) and the neuropathology is 
generally milder. Current therapeutic trials in NCL employ human patients in whom the disease is 
often too advanced for any reasonable assessment of efficacy (see Section 1.6.4). Large animal 
models of NCL bridge this gap. Naturally-occurring NCL forms that recapitulate key molecular, 
pathologic and/or clinical features of NCL phenotype have been reported in cats (Green & Little, 
1974; Nakayama et al., 1993; Bildfell et al., 1995; Weissenböck & Rössel, 1997), cattle (Read & 
Bridges, 1969; Harper et al., 1988; Hafner et al., 2005), dogs (Palmer et al., 2011), ferrets (Nibe et al., 
2011), goats (Fiske & Storts, 1988), horses (Url et al., 2001), pigs (Cesta et al., 2006) and sheep (Jolly 
& West, 1976; Jolly et al., 1982; Järplid & Haltia, 1993; Woods et al., 1994; Cook et al., 2002; Jolly et 
al., 2002). The majority of large animal NCL models under active study presently are domesticated 
production (e.g. sheep) or companion (e.g. dog) animals. 
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This thesis focusses on the comparative neuropathology and clinical characterisation of two ovine 
models of NCL, specifically CLN5 affected Borderdale (Jolly et al., 2002) and CLN6 affected South 
Hampshire sheep (Jolly & West, 1976), and the efficacy of gene therapy in these translational model 
systems. These forms of NCL in sheep are representative of two different protein classes; a lesion in a 
soluble lysosomal protein (CLN5) and a defective intracellular ER membrane-bound protein (CLN6). 
This subdivision of protein defects has consequences for the planning of therapies. For this reason, 
the next sections of this review will introduce sheep as a pre-clinical model, describing the known 
characteristics of the CLN5 and CLN6 variants in humans and animals and focussing on what has been 
discovered about disease pathogenesis from studies in NCL sheep and other animal models. The final 
section will review enzyme replacement and gene therapy as treatment strategies for NCL. 
1.2.1 Sheep as a pre-clinical model 
Of the larger species models, sheep (Ovis aries) are ideal pre-clinical subjects to fill the translational 
gap for NCL. The clinical progression and course of neuropathology in ovine NCL closely follows that 
in affected children (see Sections 1.3.1 and 1.4.1). In marked contrast to mice, which are ~2800 times 
smaller than a typical adult patient, sheep are similarly sized to humans, weighing 3.5 - 4.5 kg at birth 
and 80 – 110 kg as adults. This makes them much more suited for surgical manipulation and clinical 
evaluation, including CNS imaging. Their gyrencephalic brains are comparable in size (Figure 1.1), 
complexity and physical organization to those of non-human primates, neonates and small children, 
thus particularly relevant to paediatric neurodegenerative disorders such as NCL and obviating the 
need for scale-up of treatment doses for human patients. Sheep share similar spine dimensions, 
cerebrospinal fluid (CSF) volumes and pulmonary and cardiac parameters to humans (Scheerlinck et 
al., 2008). As domestic production animals, they have been selectively bred for ease of handling and 
economic management. The longevity of sheep (9 - 12 years) allows considered longitudinal 
assessments of therapeutic efficacy. The high level of understanding of ovine reproductive 
technology, anatomy, physiology and veterinary care provides benefits for their role in a translational 
capacity. 
Sheep are also ideally suited as behavioural models. Their docile nature permits training, their 
aptitude for shape and colour discrimination (Morton & Avanzo, 2011) and excellent facial (Kendrick 
et al., 2001; Peirce et al.,2001) and olfactory recognition (Sánchez-Andrade et al., 2005; Nowak et al., 
2011) suggest a good capacity for learning and memory. Moreover, they have been shown to 
tolerate repetitive behavioural testing without signs of stress (Morton & Avanzo, 2011; Wilkes et al., 
2012).   
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Species (adult) Average brain weight (g) Average body weight (kg) 
Human (Homo sapiens) 1400 65 
Sheep (Ovis aries) 140 55.5 
Mouse (Mus musculus) 0.4 0.023 
 
Figure 1.1    Comparison of average human, sheep and mouse brains and body weights 
Note the human-like gyrencephalic sheep brain which, at 140 grams by maturity, is larger than that 
of many non-human primates, one-tenth that of a human adult and more comparable to that of a 
neonate or small child. In comparison, the mouse brain is lissencephalic and weighs at most 0.4g. 
 
In addition to the different forms of ovine NCL, a number of other naturally occurring diseases of the 
CNS have been identified in sheep, including the monogenic neurodegenerative LSDs, GM1 and GM2 
gangliosidoses, Gaucher, Pompe and Tay-Sachs diseases (Table 1.2). A transgenic ovine model of 
Huntington’s disease has also been generated (Jacobsen et al., 2010). With the recent completion of 
a fully annotated sequence of the sheep genome (Jiang et al., 2014; http://genome.ucsc.edu/cgi-
bin/hgGateway) and advanced technologies like next generation sequencing to screen populations of 
sheep for genetic variants resembling human diseases, many new ovine models of human diseases 
could be easily identified (PInnapureddy et al., 2015).  
 
 
  
Human 
Sheep 
Mouse 
1 cm 
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Table 1.2    Naturally occurring genetic diseases of the ovine CNS 
Disease Gene Description Sheep breeds affected References 
Adult-onset Alexander disease ? GFAP Astrocytic disorder Merino Kessell et al., 2012 
Cerebellar abiotrophy ? Purkinje cell atrophy Merino, Wiltshire Harper et al., 1986; Johnstone et al., 2005 
Cerebellar cortical atrophy 
 
? Daft lamb disease Blackface, Border Leicester, 
Charollais, Corriedale, Welsh 
Mountain  
Innes & MacNaughton, 1950; Bradley & 
Terlecki, 1977; Terlecki et al., 1978; Milne & 
Schock, 1998  
Degenerative thoracic myelopathy ? Spinal cord degeneration Merino Harper et al., 1991 
Gaucher disease type 1 GBA Glucocerebrosidosis Southdown Karageorgos et al., 2011 
GM1 gangliosidosis (human type 3) ? GM1 gangliosidosis Romney, Suffolk Prieur et al., 1991; Ryder & Simmons, 2001 
Krabbe disease ? GALC Globoid cell leukodystrophy Poll Dorset Pritchard et al., 1980 
Lissencephaly with cerebellar hypoplasia RELN Lissencephaly Churra Pérez et al., 2013; Suárez-Vega et al., 2013 
Lower motor neuron disease AGTPBP1 Spinal muscular atrophy Romney Anderson et al., 1999; Zhao et al., 2012 
Morquio B disease ? Mucopolysaccharidosis IVB Suffolk Ahern-Rindell et al., 1988 
Murrurundi disease (segmental axonopathy) ? Encephalopathy Merino Harper et al., 1986 
Neuroaxonal dystrophy ? Muscular dystrophy Coopworth, Merino, Perendale, 
Romney  
Cordy et al., 1967; Harper & Morton, 1991; 
Finnie et al., 2014 
Neuronal ceroid lipofuscinosis CLN5 
CLN6 
Neurodegenerative disease Borderdale 
Merino, South Hampshire 
Jolly et al., 2002 
Jolly & West, 1976; Cook et al., 2002 
 CTSD  Swedish Landrace Tyynelä et al., 2000 
 ?  Rambouillet Edwards et al.,1994  
Pompe disease ? Glycogen storage disease   Corriedale, Merino Manktelow & Hartley, 1975 
Tay-Sachs disease HEXA GM2 gangliosidosis Jakob Torres et al., 2010; Wessels et al., 2014 
Thalamic cerebellar neuropathy ? Neuropathic disorder Merino Bourke et al.,1993 
Lysosomal storage diseases are boxed 
? = gene not known or unconfirmed
8
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1.3 CLN6 NCL 
1.3.1 CLN6 in New Zealand South Hampshire sheep 
The best characterised NCL animal model, especially at a biochemical and pathological  level, is the 
CLN6 form identified in New Zealand South Hampshire sheep over four decades ago (Jolly & West, 
1976; Jolly et al., 1980, 1989). The disease progression and course of neuropathology in this model is 
well described and closely parallels that in the human disease, particularly the severe cortical 
atrophy, profound neuronal loss, storage body accumulation and retinal degeneration (see Section 
1.5). Affected sheep are apparently normal at birth but develop clinical symptoms between 10 and 
14 months of age, notably progressive psychomotor decline and blindness as a result of atrophy of 
the occipital cortex and loss of retinal photoreceptors, with premature death when aged about two 
years (Mayhew et al., 1985; Jolly et al., 1989). The specific storage of subunit c of mitochondrial ATP 
synthase was first discovered in these sheep (Palmer et al., 1989, 1992; Fearnley et al., 1990; Palmer, 
2015). Regionally defined and selective loss of cortical neurons in the CLN6 affected sheep brain is 
preceded by prenatal neuroinflammation, starting from particular cortical foci later associated with 
symptomology and becoming more generalised with disease progression (Oswald et al., 2001, 2005, 
2008; Kay et al., 2006). These findings have subsequently been confirmed in human and other 
mammalian NCL models hence the CLN6 sheep are often regarded as a prototype of the NCLs. 
1.3.2 The CLN6 gene and protein 
The human CLN6 gene is located on chromosome 15q21-23 (Sharp et al., 1999), and contains 7 
exons, encoding a putative 311 amino acid protein (Gao et al., 2002; Wheeler et al., 2002) (Figure 
1.2). To date, 71 mutations in the CLN6 gene have been described in diverse geographical 
populations across all habitable continents (http://www.ucl.ac.uk/ncl/cln6.shtml). Seventy-three per 
cent of CLN6 patients are homozygous for their mutation (Kousi et al., 2012). 
Positional cloning localised the CLN6 gene responsible for the South Hampshire disease to a region 
on sheep chromosome 7 homologous with the 15q21–23 human CLN6 region (Broom et al., 1998). 
The ovine CLN6 ortholog has an identical gene structure of 7 exons, encoding a predicted 311 amino 
acid polypeptide (Figure 1.2) and 90% sequence homology to human CLN6 (Tammen et al., 2006). 
Long-range PCR amplification of the part of the ovine genome, followed by SOLiD (sequencing by 
oligonucleotide ligation and detection) next-generation DNA sequencing identified the disease-
causing mutation in the South Hampshire sheep as a 402 base pair (bp) deletion and 1 bp insertion in 
ovine CLN6, namely g.-251_+150del and g.+150_151insC (Mohd Ismail, 2014). The mutation is 
predicted to lead to the deletion of the ATG start codon, the whole of exon 1 and the flanking 5’ non-
coding sequence. 
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Figure 1.2    Disease-causing mutations identified within the CLN6 gene 
Schematic of the CLN6 gene (drawn to scale) with the locations of all known human disease-causing 
mutations depicted in blue. Intron 4 is represented by the black line between introns 3 and 5. A 
naturally occurring form of CLN6 in South Hampshire sheep results from a large deletion and a single 
base insertion in the GC-rich 5’ end of the gene (red) (Mohd Ismail, 2014). Given this region is 
extremely difficult to amplify, a silent allelic variant (c.822G>A) in exon 7 of ovine CLN6 is used 
instead as an indirect test for preclinical diagnosis of affected South Hampshire sheep (Tammen et 
al., 2006). The South Hampshire flock is configured now such that all heterozygous sheep are GA and 
all affected animals AA. Additionally a single substitution in exon 2 (c.184C>T) results in ovine CLN6 in 
Australian Merino sheep (Tammen et al., 2006). The Merino mutation codes for a major amino acid 
exchange (p.Arg62Cys) and is very similar to a human disease-causing substitution, p.Arg62His.  
 
 
The CLN6 protein is a 27 kDa integral membrane protein of unknown function. Two independent 
studies, using immunocytochemistry and subcellular fractionation, concluded that human and sheep 
CLN6 is an ER-resident protein (Heine et al., 2004; Mole et al., 2004). This ER-residency is seen in 
both neuronal and non-neuronal cells (Mole et al., 2004; Heine et al., 2007). The mature CLN6 
protein has been modelled to contain a cytoplasmic N-terminus, seven transmembrane domains and 
a C-terminal directed towards the ER lumen (Heine et al., 2007). Expression of retention signals in the 
first 49 amino acids of the N-terminal and in the carboxy-proximal transmembrane domains six and 
seven are predicted to maintain the ER localisation of CLN6 (Heine et al., 2007). The protein bears no 
sequence homology to other known proteins but it is highly conserved across mammalian species 
(Heine et al., 2004). Human and sheep CLN6 are 92% identical, with the majority of differences in the 
poorly conserved N-terminus. The exact function of the CLN6 protein remains elusive, however 
studies indicate that CLN6 modulates the endocytosis of exogenous lysosomal proteins (Heine et al., 
2004; Mole et al., 2004).  
 
 5’UTR Exon                                           Exon                 Exon              Exon   Exon             Exon    Exon     3’UTR 
                1                                                 2                        3                    4          5                    6          7 
Intron 1 Intron 3 
Missense x 3 
Nonsense 
Missense x 3 
Nonsense  
1bp-insertion  
Missense x 9 
Nonsense x 2 
1bp-deletion 
4bp-insertion 
Missense 
c.184C>T 
(Merino) 
Intron 2 Intron 5 
Missense x 4 
1bp-deletion 
Missense x 10 
Nonsense 
2bp-deletion 
3bp-deletion 
1bp-insertion 
3bp-insertion 
Missense 
Nonsense 
1bp-deletion 
3bp-deletion 
Missense x 10 
Nonsense x 3 
1bp-deletion 
3bp-deletion 
2bp-del/2bp-ins 
9bp-del//4bp-ins 
Splice site  
defect 
Splice site  
defect 
Splice site  
defect 
Splice site  
defect 
 * Polymorphism 
c.822G>A 
(South Hampshire) 
  g.-251_+150del 
  g.+150_151insC 
(South Hampshire) 
 * 
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1.3.3 Human CLN6 disease 
Mutations in the CLN6 gene cause an autosomal recessive, progressive neurodegenerative disorder 
with bimodal presentation of both late infantile (Lake & Cavanagh, 1978) and adult-onset NCLs 
(Arsov et al., 2011). The disease is characterised by regionally specific neuronal loss, with the 
abnormal specific accumulation of subunit c of mitochondrial ATP synthase in lysosome derived 
storage bodies in CNS neurons and in somatic cells outside of the nervous system (Palmer et al., 
1989, 1992; Goebel et al., 1999; Palmer, 2015). The late infantile form manifests at 3 to 5 years of 
age with developmental and mental retardation, followed by speech impairment, seizures, ataxia 
and myoclonus (Mole et al., 2005). Patients lose vision and motor coordination between the ages of 
4 and 10 years (Teixeira et al., 2003b) with premature death before the third decade of life (Mole et 
al., 2005). More recently cases of teenage progressive onset myoclonus epilepsy (Andrade et al., 
2012) and Kufs disease Type A (Arsov et al., 2011) have been attributed to mutations in the CLN6 
gene. The latter typically presents around the age of 30 years, but onset ranges from teenage to as 
late as the fifth decade, with progressive myoclonus epilepsy and intellectual deterioration. Strikingly 
the teenage/adult onset forms of CLN6 have no retinal involvement and vision is preserved. There is 
no specific treatment for the CLN6 disease, except for palliative care and the management of 
psychiatric symptoms which is limited as seizures do not respond well to traditional anti-convulsant 
medications (Mole et al., 2011).  
1.3.4 Other CLN6 animal models 
Aside from the CLN6 South Hampshire sheep model used in this thesis, other naturally occurring 
NCLs in animals were subsequently localized to CLN6, such as the nclf mouse (Bronson et al., 1998; 
Gao et al., 2002; Wheeler et al., 2002) and the Australian Merino sheep (Tammen et al., 2001, 2006) 
(Figure 1.2). The nclf mouse model is publically available for purchase from the Jackson laboratory 
(Bar Harbor, Maine, USA). Homozygous nclf mice develop progressive retinal atrophy early in life, 
with ataxia, neurodegeneration and ultimately paralysis and death by 9 months of age (Bronson et 
al., 1993). A CLN6 Merino flock is maintained at the University of Sydney, Australia. The disease 
manifests in Merino sheep at 7 - 12 months of age, with clinical signs and disease progression 
remarkably similar to that seen in the South Hampshires (Tammen et al., 2001; Cook et al., 2002; 
Palmer et al., 2011). Affected sheep suffer from gross brain atrophy and usually die before 24 
months. A study characterising the neuropathological changes in the affected Merino sheep brain is 
underway (Katharina Russell, PhD, Lincoln University). A missense mutation in the CLN6 gene has 
been reported to cause NCL in Australian Shepherd dogs however a colony has not been established. 
Closely related dogs were not genotyped and screening failed to find any other affected individuals 
(O’Brien et al., 2008; Katz et al., 2011).  
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1.4 CLN5 NCL 
1.4.1 CLN5 in New Zealand Borderdale sheep 
Fifteen years ago, a second naturally occurring ovine NCL was identified in New Zealand Borderdale 
sheep (Jolly et al., 2002) and the causative mutation was found to be in CLN5 (Frugier et al., 2008). 
Blindness is the first clinical sign in affected Borderdales, with presentation from 10 - 11 months of 
age. Again subunit c of mitochondrial ATP synthase was found to be the abnormally stored 
component of the lysosomal inclusion bodies. The course of the CLN5 form was predicted to be 
similar to the CLN6 form in sheep, although the brain atrophy was reported to be more severe (Jolly 
et al., 2002). One of the major objectives of this study was to characterise the Borderdale model by 
defining the progressive extent of neuronal loss, neuroinflammation and neurogenesis in a similar 
way as has been published for the South Hampshire CLN6 form. The Borderdale sheep provide an 
ideal resource for studying CLN5 NCL, and soluble enzyme forms of NCL in general, complementing 
the membrane protein mutation in the CLN6 South Hampshire model. 
1.4.2 The CLN5 gene and protein 
The CLN5 gene maps to human chromosome 13q22 and 36 disease-causing mutations have so far 
been identified in it (http://www.ucl.ac.uk/ncl/cln5.shtml) (Figure 1.3). The majority of patients carry 
a 2 bp deletion in exon 4 (c.1175delAT), which results in a truncated protein (Savukoski et al., 1998; 
Holmberg et al., 2000). Interspecies variation is almost exclusively concentrated in the N-terminus of 
the polypeptide, coded for by the GC-rich exon 1, but the rest of the coding sequence is highly 
conserved (Frugier et al., 2008). For example, human and sheep CLN5 share 84% homology. 
 
 
 
 
 
 
 
 
Figure 1.3    Disease-causing mutations identified within the CLN5 gene  
Schematic of the CLN5 gene (drawn to scale) with the locations of the known human mutations 
depicted in blue. Intron 2 lies between exons 2 and 3. A naturally occurring form of CLN5 in 
Borderdale sheep results from a single substitution at a consensus splice site (green), with resultant 
excision of exon 3 thus a truncated putative protein (Frugier et al., 2008). 
 
 
5’UTR          Exon                                        Exon     Exon                                                                 Exon                  3’UTR 
                        1                                              2            3                                                                       4     
Missense x 2 
Nonsense 
1bp-insertion 
Missense x 3 
Nonsense 
Missense x 5 
Nonsense x 4 
1bp-insertion x 2 
Missense x 5 
Nonsense x 2 
1bp-deletion x 2 
2bp-deletion x 3 
4bp-deletion 
16-bp deletion 
188bp deletion 
Intron 1 Intron 3 
 
  1bp- substitution 
c.571+1G>A 
(Borderdale) 
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The ovine CLN5 gene, located on sheep chromosome 10, also contains 4 exons and encodes a 
predicted 361 amino acid protein (Frugier et al., 2008). A substitution of the first nucleotide in intron 
3 (c.571+1G>A, Figure 1.3) segregates with the disease and was identified as the disease-causing 
mutation (Frugier et al., 2008). This mutation disrupts the normal splicing consensus sequence at the 
5′ end of the intron 3, resulting in the excision of exon 3. 
The human CLN5 gene has four possible methionine initiation sites, translation from which would 
produce polypeptides with molecular masses ranging from 39 to 47 kDa (Klockars et al., 1999; 
Isosomppi et al., 2002; Vesa et al., 2002). Initially it was suggested that the most 5′ upstream was the 
functional site in humans, providing an open reading frame of 1380 bp coding for a 407-amino acid 
47 kDa polypeptide with two transmembrane domains (Savukoski et al., 1998). Subsequent protein 
expression studies and alignment with the mouse gene, which contains only one start site, led to the 
proposal that the most 3′ AUG in humans (AUG62) was the major initiation site, resulting in a 38 kDa 
lysosomal-targeted protein, with an N-terminal signal sequence that is cleaved after entering the ER 
(Isosomppi et al., 2002; Holmberg et al., 2004; Mole et al., 2004). However later alignment of the 
human, bovine, canine, murine and ovine CLN5 showed that the third human methionine is 
evolutionally conserved and thus may be the true initiator (Houweling et al., 2006; Frugier et al., 
2008). Realignment would generate a CLN5 protein of 358 amino acids. All of the CLN5 isoforms lack 
homology to any protein of known function however there is strong evidence that CLN5 is a soluble 
lysosomal glycoprotein. Eight potential N-glycosylation sites have been identified and CLN5 contains 
a signal peptide which is cleaved in the ER and the mature polypeptide is localised to the lysosome 
(Isosomppi et al., 2002; Holmberg et al., 2004; Schmiedt et al., 2010). Three mannose-6-phosphate 
moieties are connected to asparagine residues 320, 330 and 401, which interact with the lysosomal 
targeting mannose-6-receptors, enabling CLN5 transport from the Golgi to the lysosome (Sleat et al., 
2005, 2006, 2007) and rendering it soluble.  
1.4.3 Human CLN5 disease 
The late infantile variant CLN5 disease is particularly prevalent in Finland, first described there in 
children who share the same founder mutation (Savukoski et al., 1998). However the disease is not 
confined to the Finnish population, now being recognised worldwide in a broad ethnic diversity (Xin 
et al., 2010). CLN5 disease presents with motor difficulties and visual deficits between the ages of 4 
and 7, progressing to mental and motor deterioration, ataxia, myoclonic epilepsy, and loss of vision 
by the age of 7 to 10 years (Santavuori et al., 1982, 1991; Holmberg et al., 2000; Xin et al., 2010). Age 
at death in CLN5 patients is highly variable, ranging from 10 to 30 years, with one patient surviving 
until the age of 41 (Holmberg et al., 2000; Moore et al., 2008). 
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Neuropathologically, human CLN5 manifests as generalised cerebral and extreme cerebellar atrophy 
(Autti et al., 1992; Tyynelä et al., 1997). The latter is a particularly striking abnormality in 
neuroimaging studies (Autti et al., 1992; Holmberg et al., 2000) and in autopsy specimens (Tynnelä et 
al., 1997). In late stage disease, an almost complete loss of thalamic neurons and Purkinje cells in the 
cerebellum is reported, whilst the cortical neurons in laminae III and V are most vulnerable, 
undergoing moderate loss with enlargement of the cell soma of those remaining (Tynnelä et al., 
1997). Subunit c of mitochondrial ATP synthase is the main protein stored (Tynnelä et al., 1997). 
Widespread astrocytosis can be seen in the cortex and cerebellum of CLN5 patients and CLN5 
knockout mice (Tyynelä et al., 2004; von Schantz et al., 2009).  
1.4.4 Other CLN5 animal models 
Naturally occurring CLN5 NCLs in Devon cattle (Harper et al., 1988; Houweling et al., 2006), Border 
Collie (Taylor & Farrow, 1988; Melville et al., 2005) and Golden retriever dogs (Gilliam et al., 2015) 
present with a disease course and pathogenesis matching human CLN5. A small herd of Devon cattle 
was maintained at the University of Sydney but as the animals developed clinical signs from 9 
months of age, they became aggressive (Imke Tammen, personal communication), dying about two 
years later (Harper et al., 1988). The CLN5 Borderdale ovine model was deemed easier to maintain, 
because of the greater ease of handling sheep, so CLN5 Devon cattle are no longer under active study 
however frozen semen from affected bulls has been stored. CLN5 affected Border Collies and Golden 
retrievers present with a progressive neurological disease between 15 and 22 months of age, dying 
before the age of three years (Taylor & Farrow, 1988; Melville et al., 2005; Gilliam et al., 2015). 
Research colonies of these CLN5-deficient dogs do not currently exist. However a number of carrier 
dogs have been retained under private ownership and semen stocks are maintained. A CLN5 exon 3 
knock-out mouse model has also been generated (Kopra et al., 2004), which has provided insights 
into the spatiotemporal expression of CLN5 in the CNS (Holmberg et al., 2004) but these mice lack 
the severe brain atrophy characteristic of the sheep and human diseases. 
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1.5 NCL pathogenesis – what has been learnt from animal models? 
1.5.1 Storage body accumulation 
In addition to a similar clinical phenotype, the NCLs share the common accumulation of Sudan black 
and Luxol fast blue positive fluorescent electron dense storage material within autophagic vacuoles 
(lysosomes) of most nerve cells, and many other somatic cells. These lysosomal inclusions display 
distinctive ultrastructural patterns, visualised by electron microscopy, described as curvilinear, 
fingerprint, granular osmiophilic deposit or rectilinear profiles, depending on the NCL phenotype and 
tissue (Table 1.1). Direct protein sequencing unequivocally established the specific storage of subunit 
c of mitochondrial F1F0 ATP synthase, first in the CLN6 South Hampshire sheep model (Palmer et al., 
1989; Fearnley et al., 1990) (see Section 1.3.1), and then in the CLN2 and CLN3 human diseases and 
some animal models (Fearnley et al., 1990; Palmer et al., 1992; Palmer, 2015). Subsequent subunit c 
storage has been identified by direct sequencing and/or immunohistochemistry in CLN5, CLN6, CLN7, 
CLN8 and CLN14 human forms (Faust et al., 1994; Ezaki et al., 2000; Haltia, 2006; Staropoli et al., 
2012) and other animal models (Fearnley et al., 1990; Martinus at al., 1991; Jolly et al., 1994; Palmer 
et al., 1997; Url et al., 2001; Cook et al., 2002; Katz et al., 2005; Melville et al., 2005; Frugier et al., 
2008). Of the remaining NCL forms, the sphingolipid activator proteins (SAPs) A and D are the major 
proteins accumulating in CLN1 and CLN10 (Tyynelä et al.,1993; Siintola et al., 2006), some 
uncharacterised non-neuronal storage has been reported for the CLN12 form (Bras et al., 2012) 
whilst the molecular composition of the stored material in the more recently described adult forms 
(CLN4, CLN11 and CLN13) have not been determined.  
Until recently the neuropathology seen in the NCLs was considered to be consequent to the storage 
body accumulation, but there was a growing body of evidence against this. Despite ubiquitous 
storage in most cells and most tissues, there is no obvious disruption to cellular function or specific 
tissue or organ failure (Palmer et al., 2013; Palmer, 2015). Even within the central nervous system 
(CNS), where storage accumulation is widespread and progressive, only selective neuronal 
populations degenerate during the disease progression (Oswald et al., 2005, 2008) whilst others can 
maintain a substantial storage burden to no obvious detriment. For instance, the accumulation of 
storage material in the Purkinje cerebellar cells of the ovine CLN6 model does not correlate with any 
disease-related changes, with no measurable atrophy and only minimal neuroinflammation in the 
cerebellum even at end-stage disease (Graham Kay, personal observation). Additionally the clearance 
of large amounts of CNS-derived storage material after viral-mediated gene therapy in CLN1 mice did 
not impact on neuron survival or improve the clinical outcome (Griffey et al., 2006). Thus, it is now 
thought that neurodegeneration and storage body accumulation are independent manifestations of 
the NCL genetic mutations (Palmer et al., 2013).  
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1.5.2 Selective neuron loss 
The other unifying pathological hallmark of NCL is regionally specific neurodegeneration. The disease 
selectively manifests in the CNS, with progressive loss of neuronal structure and function which is 
linked to the profound atrophy documented in all human NCL forms (Haltia, 2003, 2006) and in the 
ovine NCL models used in the current study (Mayhew et al., 1985; Jolly et al., 1989, 2002; Oswald et 
al., 2001, 2005). However not all brain regions are equally affected by the neurodegeneration. The 
cerebral cortex is severely affected in all NCL forms, whereas the pathology in other regions of the 
CNS varies. Histological studies of human NCL brains are limited to autopsy tissue by which stage 
neuronal loss is widespread (Bennett & Rakheja, 2013) and, whilst brain imaging studies on human 
patients provides some insight into the sequential anatomical and functional changes (Peña et al., 
2001; Autti et al., 2008; Paniagua Bravo et al., 2013), elucidation of the progressive and selective 
nature of neurodegeneration has relied on animal model studies. 
Given the widespread cortical neurodegeneration at end-stage disease, it could be assumed that 
neuronal loss would occur to a similar extent throughout the diseased brain. Remarkably though, 
studies of early neurodegeneration revealed regional selectivity. Comprehensive post mortem 
studies showed that the development of CLN6 affected sheep brains proceeded normally for the first 
four months after birth, then progressively reversed, diverging from that of age-matched controls 
which continued to grow (Oswald et al., 2005). Gross atrophy of the cerebral cortex was apparent 
from six months, with a reduction in cortical thickness commencing and progressing fastest in the 
parieto-occipital and visual cortices, the regions first associated with clinical symptomology. By 12 
months of age atrophy was apparent in all cortical regions (Figure 1.4). In contrast, the subcortical 
nuclei and cerebellum of CLN6 affected brains retained a normal appearance, even at an advanced 
disease stage.  
 
 
Figure 1.4    Cortical atrophy in ovine CLN6 compared to normal control animals 
At 12 months there is marked atrophy of the cerebral cortex in CLN6 affected sheep compared to 
age-matched controls. By 19 months, this is even more pronounced, especially in the visual cortex 
(modified from Oswald et al., 2005). 
       Control 12 months     CLN6 Affected 12 months   CLN6 Affected 19 months 
Visual cortex
Motor cortex
1cm 
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A spatiotemporal survey of cortical interneuron phenotypes in CLN6 affected sheep demonstrated 
selective neuronal loss, with cellular location and connectivity the overriding influences rather than 
early preferential loss of specific cell types (Oswald et al., 2008). Interneurons are specialised nerve 
cells whose primary role is to form connections between other types of neurons, creating neural 
circuits. Within the CNS, interneurons are primarily inhibitory using γ-aminobutyric acid (GABA) 
neurotransmission and can be categorised into subtypes based on the surface markers they express. 
Consistently, populations of inhibitory GABAergic interneurons have been shown to be vulnerable in 
human, mouse and sheep NCLs (Williams et al., 1977; Cooper et al., 1999; Mitchison et al., 1999; 
Oswald et al., 2001; Bible et al., 2004; Pontikis et al., 2004; Tyynelä et al., 2004; Kielar et al., 2007). 
Study of the ovine CLN6 model revealed an early and severe loss of parvabumin-positive GABAergic 
interneurons, which began in the visual and parieto-occipital cortices (Oswald et al., 2008), 
paralleling the regionally specific neurodegenerative changes and cortical atrophy (Oswald et al., 
2005). Loss of somatostatin and neuropeptide Y-positive interneurons followed the same regional 
trend but later in disease progression, whilst calretinin and calbindin-positive neuron populations 
were relatively well preserved, confirming the marked differences in the survival of different 
interneuron subtypes and between different brain regions during disease progression. 
Studies in NCL mouse models have surprisingly shown that, despite profound cortical degeneration, 
the thalamus appears to be pathologically targeted early in disease progression (Pontikis et al., 2005; 
Kielar et al., 2007; Partanen et al., 2008; Kuronen et al., 2012; Morgan et al., 2013). In most NCL 
murine forms, loss of thalamic relay neurons preceded neurodegeneration in the corresponding 
cortical region to which they project. However the sequence of neuron loss is reversed for CLN5 
mutant mice, with an earlier susceptibility of cortical neurons than thalamic ones (von Schantz et al., 
2009). An explanation for this difference has not been elucidated but indicates the contrasting 
consequences of the different gene mutations. Morphometric analysis from a longitudinal MRI study 
indicated some thalamic atrophy in the CLN6 affected sheep brain at end-stage disease (Sawiak et al., 
2015), but no early neuronal loss from the ovine thalamocortical system has been observed in 
histological studies in sheep (Oswald et al., 2005, 2008; Kay et al., 2011).  
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1.5.3 Neuroinflammation 
NCL is not simply a disease of neurons. A primary role for glial activation has been implicated in NCL 
pathogenesis. Spatiotemporal studies in ovine NCL established that reactive astrocytosis and 
microglial activation begins in prenatal, pre-symptomatic CLN6 affected sheep brains, long before 
significant storage body accumulation or neuronal loss (Oswald et al., 2005; Kay et al., 2006). 
Hypertrophic and proliferating perivascular macrophages and activated astrocytes were present at 
40 and 20 days before birth respectively, spreading to form reactive clusters in the cortex at birth. 
The glial activation proceeded in a progressive, regionally specific manner, beginning in the visual, 
parieto-occipital and somatosensory cortices, the regions associated with the later development of 
neurodegeneration, atrophy and clinical symptoms (Kay et al., 2006). Activation in the primary motor 
and entorhinal cortices followed (Oswald et al., 2005). Localised microglial and astrocyte activation, 
which precedes and accurately predicts where subsequent neuronal loss will occur, has since been 
substantiated in multiple mouse models of NCL (Pontikis et al., 2004, 2005; Kielar et al., 2007; 
Partanen et al., 2008; Macauley et al., 2009; von Schantz et al., 2009; Kuronen et al., 2012; Schmiedt 
et al., 2012; Thelen et al., 2012; Morgan et al., 2013). Neuroinflammation has also been indicated as 
a major contributor to disease pathogenesis in many neurodegenerative CNS disorders, including 
Alzheimer disease, Huntington’s disease, Parkinson disease, multiple sclerosis and amyotrophic 
sclerosis (Block & Hong, 2005; Mrak & Griffin, 2005; McGeer & McGeer, 2007; Eikelenboom et al., 
2006). 
A CNS injury or insult can result in reactive gliosis through a transient inflammatory response, as glial 
cells endeavour to remove the insult whilst providing trophic support to neurons. However, chronic 
inflammation is thought to be detrimental to neurons, creating a neurotoxic environment due to 
elevated levels of inflammatory cytokines and chemokines, and pro-apoptotic molecules accelerating 
cell death (Stoll & Jander, 1999; Streit et al., 2004; Lyman et al., 2014; Lee & MacLean, 2015). It 
follows that drug inhibition or suppression of neuroinflammation in NCL may be neuroprotective and 
thus therapeutic. However chronic oral administration of a broad-spectrum anti-inflammatory, 
minocycline, to pre-symptomatic CLN6 affected lambs did not change the course of the disease (Kay 
& Palmer, 2013). Molecular dissection of the ovine CLN6 neuroinflammatory cascade, by quantitative 
PCR, Western blot and immunohistochemistry revealed a complex but uncontrolled pathway with 
differential regulation of a number of genes but could not identify causal initiators of 
neuroinflammation or potential druggable targets (Chen, 2016).  
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1.5.4 Extended neurogenesis 
Evidence of extended neurogenesis has also been found in the CLN6 sheep model (Dihanich et al., 
2009, 2012). Neurogenesis, the generation of new neurons from precursor neural stem (progenitor) 
cells, was traditionally thought to occur only during embryonic or perinatal development (Ming & 
Song, 2005). However, active adult neurogenesis has been found to occur in two specific neurogenic 
regions of the brain; the subgranular zone in the hippocampal dentate gyrus where new granule cell 
neurons are generated, and the subventricular zone (SVZ) of the lateral ventricles, where neuroblasts 
are generated and migrate through the rostral migratory stream to the olfactory bulb to differentiate 
into interneurons (Eriksson et al., 1998; Gage, 2000). 
Like humans, the normal sheep SVZ is stratified and is the main site of progenitor cell proliferation 
and adult neurogenesis (Brus et al., 2010, 2013; Low et al., 2013). However immunohistochemical 
staining for newly generated and migratory neurons revealed a band of immunoreactive cells and 
fibres along the SVZ much more prominently in the CLN6 diseased state than in the normal sheep 
brain (Dihanich et al., 2009, 2012). Newly generated SVZ neurons migrated through the rostral 
migratory stream but also radially away from the SVZ, via white matter tracts, aggregating to form 
large clusters in the outer laminar layers of the cerebral cortex of older affected animals, particularly 
in the regions undergoing neurodegeneration. The clusters contained mature and immature 
neuronal cells, but not glial cells, and were absent in normal brains. Analysis of human CLN6 autopsy 
brains revealed newly generated neurons in lamina II and the deeper laminae of the cerebral cortex, 
supporting the idea that ongoing neurogenesis occurs even in the severely diseased brain (Dihanich 
et al., 2012). Upregulation of neurogenesis has also been reported on brain trauma or after neuronal 
death in a number of other neurodegenerative diseases, including Alzheimer, Huntington’s and 
Parkinson disease (Curtis et al., 2003; Winner et al., 2011). Thus it seems plausible that this is an 
intrinsic attempt at “self-repair” in the diseased brain. This finding is pertinent for therapy in NCL, as 
it could indicate an accessible key target site for viral-mediated gene correction of neural progenitor 
cells, daughters of which differentiate into neuroblasts and new neurons and migrate globally 
through the brain, allowing cross-correction of diseased neurons (or glia).  
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1.5.5 Loss of vision and retinal degeneration 
Visual failure also occurs in most forms of NCL. Sequential studies in the CLN6 ovine model have 
shown that the visual deficits have two components, primary central (cortical) blindness and a 
secondary peripheral (retinal) lesion (Mayhew et al., 1985). Early loss of vision is probably due to the 
atrophic changes and neuronal loss seen in the occipital (visual) cortex of the CLN6 affected sheep 
from 6 months, well before the onset of visual deficits at 10 - 14 months of age (Oswald et al., 2005). 
The occipital cortex is unlikely to be able to correctly process and interpret input coming from the 
still intact retina. An alternative primary upstream insult to the dorsal lateral geniculate nucleus 
(LGN), with selective loss of these neurons, has been suggested to cause cortical lesions, optic 
atrophy and retrograde retinal dysfunction in the CLN3 mutant mouse model (Weimer et al., 2006). 
Patients with central blindness lack a menace response (a blink elicited by a threatening, sudden 
movement towards the eye) (see Table 1.3). Stimulation of this reflex is used as a diagnostic 
procedure in human and veterinary medicine to determine whether a subject’s post-retinal visual 
system has suffered damage. The menace response is cortically-mediated, with the afferent arm 
involving visual fibres through the optic nerve, optic chiasm and LGN to the occipital cortex. The 
information generated in the contralateral occipital cortex is projected efferently to the motor cortex 
and ipsilateral facial nerve to generate the blink movement. Responses to other subcortical neuro-
ophthalmic tests (e.g. direct and consensual pupillary light response (PLR), dazzle and palpebral 
reflexes) (see Table 1.3 and Section 3.3.1) are intact in early-stage ovine NCL, allowing some 
distinction between light and dark, colour, general shape and the ability to perceive moving but not 
static objects. The appearance of the NCL retina is initially normal in all species under funduscopy 
(Katz et al., 2008; Hainsworth et al., 2009). Electroretinography (ERG), which measures the 
electrophysiological response of the retina to visual stimulation, is also relatively normal during the 
early central (post-retinal) blindness phase in the canine and ovine disease course (Graydon & Jolly, 
1984; Mayhew et al., 1985; Weleber, 1998; Katz et al., 2008). 
However temporal pathophysiological studies in NCL animal models, particularly dogs and sheep, 
have shown that with disease progression, the structural integrity of the NCL retina is also 
compromised through selective loss of neuroretinal cells. Retinopathy in sheep results from the 
degeneration of rod and cone photoreceptor cells and bipolar neurons of the outer nuclear layer 
(Graydon & Jolly, 1984; Mayhew et al., 1985; Goebel, 1992). This mirrors historic morphologic 
findings from autopsied human eyes at end stage disease (Goebel et al., 1977; Schochet et al, 1980; 
Traboulski et al., 1987). There is an accumulation of storage material in the photoreceptor cells and 
retinal ganglion cells. Despite prominent storage in the latter neurons, they show few signs of 
degeneration, even at advanced stages of retinal atrophy (Graydon & Jolly, 1984; Mayhew et al., 
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1985; Goebel, 1992), reinforcing the theory that storage body accumulation per se does not cause 
the retinopathy. 
As the disease progresses to involve both cortical and retinal lesions, NCL patients become 
functionally blind although some light-dark perception may be retained (Mink et al., 2013). At this 
stage, PLR and dazzle reflexes are depressed (Table 1.3) however, as these are sub-cortical responses 
and not routed through the visual cortex, they cannot be regarded as “true” indicators of central 
vision or retinal function. In fact, comparatively few functional photoreceptor cells are required for a 
positive PLR. ERG provides a better longitudinal in vivo measure of retinal dysfunction. ERG 
responses can still be elicited during the functional blindness phase but become increasingly 
abnormal, and by end-stage NCL disease scotopic and photopic ERG extinction has been reported for 
human patients and affected dogs and sheep (Graydon & Jolly, 1984; Mayhew et al., 1985; Weleber, 
1998; Haltia, 2003; Katz et al., 2008; Sanders et al., 2011). 
 
Table 1.3   Clinical neuro-ophthalmic tests to assess loss of vision in NCL 
Lesion Menace 
response* 
Pupillary light 
response* 
Dazzle 
reflex* 
Palpebral 
reflex* 
ERG Fundus Vision 
Visual cortex - +/- + + + Normal - 
Retina - -  - + - Normal or abnormal - 
* These tests are described in further detail in Section 3.3.1 
The ovine eye closely resembles the human eye. Whilst lacking a fovea, a central depression of cones 
in the human retina, sheep eyes share the typical multi-layered human retinal structure. They also 
possess an extra layer, the tapetum lucidum, which lies directly behind the retina and reflects visible 
light back through the retina, increasing the light available to the photoreceptors and providing this 
species with superior night vision. In NCL, ideal therapeutic interventions will ameliorate 
degeneration in both the retina and the CNS regions associated with vision. Because of the size of the 
large animal eye, particularly those of sheep, they represent an ideal resource for characterising the 
similar pathological changes associated with loss of vision and for testing and translation of potential 
therapeutic strategies. 
1.5.6 Therapeutics for NCL 
Although much has been discovered about the genetics, cell biology and pathogenesis of NCL 
(described above), a key question still remains in developing therapeutics for this group of diseases: 
Are the pathological changes described in NCL haltable or reversible? 
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1.6 Gene and enzyme replacement therapeutic options for NCLs 
Most treatment strategies for LSDs, including the NCLs, are based on the seminal observation that 
small amounts of lysosomal proteins and enzymes are secreted and can be recaptured and targeted 
to the lysosomes of adjacent and distal enzyme-deficient cells (Fratantoni et al., 1968). Enzyme 
replacement and gene therapies take advantage of this physiologic lysosome-specific trait termed 
‘cross-correction’, and the normal lysosomal enzyme trafficking system. Nascent lysosomal enzymes 
are synthesised and glycosylated in the rough endoplasmic reticulum (RER) before undergoing 
vesicular transport to the Golgi apparatus for post-translational modification including the addition 
of mannose and/or mannose-6-phosphate (M6P) moieties (Kornfeld, 1987). These modified proteins 
then bind integral membrane mannose-6-phosphate receptors (M6PR) in the Golgi and the majority 
are trafficked to the mature lysosome. However 5 - 20% of the M6P-modified enzymes are secreted 
extracellularly and are taken up by neighbouring cells through a M6PR-mediated endocytic clearance 
pathway (Kaplan et al., 1977). The plasma membrane receptors involved are the cation-independent 
M6PR (Kornfeld, 1987), which is ubiquitously expressed, or the mannose receptor, found only in cells 
of the reticuloendothelial system (Achord et al., 1978) and both mediate the endocytosis and 
subsequent lysosomal targeting of the secreted enzymes. 
Fortunately for therapy, the amount of enzyme needed in the lysosome for phenotypic correction of 
an individual cell is only a small percentage of ‘normal’ amount. It is widely accepted that enzyme 
activity representing as little as 1 - 5% of normal levels in the CNS can be sufficient to rescue 
phenotype in experimental models of LSD (Sands & Davidson, 2006). Successful treatment will 
however require direct therapy to, or systemic therapy that targets, the CNS. One of the greatest 
challenges is bypassing the blood brain barrier to repair or prevent the neurodegeneration and 
restore the CNS functionality. 
1.6.1 The blood brain barrier 
The blood brain barrier (BBB) separates the brain, spinal cord and CSF from the blood and represents 
a major obstacle to the delivery of therapeutics to the CNS. It is a network of cerebral blood vessels 
lined by endothelial cells and supporting cells, such as astrocytes, neurons, pericytes and perivascular 
microglia. The blood capillaries of the BBB are rarely more than 8 to 25 m from each neuron 
(Schlageter et al., 1999). Endothelial cells of the BBB differ from those elsewhere in the body, by 
forming a physical barrier through continuous intercellular tight junctions, with low endocytic activity 
and thus extremely low rates of vesicular transport and permeation. The BBB has been reported to 
deprive the brain of greater than 98% of neurotherapeutic compounds in visceral circulation 
(Pardridge, 2002). Excluded are large or hydrophobic molecules, such as viruses or conventional gene 
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vectors, large pharmaceuticals and corrective proteins or enzymes, which cannot passively cross the 
BBB from the blood circulation to the neural tissues (Scherrmann, 2002).  
1.6.2 Enzyme replacement therapy 
Enzyme replacement therapy (ERT) typically involves repeated (life-long) intravenous administration 
of an exogenous lysosomal enzyme into affected patients. From the bloodstream, the recombinant 
enzyme enters enzyme-deficient cells, through the secretory pathway described above, partially 
restoring deficient lysosomal enzymatic function with subsequent reversal of tissue pathology. This 
strategy has been successful in some non-neuropathic LSDs, and Food and Drug Administration 
(USA)-approved ERTs are now available for Fabry, Gaucher and Pompe diseases as well as 
mucopolysaccharidosis (MPS) types I, II, and VI (reviewed by Ohashi, 2012). Unfortunately, in some 
patients, repeated ERT administration has triggered immune responses to the infused enzyme, 
blocking efficacy and neutralising product activity (Wang et al., 2008). Moreover, although ERT 
strategies effectively treat the visceral manifestations of LSDs, the enzymes in systemic circulation 
either do not traverse the BBB or in therapeutic quantities, and hence do not resolve the neuropathic 
disease (Sands, 2014).  
ERT strategies are being explored in the NCLs but are likely to only be effective for the subtypes 
involving soluble proteins (e.g. CLN1, 2, 5, 10 and 13). To circumvent the BBB limitations, deficient 
enzyme has been administered directly to the CSF through intracerebroventricular (ICV) delivery in a 
naturally occurring canine model of CLN2. This approach has proved successful, with widespread 
distribution of active enzyme through the brain and reduced neuronal storage (Vuillemenot et al., 
2011) and attenuation of brain atrophy, neurological and cognitive decline and increased lifespan in 
CLN2 affected Dachshunds following biweekly recombinant human tripeptidyl peptidase-1 (rhTPP1) 
ERT (Katz et al., 2014). Subsequently, a clinical study evaluating the potential therapeutic value of 
rhTPP1 administration into the CSF of children with CLN2 disease was initiated (NCT01907087, 
http://clinicaltrials.gov). Promising interim results reported that ICV-administered rhTPP1 was well 
tolerated and described stabilization in disease progression for some of the treated patients (Schulz 
et al., 2016).  
1.6.3 Gene therapy 
Gene therapy offers an alternative or supplementary option to ERT for the NCLs which have 
significant CNS lesions. It can pertain to either the ex vivo genetic modification of donor cells or to 
the introduction of a correct copy of a defective gene into host cells in vivo for therapeutic benefit. 
For the NCL forms resulting from mutations in soluble lysosomal proteins (CLN1, 2, 5, 10 and 13) 
genetic correction of a small subset of neural cells may be sufficient to correct large regions of the 
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CNS via diffusion through the brain parenchyma and the phenomenon of “cross-correction”. Gene 
therapy is considered less likely to correct the deficit of membrane bound NCL proteins (CLN3, 6, 7, 8 
and 12), unless they are involved in the processing of diffusible agents, such as neurotrophic factors, 
which can rescue neighbouring cells. Despite this, gene therapy using viral vectors is being 
investigated for membrane-bound and soluble protein forms of NCL as a potential treatment, with 
the hope that sufficient expression of the corrective gene product could compensate for the disease-
related deficiency. 
Viral-mediated gene therapy uses modified viruses to infect a small percentage of target host cells, 
delivering a corrective copy of a mutated gene to these cells, and hijacking the host cell machinery to 
make functional therapeutic protein to either stabilise or reverse a clinical disease state. The viruses 
used are termed vectors and have been rendered replication-deficient by the deletion of the 
structural and packaging (replication) elements of the viral genome. The only viral DNA sequences 
remaining in the viral vector are the terminal repeats into which the therapeutic constructs are 
packaged (described below). Such a virus can efficiently enter a cell, but can neither cause a ‘viral 
disease’ nor replicate. The key features of some viral vectors currently in use for gene therapy of the 
LSDs are described in Table 1.4. HIV-1-derived lentiviral and adeno-associated viral vectors, encoding 
either a reporter gene or therapeutic NCL genes were delivered to the sheep CNS in vivo in the 
current study. These vectors will be discussed in greater detail. 
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Table 1.4    Biological properties of gene therapy viral vectors in current use for the lysosomal storage diseases 
* The Journal of Gene Medicine Clinical Trial site, http://www.abedia.com/wiley/ (May 2016). Other platforms make up the remaining 48 % of viral vectors used in human clinical 
trials (e.g.retrovirus) 
 
 
Viral vector Adenovirus Adeno-associated virus (AAV) Lentivirus (HIV) Retrovirus 
Family Adenoviridae Parvoviridae Retroviridae Retroviridae 
Pathogenicity of parent virus Yes No Yes Yes 
Transgene capacity 37 kB 4.7 kB ssAAV 
2.2 kB scAAV 
8 - 10 kB 8 kB 
Genome dsDNA ssDNA ssRNA ssRNA 
Chromosomal integration No (episome) No (circular episome) Yes Yes 
Transduction of non-dividing cells Yes Yes Yes Yes 
Immunogenicity High Low Limited Limited 
Duration of expression Transient Stable Stable Stable 
Use in human clinical trials * 21.7% 6.2% 5.2% 18.9% 
Advantages Large packaging capacity 
Transient delivery  
Low host immunogenicity 
Persistent delivery 
Low host immunogenicity 
Persistent delivery 
Low host immunogenicity 
Persistent delivery 
Limitations Host immunogenicity 
Transient delivery 
Small packaging capacity Risk of insertional mutagenesis 
Immunodeficiency origin 
Risk of insertional 
mutagenesis 
Relies on target cell mitosis 
2
5
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A lentiviral vector uses receptor-mediated cell entry and once it is inside the host cell, the reverse 
transcriptase enzyme, encoded by pol, produces a double stranded DNA copy of the RNA viral 
genome (Temin & Baltimore, 1972). Lentiviral DNA enters the nucleus and is integrated directly into 
the host genome by the virally encoded integrase enzyme. This has both advantages and 
disadvantages. Integration allows persistence within the host cell for its lifetime, through repeated 
cell division, providing permanent expression of the gene delivered in host cells. On the other hand, 
the chance of insertional mutagenesis is increased with integrating vectors. This risk was highlighted 
following ex vivo gene therapy trials using a murine leukaemia retrovirus to treat X-linked severe 
combined immunodeficiency (SCID) (Cavazzana-Calvo et al., 2000; Gaspar et al., 2004). The clinical 
benefit was tempered by the development of T-cell acute lymphoblastic leukaemia in 20% of patients 
that was directly attributable to the vector randomly integrating next to, and activating, a specific 
oncogene (Hacien-Bey-Abina et al., 2003; McCormack & Rabbitts, 2004). Fortunately lentiviral 
vectors have a lower tendency to integrate into potentially carcinogenic hot-spots than other 
retroviruses (Cattaglio et al., 2007). 
1.6.3.2 Adeno-associated viral vectors  
Adeno-associated viruses (AAVs) are small (20 - 25 nm), non-enveloped single stranded DNA 
parvoviruses. Although AAVs naturally infect humans and other species, they have no known 
pathogenicity (Lin & Ertl, 2008). They are classified as a dependovirus, as they rely on co-infection 
with helper virus (e.g. adenovirus or herpesvirus) to complete the viral life cycle and cause a 
productive infection (Atchison et al., 1965; Buller et al., 1981; Bauer & Monreal, 1986; Conway et al., 
1997).  
Numerous different AAV serotypes have been identified with variable CNS tropism. After direct 
delivery to the murine brain parenchyma, AAV serotypes 1, 2, 7, 8, 9 and rh10 primarily result in 
neurotropism whilst AAV5 is more efficient in transducing neurons and glial cells to a lesser extent 
(Cearley & Wolfe, 2006; Gray & Samulski, 2011). Of these, AAV1, AAV9 and AAVrh10 exhibit superior 
spread and transduction efficiency. AAV4 preferentially targets astrocytes, even after intrastriatal 
injection, and including those astrocytes in the subventricular zone lining the lateral ventricles after 
ICV delivery (Davidson et al., 2000; Burger et al., 2004; Liu et al., 2005a, 2005b; Cearley & Wolfe, 
2006; Markakis et al., 2010).  
Recombinant AAV vectors have risen to prominence for the treatment of the CNS disease associated 
with LSDs, because of their ability to transduce non-dividing post-mitotic cells and to confer long-
term stable gene expression for up to 10 years (Mingozzi & High, 2013), with minimal associated 
inflammation or toxicity (McCarty et al., 2004; Gonçalves, 2005). Therapeutic effectiveness using AAV 
has been shown recently in animal models of a number of LSDs, including α-mannosidosis, GM1-
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gangliosidosis, GM2-gangliosidosis (Tays-Sachs and Sandhoff diseases), Krabbe disease, 
metachromatic leukodystrophy, MPS types I, IIIA, IIIB, and VII,  and Niemann-Pick A as well as the 
CLN2 form of NCL (e.g. Liu et al., 2005b; Sondhi et al., 2005, 2012; Fu et al., 2011; Haurigot et al., 
2013; McCurdy et al., 2015; Ribera et al., 2015; Rockwell et al., 2015). 
The genes that encode packaging (replication) and structural proteins are removed from the viral 
genome to generate therapeutic recombinant AAV vectors and are replaced with a transgene 
expression cassette (Figure 1.6). Removal of the viral genes renders the vectors non-integrative, 
replication-deficient and minimizes potential immune response risks. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6    Structure of the wild-type adeno-associated virus (AAV) and recombinant AAV genome 
A. Wild-type AAV has a linear single-stranded DNA genome of ~4.7 kb, containing two open reading 
frames, rep required for replication and virion assembly and cap that encodes the structural viral 
capsid proteins. The virus does not encode a polymerase and uses cellular polymerases for genome 
replication. The genes are flanked by two 145 bp inverted terminal repeats (ITRs) which are required 
as signals for packaging.  
B. Recombinant AAV vectors lack the rep and cap viral genes, hence rendering them replication-
deficient. Instead the gene of interest, an exogenous enhancer and/or promoter and a 
polyadenylation signal (pA) reside between the AAV ITRs, the only viral sequences retained from the 
parent virus. 
 
 
AAVs enter the cell through receptor mediated endocytosis. Inside the cell, an AAV translocates its 
genome into the nucleus where it is made into double-stranded DNA. This DNA persists as an 
episome with only sporadic transgenic integration, thereby reducing the potential for insertional 
mutagenesis and oncogenesis. No evidence for tumorigenesis from AAV vectors was reported in a 
large study of over 600 mice (Bell et al., 2005), although an increased incidence of hepatocellular 
carcinoma (HCC) has been noted in several long-term mouse studies following systemic 
administration of AAV vectors (Bell et al., 2006; Donsante et al., 2007). AAV2-related insertional 
mutagenesis has also been reported in human HCC (Nault et al., 2015) yet this remains contentious, 
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being found in only 7% of HCC tumours compared with 21% of adjacent normal liver tissue samples 
(Berns et al.,  2015). 
1.6.4.1    Gene therapy approaches to bypass the blood brain barrier  
The most direct gene therapy stratagem developed to anatomically bypass the BBB is via direct 
stereotaxic injection of viral vectors into the brain parenchyma. This approach has been used in a 
number of animal model studies (Di Domenico et al., 2009; Jarraya et al., 2009; Haurigot et al., 2013), 
including the current study, as well as in human gene therapy trials for infantile NCL (INCL) (Worgall 
et al., 2008) and MPSIIIA (Tardieu et al., 2014). An alternative mechanical way is to administer viral 
vectors into the CSF of the ventricular system, allowing distribution through the CSF flow and hence a 
more global delivery. This approach is tested in sheep in the current study and has been gaining in 
popularity as a therapeutic delivery route (Haurigot et al., 2013; McIntyre et al., 2014; Katz et al., 
2015).  
The BBB can also be breached biologically. Certain AAV serotypes can cross the intact BBB, including 
AAV9 into neonatal mice (Foust et al., 2009) and into adult non-human primates (Gray et al., 2011), 
as well as AAVrh8 and rh10 into adult mice (Yang et al., 2014). A number of these vectors can also 
undergo axonal transport, mainly in the retrograde but sometimes the anterograde direction. 
Vectors can enter the synaptic terminals and be transported in the retrograde direction within axons 
to the cell somas where transgene expression is induced. Targeted delivery to regions rich in efferent 
and afferent projections has the advantage of transferring genes to cells in regions distal to the 
vector injection site, improving efficacy. For example, AAV serotypes 1, 9 and rh10 can be 
disseminated along axonal projections in both directions after injection into the ventral tegmental 
area in mice, a region in the midbrain with known neural circuitry (Cearley & Wolfe, 2007).  
1.6.4 Gene therapy in the NCLs 
Most reported NCL cases are caused by mutations in the CLN1, CLN2 and CLN3 genes. The former 
two encode soluble lysosomal proteins of known function and as such are regarded to be the most 
amenable to gene or enzyme replacement therapies. The first demonstration of gene therapy in NCL 
was performed by Sands and colleagues, using intracranial injection of AAV2 expressing human CLN1 
cDNA into a neonatal mouse model of infantile NCL (INCL) (Griffey et al., 2004). Approximately 15% 
of normal enzyme activity was detected at the injection sites, with partial correction of phenotype. 
Despite functional improvements, there was no increase in longevity in AAV2-CLN1 treated INCL mice 
(Griffey et al., 2006).  
Therapeutic studies in late infantile NCL (LINCL) are well advanced. Direct central nervous system 
delivery of AAV2 expressing human CLN2 cDNA into mice, rats and non-human primates mediated 
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long-term gene expression in the brain with partial correction of hallmark NCL cellular pathologies 
(Haskell et al., 2003; Hackett et al., 2005; Sondhi et al., 2005; Passini et al., 2006; Cabrera-Salazar et 
al., 2007). The CLN2 gene encodes a lysosomal serine protease, tripeptidyl peptidase-1 (TPP-I), which 
is secreted from expressing cells in vivo and endocytosed into non-expressing cells, trafficking via the 
classical mannose-6-phosphate receptor mechanism (Lin & Lobel, 2001). TPP1 activity at the injection 
sites after intraparenchymal (IP) delivery into the various animal models ranged from 0.5- to 7-fold 
higher than endogenous levels (Haskell et al., 2003; Passini et al., 2006) indicating the feasibility of 
this approach in the clinic. The resultant Phase I clinical trial (NCT00151216; https://clinicaltrials.gov) 
(Crystal et al., 2004), administering AAV2-hCLN2 through 12 parenchymal injections into the CNS of 
10 children with moderate to severe LINCL phenotype, demonstrated a reduction in the rate of 
neurological decline, but not a complete halt in pathology (Worgall et al., 2008). Minor, ephemeral 
humoral responses to the vector were reported in 40% of subjects. This study highlighted that the 
clinical course was not the ideal estimate of therapeutic efficacy, given the different mutations and 
considerable variation seen between individual humans suffering from the same NCL variant. 
The safety and efficacy of a second-generation AAVrh.10, a serotype derived from the rhesus 
monkey, to mediate CLN2 delivery was studied in a number of animal models (Sondhi et al., 2007, 
2012). Recent initiation of parallel Phase I and Phase I/II clinical trials for children with mild to 
moderate and moderate to severe cases and to uncommon genotypes of LINCL respectively followed 
(NCT01161576, NCT01414985). Children received delivery of one of two viral vector doses (2.85 x 
1011 or 9 x 1011 viral genomes (vg) total) into 12 parenchymal locations through six entry sites. No 
adverse safety events were noted but reports on efficacy will not be made until the completion of 
the trial in 2016 (Crystal, 2014). 
Development of gene therapies for the lesser common NCLs has long been a major initiative within 
the BARN research programme (Palmer et al., 2015). Neural cell cultures, isolated from foetal sheep 
(Kay et al., 1999), have proven beneficial in testing the efficacy of gene therapy prior to whole animal 
studies (Linterman et al., 2011; Hughes et al., 2014a). The transgenic expression, transduction 
efficiency and cell tropism of lentiviral vectors have been tested in mixed cultures of neural 
precursors (neuroblasts), mature neurons, astrocytes and microglia generated from both South 
Hampshire CLN6 and Borderdale CLN5 affected sheep. Lentiviral vectors, pseudotyped with VSV-g 
and under the control of a constitutive myeloproliferative sarcoma virus promotor (MND) were used 
to deliver a green fluorescent protein (GFP) reporter gene to control and CLN6 affected neural 
cultures (Linterman et al., 2011). A greater tropism for neuronal and neuroblast cells was seen over 
glia. More recently, a significant diminution of storage body accumulation was observed in CLN5-
deficient neural cells after transduction with a CLN5 expressing lentiviral vector (Hughes et al., 
2014a). Both findings supported the use of lentiviral mediated gene transfer in vivo. 
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A program of direct lentiviral injections into sheep brains in vivo was initiated. Despite positive 
indications from murine studies (Fu et al., 2003), no transduction of cells followed intracisternal 
injections of lentiviral GFP constructs in sheep, however columnar infusion into the cortical 
parenchyma resulted in stable yet localised GFP transduction evident up to 80 day post-injection 
(Linterman et al., 2011). Of importance was the targeted transduction of ependymal and 
subependymal cells along the extent of the ventricular surface, including type B astrocytic cells, 
thought to be equivalent to the bona fide human adult neural stem cells (Doetsch et al., 1999). These 
findings were encouraging for human translation. Given the restricted parenchymal spread of 
lentiviruses (Cetin et al., 2006; Lerchner et al., 2014), an alternative ICV injection strategy was 
attempted in the current study. Targeted correction of the ependyma lining the ventricles could 
result in protein secretion into the cerebral spinal fluid (CSF) for circulation to the entire CNS, whilst 
transduced neuroblasts could provide an alternative route for the spread of the gene product to the 
degenerating cortex in NCL patients via the chain migration of neuroblastic granule cells (see Section 
1.5.4). The reported long-term transduction efficiency and spread of AAV vectors in the CNS, 
described above, also supported their inclusion in the therapeutic trials in ovine NCL detailed in this 
thesis. 
 
  

 33 
transduce target cells, causing them to express the corrective gene, and provide the surrounding 
cells and tissue with a continuous supply of soluble functional enzyme. Once secreted, the corrective 
enzyme can be endocytosed by neighbouring enzyme-deficient cells via the return plasma membrane 
mannose-6-phosphate receptor pathway, potentially correcting their deficiency (see Section 1.6). In 
vitro cross-correction studies and in vivo preclinical studies in animal models support the hypothesis 
that restoration of 5 – 10% of normal enzyme activity would be sufficient to facilitate normal cellular 
function (Sands & Davidson, 2006), indicating that only a subset of cells may need to be genetically 
modified to secrete the deficient enzyme to cross-correct other cells at a distance.  
In contrast, defects in membrane-bound proteins are predicted to be harder to correct, unless the 
transmembrane protein is involved in the processing of secreted proteins. Chimeric studies in sheep 
have shown this may be the case in ovine CLN6 (Barry, 2011). Chimeras, generated from normal and 
CLN6 affected sheep embryos, showed no evidence of neurodegeneration or disease-associated glial 
activation, despite having varied ratios of normal to affected tissue composition and the sheep 
retained their vision, long after natural disease progression in affected animals. This intimates a 
neuroprotective role of normal cells over diseased cells and suggested that attempts at gene therapy 
may be warranted even in the case of membrane-bound defects.  
2.2 Research aims and hypotheses 
The first aim of this study was to elucidate the pathological changes within the diseased brain and to 
define windows for possible therapeutic intervention. The preclinical and progressive changes in the 
CNS of the ovine CLN6 model have already been described (Oswald et al., 2005, 2008; Kay et al., 
2006) however data from the Borderdale CLN5 model are presently limited, and a proper definitive 
time course neuropathological study was required. The current study sought to provide comparative 
and quantitative histological and immunohistochemical measures of the sequential changes in both 
disease models relative to the normal brain. The variables analysed were cortical thickness, 
astrocytosis, microglial activation, storage body accumulation and neurogenesis. Expression of the 
endogenous CLN5 and CLN6 proteins in the normal sheep brain was also examined for the first time. 
Results are described in Chapter 4.  
The second aim was to test the efficacy and tropism of adeno-associated virus serotype 9 (AAV9) as a 
gene transfer vector in the normal sheep brain. Naïve, juvenile sheep received injections of AAV9 
expressing a marker gene (green fluorescent protein; GFP) into the brain parenchyma or cerebral 
lateral ventricles and GFP expression through the CNS was analysed one month later (Chapter 5).  
Lastly, Chapters 6 and 7 describe longitudinal in vivo monitoring of the efficacy of lentiviral- and 
AAV9-mediated delivery of the therapeutic NCL genes to pre-clinical CLN5 and CLN6 affected sheep.  
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administration of 50 mg ammonium molybdate and 500 mg soldium sulphate for 3 week periods to 
abrogate concentrate-feed induced copper toxicosis. Sheep were housed under a natural daylight 
regimen, monitored daily with any abnormal behaviours recorded, and weighed monthly. Every 6 
months, jugular blood samples were sent to Gribbles Veterinary Pathology, Christchurch, NZ for 
plasma copper testing, and  haematological and biochemical analysis for signs of liver or other organ 
damage. 
3.1.2 Genotyping 
The causative mutations of ovine CLN6 and CLN5 have been identified (see Sections 1.3.2 and 1.4.2) 
and preclinical molecular genetic diagnoses developed (Tammen et al., 2006; Frugier et al., 2008).  
3.1.2.1    Ovine CLN6 genotyping 
The large disease-causing mutation in the South Hampshire sheep falls in the 5’ region of the gene, a 
very difficult region to amplify by PCR (Mohd Ismail, 2014). Instead an indirect DNA test was used to 
genotype lambs born into the CLN6 flock. This test exploits a silent single nucleotide polymorphism 
marker (c.822G>A) in the coding region of CLN6, 111 bp downstream of the 5´ end of exon 7, which 
introduces a differential cut site for the restriction enzyme Hae II (Tammen et al., 2006). This silent 
substitution shows tight linkage with the disease (LOD score of 13.3,  = 0.01). In brief, amplification 
from genomic DNA (as above), enzymatic cleavage and agarose gel separation of the products 
allowed allelic discrimination (Figure 3.1). The CLN6 South Hampshire flock has been configured so 
that all normal sheep used carry only the G allele, affected sheep carry only the A allele and South 
Hampshire heterozygotes carry both. This test has proven to be entirely reliable over 15 years and 
800 sheep, as judged by subsequent clinical and pathological diagnosis. 
 
 
3.1.2.1 Ovine CLN5 genotyping  
 
Figure 3.1    An indirect test for the preclinical diagnosis of ovine CLN6 
Restriction enzyme detection of the discriminatory c.822G>A polymorphism in ovine CLN6 in South 
Hampshire sheep (Tammen et al., 2006). A 251bp PCR product cleaved with Hae II results in a 
differential banding pattern for unaffected (GG), heterozygous (GA) and CLN6 affected (AA) sheep 
Lane 1 contains a size standard with 300, 200 and 100 bp bands visible.  
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3.1.2.2    Ovine CLN5 genotyping 
The ovine CLN5 disease is caused by a nucleotide substitution at a consensus splice site in the CLN5 
gene (c.571+1G>A) with subsequent excision of exon 3. This mutation was detected by either 
reverse-transcription PCR amplification of mRNA over the exon 3/ intron 3 splice site or by 
sequencing a PCR product amplified from genomic DNA which spans this region (Frugier et al., 2008) 
(Figure 3.2). In brief, RNA isolated from whole blood using PureLink Total RNA blood kits (Invitrogen, 
Carlsbad, CA, USA) was converted to cDNA using SuperScript III RNase H reverse transcriptase 
(Invitrogen) and oligo d(T)15 primers. CLN5 cDNA was amplified with primers in exons 2 and 4 to give 
a differential banding pattern on agarose gel electrophoresis (Figure 3.2A). 
Alternatively, sheep genomic DNA was extracted from heparinized venous blood by NaCl 
fractionation (Montgomery & Sise, 1990), from Whatman FTA cards (Whatman, Brentford, 
Middlesex, UK) or from EDTA blood samples using QIAamp DNA mini extraction kits (Qiagen, Hilden, 
Germany). CLN5 gDNA was amplified with primers in exon 3 and intron 3 and the 538 bp PCR product 
sequenced at the Lincoln University Sequencing Facility, using Big Dye terminator v3.1 Cycle 
sequencing (Applied Biosystems, Foster City, CA, USA). Pre-sequencing clean-up was performed with 
CleanSEQ Dye-Terminator removal kits (Agencout Bioscience Corporation, Beverly, MA, USA) and 
samples were sequenced on an Applied Biosystems 3130xl Genetic Analyzer (Figure 3.2B). 
 
 
 
 
 
 
 
Figure 3.2    Alternative methods for the genetic diagnosis of ovine CLN5  
A. Reverse-transcriptase PCR of CLN5 between exons 2 and 4 shows retention of exon 3 in normal 
transcripts (647 bp) whilst exon 3 is lacking in affected transcripts (421 bp). Both bands are seen 
in the heterozygote. Sequencing the two bands confirmed this observation (Frugier et al., 2008).  
B. Comparative sequence analysis of normal, affected and heterozygous CLN5 PCR products from 
genomic DNA. The affected sheep electropherogram shows the substitution c.571+1G>A (*). 
Note the presence of both alleles (G/A) in the heterozygote Borderdale animal. The arrow 
indicates the exon 3/intron 3 boundary (Frugier et al., 2008). 
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3.2 Gene therapy protocols 
Whilst this section describes the general gene injection strategy, specific protocols, including cloning 
of the NCL transgenes, delivery doses and target sites are included in the appropriate chapters. 
3.2.1 Viral constructs and in vitro analysis 
Full-length ovine CLN5 (GenBank accession number NM_001082595; Frugier et al., 2008) and CLN6 
(GenBank accession number NM_001040289; Tammen et al., 2006) cDNA was cloned at Lincoln 
University (see Sections 6.2.3 and 7.2.3). Both lentiviral and AAV9 constructs expressing these cDNAs 
were produced, titred and in vitro analyses performed by Batten Animal Research Network (BARN) 
collaborators, led by Dr. Stephanie Hughes based at the Otago Viral Vector Facility, University of 
Otago (Dunedin, New Zealand). The viral constructs were then transported to Lincoln University for 
in vivo administration to the sheep brain. 
3.2.1.1 Lentiviral constructs 
HIV-1 derived lentiviral plasmids (Meyerrose et al., 2008) expressing ovine CLN5 or CLN6, under the 
control of the myeloid proliferative U3 enhancer element (MNDU3) and pseudotyped with the 
vesicular stomatitis virus glyocprotein (VSV-G), were packaged using a third generation packaging 
system (Zufferey et al., 1998). Briefly, 293FT cells (Life Technologies, Carlsbad, CA, USA) were 
transfected with plasmids containing the NCL transgene, packaging and VSV-G envelope genes in 
OptiMEM containing Lipofectamine-2000 (Life Technologies) (Linterman et al., 2011). Media was 
recovered 48 hours post-transfection, concentrated by ultracentrifugation at 25,000 rpm for 90 min, 
resuspended in PBS containing 40 mg/mL lactose, and stored at -80C until required. Functional viral 
titres were determined by serial dilutions on HT1080 cells (ATCC, Manassas, VA, USA) 
3.2.1.2 Recombinant adeno-associated virus serotype 9 (AAV9) constructs 
Recombinant AAV (serotype 9; AAV9) constructs of ovine CLN5 or CLN6 were produced, under the 
control of the MNDU3 promoter. In brief, 293FT cells (Life Technologies) were triple transfected with 
plasmids encoding the CLN5 or CLN6 transgene; the pAAV2/9 packaging plasmid (containing AAV2 
rep and AAV9 cap viral genes); and the pAd delta F6 Helper plasmid containing the adenoviral genes 
required to drive AAV replication (University of Pennsylvania, Philadelphia, PA, USA). Cells were 
harvested 48 hours post-transfection, and cell pellets frozen at -80 °C before sodium deoxycholate 
and benzonase-driven cell lysis and iodixanol gradient purification. Purified virus was concentrated in 
a centrifugal concentrator and stored at -80 °C. Genomic titres were determined by quantitative real-
time PCR analysis of woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) 
expression (Clark et al., 1999). Functional titres were were determined by serial dilutions on 293FT 
cells, with confirmation by in vitro immunofluorescence 72 h post-infection (McClure et al., 2011).  
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3.2.2 In vivo viral injections 
The design, planning and stereotactic gene injections were carried out by a team consisting of Nadia 
Mitchell, Martin Wellby and Dr. Graham Barrell at Lincoln University, based on stereotactic surgical 
procedures described previously (Linterman et al., 2011). 
Sheep were fasted overnight. Intravenous anaesthesia was induced with a mixture of ketamine 
hydrochloride (7.5 mg/kg live weight (LW); PhoenixPharm Distributors Ltd, Auckland, NZ) and 
diazepam (0.3 mg/kg LW; Ilium, Troy Laboratories NZ Pty Ltd, Auckland, NZ). Sheep were then 
intubated (8 – 9.5 mm cuffed endotracheal tube) and maintained on isoflurane inhalation (2 – 4% in 
oxygen), within a closed circuit system. A dose of buprenorphine hydrochloride (Temgesic, 324 μg/ 
animal; Reckitt Benckiser (NZ) Ltd, Auckland, NZ) was given intramuscularly for analgesia. 
With the sheep in the sternal recumbency position, the head was secured for injection in a 
stereotactic frame (Kopf, model 1630; David Kopf Instruments, Tujunga, CA, USA) and the surgical 
site clipped and prepared for surgery by repeated scrubs with povidone-iodine solution (Biodine, 
VetPharm NZ Ltd, Auckland, NZ), an alcohol spray and subsequent draping. Following a medial skin 
incision and retraction of the underlying musculature and fascia, bregma (the junction of the sagittal 
and coronal sutures on the top of the skull) was identified. Three mm holes were drilled through the 
frontal and/or parietal bones at co-ordinates relative to bregma (Figure 3.3, I1 and I2). These co-
ordinates and the needle depths differed slightly for each study, depending on the age of the animals 
and the underlying parenchymal or ventricular target, and are described in the appropriate chapters. 
For the parenchymal injections, two 25 μl Hamilton syringes (Harvard Apparatus, Holliston, MA, USA) 
with 26 gauge needles were lowered into each hemisphere of the brain using a stereotaxic 
manipulator. Two μl of viral vector solution was infused at the greatest depth over 30 secs, then the 
complete needle unit was withdrawn 0.5 mm and the process repeated until the full volume was 
discharged. The syringe was left in place for 5 min after the specified dose was administered to 
ensure tissue penetration, before slow retraction. 
The intracerebroventricular injections used the same drill holes as the parietal injections but the 
needle was directed 10° rostral for the latter to avoid following the same needle tracks. To establish 
the depth of the tissue-ventricle interface, a 500 μl Hamilton syringe with a 26 gauge needle filled 
with sterile saline was lowered into the brain. The ventricular interface was indicated by the positive 
flow of CSF once the ventricle was reached. Viral vector solution was infused at a rate of 0.1 mL/ min. 
After the full volume had been dispensed, the syringe was left in place for a further min before 
removal. 
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3.3 Clinical progression and staging of ovine NCL 
The methodology for clinically staging neuronal ceroid lipofuscinosis was based on previous clinical 
descriptions of the ovine form of the disease (Mayhew et al., 1985; Westlake et al., 1995; Cook et al., 
2002) and neurological prototypes in goat (Konold et al., 2010) and sheep (Passler et al., 2012). The 
general health and neurological status of normal (heterozygous) and affected lambs of both 
genotypes were assessed monthly in conjunction with the affected lambs which had undergone CLN5 
or CLN6 gene therapy. Live weight and body condition score data were also collected. 
Initially a full neurological examination following the method of Konold (2010) was carried out on 
each sheep. Many of the parameters examined, such as the five spinal reflexes and some of the 
cranial nerve reflex tests, were not found to be helpful in the diagnosis of NCL hence these 
components were abandoned and a modified procedure was adopted (Appendix A). 
3.3.1 Neuro-opthalmic and auditory testing 
In the adapted testing paradigm, sheep were handled individually for basic neuro-opthalmic 
examination including assessment of the cranial nerves (CN) involved in ocular function (Optic II, 
Oculomotor III, Trigeminal V and Facial VII), the central visual pathways and the visual cortex. The 
tests (and their possible points of lesion) included: 
1. Menace response (CN II and VII, visual cortex and cerebellum), characterised by an eyelid 
blink, ocular retraction and head aversion as the examiner rapidly moved a finger toward the 
eye from a medial and rostral direction. 
2. Palpebral and corneal reflexes (CN V and VII), which elicited involuntary blinking of the 
eyelids by touch stimulation of the lateral or medial canthi and the cornea respectively. 
3. Direct and consensual pupillary light responses (CN II and III, and central visual pathways 
excluding the visual cortex), indicated by the constriction of both pupils upon shining a light 
beam in a nasotemporal direction toward the temporal region of the retina. 
4. Dazzle reflex (CN II and VII, retina, and subcortical visual pathways), characterised by an 
involuntary aversion response (blinking, globe retraction, third eyelid protrusion and/or head 
movement) to intense illumination of the eye.  
5. Visual tracking (CN II, visual cortex and all areas involved in motor function), evidenced by 
following a visual stimulus without auditory or olfactory clues. 
Auricular (acoustic startle) reflexes (CN VII) - the movement of the pinna in response to a loud noise 
(handclap) - were also tested. Visual and auditory reflexes were assessed as normal, decreased or 
absent. Mentation, gait, head carriage and postural traits, as well as manifest tremor or seizure 
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onset, were assessed while sheep were herded up a set of stairs and a graded slope to the testing 
facility. The functionality of the optic cranial nerve II, visual cortex and all cerebral areas associated 
with motor function were subsequently assessed by behavioural vision testing through negotiation of 
a maze (see Section 3.4).  
Finally the sheep were assigned a clinical rating score from the scale in Table 3.1 by two independent 
evaluators (including the author). Where there was a discrepancy in scores between assessors, the 
scores were averaged.  
Table 3.1    Clinical rating criteria for assessing neurological dysfunction in sheep 
Clinical score Clinical phenotype Clinical status  
5 Normal Normal 
4 Pre-clinical Low head carriage 
Propensity to crouch, baulk and stumble 
Normal visual and acoustic reflexes 
3 Blind Head tilt/stargazing 
Visual deficits 
Decreased or lost menace (blink) response 
Loss of visual tracking 
Reduced herding 
2 Overt/neurological Onset of motor, cognitive and proprioceptive deficits* 
Decreased startle to auditory stimuli 
Decreased pupillary light reflex 
Wide stance 
1 Advanced Progressive disease 
+/- induced tetanic seizures 
Localised tremors 
Minimal pupillary light and absent dazzle reflexes 
Repetition in activities (compulsive circling) 
Low mentation 
Somnolence 
Non-responsiveness to external stimuli 
Loss of body condition 
Hindlimb paresis 
0 Terminal Spontaneous tetanic seizures 
* Motor and proprioceptive dysfunction was evidenced by ataxia, stumbling, dragging of the feet, and 
intermittent episodes of localised muscle tremors (particularly of the ears, eyelids, lips, and hind limbs). 
Behavioural changes from this age included a reduced awareness of surroundings, repetitive actions (aimless 
circling, teeth grinding) and feeding abnormalities (dribbling and inefficient or sham eating) 
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3.4 In vivo cognitive maze testing  
A simple closed-field maze behavioural task was utilised to assess the visual and cognitive faculties of 
normal (heterozygous), NCL deficient sheep, and affected sheep of both genotypes who had received 
gene therapies. A 15.5 m x 3.5 m outdoor maze was constructed beside wooden yards between two 
existing buildings (Figure 3.4), with a start box and goal pen positioned at opposite corners of the 
maze. The wooden yards were 1.2m high and covered in opaque shade cloth. Internal barriers were 
positioned as visual obstacles around which the sheep manoeuvred to reach the goal area. These 
moveable fence panels were open-barred to enable animals to view conspecifics at the opposite end 
of the maze, providing motivation for sheep to traverse the maze and join their flockmates.  
 
 
 
 
Figure 3.4    Configuration of the maze 
Sheep for testing were housed in a group pen, before being released individually into a race by a 
handler for entry into the testing arena and maze negotiation. Conspecifics were penned in the 
shaded goal area near the exit. Food, in the form of lucerne pellets, was also available there. A 
drainpipe (5 cm diameter; dashed line) was included as an extra hindrance. The middle gate (dotted) 
alternated from left to right between runs. The handler remained at the entrance during each maze 
run, out of sight of the traversing sheep. 
Maze testing was conducted under daytime photopic light between the hours of 9:00 am and 1:00 
pm. Prior to each test, sheep were given a 15 min habituation period as a group, to allow them to 
explore the testing area. Animals were then randomly allocated, with half used as conspecifics and 
penned in the goal pen at the opposite end of the maze whilst the remainder were housed in the 
group pen near the maze entry. Individual sheep were released from the group pen by a handler, 
entering a race which led onto the maze entry. Timing commenced on entry and the criterion for 
successful completion was exit from the maze in 2 min or less. Reward for completion consisted of 
entry into the goal area with conspecifics and food (lucerne pellets). If an animal failed to traverse 
the maze in less than 2 min, they were steered to the exit by a handler. Sheep negotiated the maze 
twice on each testing day and the configuration of the maze remained unchanged between runs, 
except for the position of the gap at the middle gate, which alternated between left and right to 
reduce a learning effect.  
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Total times required to successfully traverse the maze and any errors committed (failure to enter the 
maze arena unassisted and the sum of time spent in the error zone) were recorded by the handler at 
the time and verified from video footage.  The handler was not blinded to the disease status of the 
sheep but retrospective video analysis and maze grading (Table 3.2) was performed by a second, 
independent investigator in a blinded fashion, to eliminate observer bias.  
Table 3.2    Criteria for assessing cognition and behaviour during maze negotiation 
Maze score Descriptor 
5 Traverse the maze with no pauses or difficulty 
4 Traverse the maze but with small pauses 
3 Traverse the maze with no major difficulty but overt behavioural phenotype* 
2 Traverse the maze with or without pauses, but missed entry 
1 Traverse with errors 
0 Failure to traverse (needs assistance) 
*Behavioural phenotypes included low head carriage, crouching when walking through gateways, self-
spooking, stumbling, circling or a reluctance to walk in and around shadows or across the drainpipe, contact 
with or failure to avoid obstacles 
3.5 In vivo quantitative neuroimaging 
Computed tomography (CT) scans were performed every 2 months on animals who received 
intracranial gene therapy. Sheep were fasted overnight. Anaesthesia was induced with a single 
intravenous injection of a mixture of diazepam (0.5 mg/kg LW) and ketamine (10 mg/kg LW). The 
anaesthetised sheep was then loaded into the CT scanning stretcher in the sternal recumbency 
position, with the feet tucked under the body. Coronal slices 1 mm thick were scanned at 5-mm 
intervals, 120 kV, 160 mA, 2 s on a GE ProSpeed CT Scanner (GE Healthcare, Hyogo, Japan) and 
intracranial volumes were determined by the Cavalieri method from the areas of each slice using 
STAR (Sheep Tomogram Analysis Routines) software (version 3.9; Biomathematics and Statistics 
Scotland (BioSS), Dundee Scotland, and Scottish Agricultural College (SAC), Perth, UK). Intracranial 
volumes from the experimental animals were then compared with historical cohorts of untreated 
affected and heterozygous control sheep of both genotypes. 
Magnetic resonance imaging (MRI) was performed in collaboration with Dr. Tracy Melzer, at the NZ 
Brain Research Institute. Sheep were anaesthetised with higher doses of diazepam (1 mg/kg LW) and 
ketamine (15 mg/kg LW) delivered intravenously, loaded in the supine position into the 3 Tesla HDx 
MRI scanner (General Electric, Fairfield, Connecticut, USA) and scanned.  
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3.6 Ophthalmology and electroretinography 
Ophthalmic examinations were performed on the treated sheep by an independent veterinary 
ophthalmologist (Dr. Steve Heap, McMaster and Heap Veterinary Practice, Christchurch, NZ) who 
was blinded to treatment. Pupils were dilated with a short acting mydriatic agent (Mydriacyl, 
tropicamide 1%; Alcon NZ Ltd) 30 min prior to indirect ophthalmoscopy with a wireless indirect 
headset and a hand held lens. 
Electroretingraphic (ERG) and funduscopic techniques to monitor disease-associated loss of vision 
longitudinally were developed by Katharina Russell (Lincoln University) as part of her PhD studies. 
Both techniques were performed on treated sheep at 27 months of age. Pupils were dilated 30 min 
prior to ERG with Mydriacyl and 15 min later, sheep were sedated with an intravenous injection of 
diazepam (0.1 mg/kg) and ketamine (10 mg/kg). The trachea was intubated and oxygen was 
delivered through a closed circuit anaesthetic machine. Anaesthesia was maintained using 1-4% 
isoflurane. Each animal was laid in lateral recumbency and its eyelids retracted with a lid speculum. 
Two subdermal electrodes (Eickemeyer Veterinary Equipment Inc, Tuttlingen, Germany) were placed 
on the sheep’s head; the first (ground) overlying the occipital tuberosity and the second reference 
electrode 1 cm caudal to the lateral canthus of the eye. A gold-plated corneal contact lens was 
placed on the cornea with sterile saline solution. All preparations were conducted in ambient 
lighting. 
Photopic (cone) responses were examined first. A light stimulator (Eickemeyer) was held 2 cm from 
the eye and flashed 4 times at 0.8-sec intervals. The light-adapted ERG waveform, an average of 4 
responses, was recorded on the provided software (Eickemeyer). The sheep was then dark-adapted 
for 5 min, with scotopic (rod) recordings taken at the start and completion of this adaptation. The 
ERG was then repeated on the opposite eye. ERG waveforms in all recordings were evaluated, and 
the amplitudes and latencies of the a- and b-waves measured as part of Katharina Russell’s doctorate 
studies. 
Fundus appearance was documented using a ClearView digital fundus camera (Eickemeyer) with 
images archived on the Optibrand ClearView Optical Imaging System (Eickemeyer).  
3.7 Euthanasia and tissue collection 
Sheep for neuropathological analyses were euthanized by penetrating captive bolt stunning between 
cervical vertebrae C1 and C2 followed by immediate exsanguination, and brain perfusion fixation 
performed as before via one of the carotid arteries with 10% formalin in 0.9% NaCl, pH 7.4, after the 
blood was first cleared with 0.9% NaCl at 37 oC (Oswald et al., 2005). The brains were removed intact, 
bisected at the sagittal midline and left in fixative (10% formalin) for a further 7 days. Fixed brains 
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were then equilibrated in cryoprotective solution (10% ethylene glycol, 20% sucrose in 0.9% NaCl) at 
4°C for 5 days and stored frozen at -80 oC until they were sectioned. Sequential 50 μm sagittal brain 
sections were cut through the medio-lateral extent of one hemisphere using  a freezing sliding 
microtome (MICROM International, Walldorf, Germany). Sections were collected, one per well, into 
96-well plates containing cryopreservative (30% ethylene glycol, 15% sucrose and 0.05% sodium 
azide in phosphate buffered saline, pH 7.4) and stored at -20 oC until required. 
3.8 Histology and immunohistochemical methods 
For Nissl and Luxol fast blue (LFB) histological staining, formalin fixed sagittal brain sections (from 
mediolateral levels 2 – 5, see Figure 4.1) were mounted in a solution of 0.5% gelatine and 0.05% 
chromium potassium sulphate on glass slides and air-dried overnight. Mounted slides were then 
dehydrated through a series of ethanol dilutions and cleared in xylene. One set of sections was 
rehydrated through the ethanol gradient, equilibrated in water and then incubated for 10 min in a 
pre-warmed Nissl staining solution (0.05% cresyl violet acetate C5042; Sigma-Aldrich, St. Louis, MO, 
USA, 0.05% acetic acid in water) at 37 °C and rinsed in water. They were then dehydrated through 
the ethanol gradient, and cleared in xylene prior to coverslipping with DPX (BDH, Poole, England). 
Another set of sections was equilibrated in ethanol, incubated for 24 h at 40 °C in an air-tight 
container in LFB staining solution (0.1% Solvent Blue 38, S3382; Sigma-Aldrich, 95% ethanol), rinsed 
in 70% ethanol for 3 min, incubated in 0.05% lithium carbonate, 10 min, taken through the alcohol 
gradient back to xylene, then mounted in DPX. 
For immunohistochemistry, the primary antibodies used were rabbit anti-sheep CLN5 and CLN6 (both 
1:500, polyclonal; Dr. Stephanie Hughes, University of Otago, Dunedin, NZ) to detect endogenous 
and exogenous protein; rabbit anti-cow glial fibrillary acidic protein (GFAP, 1:5000; Z0334, polyclonal; 
Dako, Ely, England) to detect astrocytes; a biotinylated form of the α-D-galactose specific isolectin I-
B4 from Griffonia simplicifolia (GSB4, 1:500; B-1205; Vector Laboratories, Burlingame, CA, USA) for 
microglia and mouse anti- PSA-NCAM (1:1000; MAB5324, monoclonal; Chemicon, Temecula, CA, 
USA) for newly generated and migrating cells. All antibodies were diluted in 10% Gibco normal goat 
serum (NGS) (Life Technologies NZ Ltd, Auckland, NZ) in phosphate buffered saline (PBS), pH 7.4, 
containing 0.3% Triton X-100 (PBST). 
Routine immunohistochemical detection was carried out using an avidin-biotin amplification system. 
For each antigen, sections from all ages and levels were processed simultaneously as a batch. All 
steps were performed on a rocking platform, and were followed by three 10 min washes with PBS. 
Test cryosections were thawed and blocked for 30 min with either 1% H2O2 in PBS (anti-CLN5, CLN6 
and GFAP) or 1% H2O2 in 50% methanol in PBS (anti-PSA-NCAM and GSB4), 30 min, at room 
temperature. Sections were then pre-incubated in 15% NGS in PBST prior to overnight incubation at 
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4 oC in primary antibody. Immunoreactivity was detected using the appropriate secondary 
antibodies; biotin-conjugated affinity purified IgM (1:500; AP500B; Chemicon) for PSA-NCAM and 
biotinylated goat anti-rabbit IgG (1:1000; B7389; Sigma-Aldrich) for all other antigens for 2 h at room 
temperature, followed by ExtrAvidin peroxidase (1:1000; E2886; Sigma-Aldrich) for 2 h at room 
temperature. Staining was visualized by incubation in 0.05% (0.5 mg/ml) 3, 3’-diaminobenzadine 
(DAB; D5637; Sigma-Aldrich) and 0.01% H2O2 in PBS. The optimal incubation period with DAB 
substrate solution was tested for each antigen (Table 3.3) and negative control sections, in which 
either the primary or secondary antibody was omitted, were included in all staining runs. No 
immunostaining was observed in any of the negative control sections. Sections were mounted in a 
solution of 0.5% gelatine and 0.05% chromium potassium sulphate on glass slides, air dried, 
dehydrated in 100% ethanol, cleared in xylene and coverslips mounted with DPX. Further unstained 
sections were mounted as above, air dried and coverslipped with glycerol for observation of 
fluorescent storage body accumulation. 
Table 3.3    Primary antibodies, with associated DAB incubation times 
Primary antibody Concentration Host      Supplier DAB incubation time (min) 
CLN5 1:500 Rabbit        In-house 7 
CLN6 1:250 - 1:500 Rabbit        In-house 7 
GFAP 1:5000 Rabbit        Dako 7 
GSB4 1:500         Vector 5 
PSA-NCAM 1:1000 Mouse        Chemicon 3 
3.9 Microscopy 
Digital images of CLN5, CLN6, GFAP, GSB4, Nissl and PSA-NCAM stained sections were obtained with 
a Nikon Digital Sight DSFi1 camera attached to a Nikon Eclipse 50i model microscope (Nikon 
Instruments Inc., Tokyo, Japan) utilising NIS-Elements Software (Nikon Instruments). A second set of 
images, representative of the upper and lower layers of selected cortical regions, were acquired with 
the x20 objective for GSB4 stained sections and for sections immunostained for GFAP. The 
microscope lamp intensities, exposure times, condenser aperture settings, video camera set-up and 
calibration, and use of neutral density filters were kept constant for capturing all images of a 
particular immunostain. Digital images were saved as .tif and .jpg files and figures and 
photomontages prepared in Corel Photopaint 12 (Corel Co., Ontario, Canada). For GSB4 and GFAP 
threshold analysis, digital images (RGB, .jpg, three different fields per section per animal) were 
analysed with the public domain Image J programme (version 1.28u; National Institutes of Health 
(NIH), Bethesda, MD, USA). Red bandwidth filters were applied for the DAB images, and the number 
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of pixels with brightness levels above a set threshold was expressed as a percentage of the total pixel 
area. Threshold values for images of a particular immunostain at the same magnification were set so 
that positively stained structures at low reactivity were still selected, but not background staining in 
regions of high reactivity. Data were transferred to Microsoft Excel 2013 (Microsoft Corp., Seattle, 
WA, USA) for analyses. 
Cortical and commissural thickness in Nissl and LFB stained sections, respectively, were measured 
with the x4 objective on a Nikon Eclipse 50i microscope using NIS-Elements Software (Nikon). 
Perpendicular distances were measured from the surface of the pia mater to the boundary between 
the grey and white matter in the cerebral cortex. In the cerebellum, the cortical thickness of the 
anterior lobe at sagittal level 4 was measured from the pial surface to the granular boundary with the 
white matter. The thickness of the corpus callosum at sagittal level 5 was measured. At least 25 
measurements were taken at regular intervals for each region. 
Unstained sections were examined using a Nikon Eclipse 50i microscope, fitted with a 450-490 
excitation/510 emission filter set for observation of fluorescent storage body accumulation. 
3.10 Statistics 
All statistical analysis was performed in Microsoft Excel 2000. For the neuropathological studies, 
means (% area stained, cortical/commissural thickness) and the corresponding standard errors of the 
mean (SEM) were computed for each brain region for each animal. These means were used in a one 
way analysis of variance (ANOVA) to test each region separately for differences between normal and 
affected sheep, and between upper and lower cortical layers within affected sheep. A P-value less 
than 0.05 was considered statistically significant. 
For the gene therapy efficacy and behavioural studies, quantitative data are presented as means  
SEM. ANOVA was performed for each time interval separately for the maze data to determine 
whether transit times varied between the cohorts. Mean transit times were then compared between 
cohorts using the Student’s t-test. Differences were considered significant if P ≤ 0.05. 
3.11 Special methods 
Special methods relating to particular experiments are included in the appropriate chapters. 
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Subsequent studies describing pathogenesis in several murine NCL disease models (Pontikis et al., 
2005; Weimer et al., 2006; Kielar et al., 2007; Partanen et al., 2008; Macauley et al., 2009; von 
Schantz et al., 2009; Kuronen et al., 2012; Schmiedt et al., 2012) revealed a similar pathological 
phenotype with generalised thinning of the cortex and widespread regional atrophy, pronounced 
astrocytosis and microglial activation. However a consistent finding from the murine studies was the 
early vulnerability of the thalamocortical system, neuronal loss commencing in thalamic relay nuclei 
and subsequently within the corresponding cortical regions. The reason why the thalamus is 
pathologically targeted early in murine NCLs is not clear (Cooper 2006). However, in marked contrast 
to the other murine forms, cortical neuron loss preceded that in the thalamus in CLN5 mutant mice 
(von Schantz et al., 2009), which correlates with the large animal and human NCLs in which cortical 
lesions are foremost (Mayhew et al., 1985; Jolly et al., 1989; Palmer et al., 2011). Also, the overt 
atrophy seen in ovine and human NCLs (Jolly et al., 1989; Oswald et al., 2001; Haltia, 2003; Palmer et 
al., 2011) is not nearly so apparent in most NCL murine models (Cooper et al., 2006; Cooper, 2010), 
with the exception of the CLN2 knockout mice (Sleat et al., 2004). These findings highlight the 
discrepancies between the mouse and human NCLs and emphasise the translational usefulness of 
larger animal NCL models with their more complex human-like CNS. 
A large animal model of CLN5 deficiency has been described in New Zealand Borderdale sheep (Jolly 
et al., 2002; Frugier et al., 2008). Specific lysosomal storage of subunit c of mitochondrial ATP 
synthase has been shown in these sheep and preliminary studies indicate the clinical disease and 
neuropathological progression closely follows that seen in CLN6 South Hampshire sheep (Jolly et al., 
2002; Frugier et al., 2008). Clinical onset is slightly earlier in the ovine CLN5 model, being apparent 
from 10 -11 months of age, and affected sheep reach a humane endpoint between 22 - 24 months of 
age. Whilst the CLN6 disease results from a defective endoplasmic reticulum-resident 
transmembrane protein (Mole et al., 2004; Heine et al., 2004), the CLN5 gene product is a soluble 
lysosomal glycoprotein which traffics via the mannose-6-phosphate pathway (Holmberg et al., 2004; 
Sleat et al., 2005, 2007) and this form of NCL is deemed to be a strong candidate for gene therapy. In 
vitro studies showed that lentiviral-mediated cross-correction of CLN5 deficient neurons is possible 
(Hughes et al., 2014a) and gene therapy approaches are more likely to succeed if targeted to where 
the pathology is first apparent. This chapter provides a comparative description and quantitative 
assessment of the neuropathological cascade in ovine CLN5 and CLN6 brains during disease 
progression, whilst determining temporal windows in which to administer therapeutic intervention 
before the cascade becomes fatally damaging. 
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4.2 Materials and Methods 
4.2.1 Animals 
The breeding, maintenance and diagnosis of the CLN5 and CLN6 sheep flocks are described in 
Chapter 3. A series of brains from CLN5 affected sheep aged 1 day (newborn), and 4, 6, 9, 12, 15, 18 
and 24 months, were used together with age-matched control sheep brains. In parallel, brains from 
CLN6 affected sheep aged 2, 6, 9, 12, 18 and 24 were processed for comparative analysis and to 
replicate the findings of Oswald et al. (2005). At each age, one control and one to four affected sheep 
brains of each genotype were selected for analysis. 
4.2.2 Tissue preparation and sectioning 
Sheep were killed by exsanguination, the brains perfusion fixed in situ and processed as described in 
Section 3.7. Each brain was weighed, post-fixed, bisected down the sagittal midline, equilibrated in 
cryoprotectant and stored at -80 °C until sectioning. 
Subsequently, 50 μm serial sagittal sections were cut through the medio-lateral extent of the left 
hemisphere (Section 3.7) and cryopreserved in 96-well plates at -20 °C. For all subsequent analyses, 
matched series of sections from each animal were selected at five medio-lateral levels (Figure 4.1), as 
previously described (Oswald et al., 2005). Digital images of the tissue blocks, taken during 
sectioning, aided in the matching of sections to the five sagittal levels. The CNS regions, with 
corresponding sagittal levels that were used in the quantitative image analyses, are summarised in 
Table 4.1. 
4.2.3 Histological analysis, quantification and statistics 
Histological and immunohistological staining was carried out as described in Section 3.8. For Nissl 
staining, sections from two to four individual CLN5 affected sheep brains were processed at each 
timepoint to test for inter-animal variation. Sequential sections from one brain of each genotype at 
each age were then used for all subsequent immunohistochemical and lectin histochemical studies. 
Cortical thickness measurements, thresholding image analysis methods and statistical analysis are 
described in Sections 3.9– 3.10. All histological processing and subsequent analyses were performed 
with no prior knowledge of genotype.  
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Table 4.1     CNS regions and sagittal section levels in which they were investigated (adapted from 
Oswald, 2004) 
Level  1 2 3 4 5 
 Symbol Lateral    Medial 
Hippocampus HC ** *** ** ** * 
Entorhinal cortex Ent ** *** *   
Parieto-occipital cortex POC ** *** *   
Primary somatosensory cortex S1  ** ***   
Lateral geniculate nucleus LGN  ** ***   
Striatum Str   ***   
Cerebellar cortex CB  * ** *** ** 
Frontal association cortex FA   * *** * 
Optic tract Opt   * *** * 
Olfactory cortex Olf   * ***  
Superior colliculus SC    *** ** 
Corpus callosum Cc    ** *** 
Thalamus Th    ** *** 
Caudate nucleus CN    ** *** 
Primary visual cortex V1     *** 
Primary motor cortex M1     *** 
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4.3 Results 
4.3.1 General organisation and development of the ovine NCL brain 
Normal sheep brains grew rapidly from birth to reach an early peak at 4 months. After a 3% decline 
in mean normal brain mass at 6 months, brain growth recommenced, approaching a plateau at 12 
months and mature weight by 24 months (Table 4.2).  At birth, affected sheep brains of both 
genotypes appeared to be normally developed and although divergent in weight from the normal 
newborn brain, this difference was not significant. The brain masses of CLN5 and CLN6 affected 
sheep also peaked at 4 months of age, falling behind normal controls at this stage by 11% and 19% 
respectively, marking the start of progressive brain atrophy. This decline was more obvious in the 
CLN6 affected brain which was reduced to 69% and 54% of the normal brain weight by 12 and 24 
months of age, respectively (Table 4.2). In contrast, the CLN5 affected brain mass changes were less 
overt, plateauing on average at 79.3  0.8 g from 6 to 12 months, however this converged to 58% of 
normal brain weight by 24 months of age (Table 4.2). 
Table 4.2    Mean brain weight of normal and affected sheep from birth to 24 months of age 
Age (m) Normal (g) CLN5-/- (g) CLN6-/- (g) CLN5 / 
Normal 
CLN6 / 
Normal 
0 – 1 58.0  1.7* (n† = 11) 55.5  1.4  (n = 2) 52.4  3.2  (n = 9) 96% 90% 
2 74.1  2.5   (n = 5)  70.4  2.3  (n = 7)  95% 
4 92.1  3.7   (n = 13) 81.8  0.7  (n = 2) 74.7  3.3  (n = 7) 89% 81% 
6 89.2  1.7   (n = 17) 79.5  2.2  (n = 5) 70.4  3.6  (n = 6) 89% 79% 
9 92.2  2.2   (n = 9)  78.4  1.6 (n = 4) 68.2  2.1  (n = 5) 85% 74% 
12 98.2  1.6   (n = 16) 79.5  1.1  (n = 16) 67.7  5.6  (n = 5) 81% 69% 
15    76.1  1.8  (n = 7) 66.2  1.9  (n = 8)   
18 98.1  1.1   (n = 16) 71.2  1.5  (n = 13) 66.0  2.4  (n = 18) 73% 67% 
24 106.1  1.5 (n = 17) 62.0  1.0  (n = 5) 57.5  2.5  (n = 8) 58% 54% 
* Standard error of the mean (SEM) 
† Number of brains collected. One to four brains of each category was used for subsequent analysis 
   No brains were available to be analysed at those ages where values are missing 
 
By 6 months, the disparate effect of the diseases on the cerebral hemispheres was macroscopically 
apparent, with obvious volume loss in the parietal and occipital lobes, medial and caudal to the 
suprasylvian sulcus, of both CLN5 and CLN6 affected brains. By 18 months, gross atrophy of the 
cerebral hemispheres, with concomitant dorsoventrally flattened, narrowed gyri and widened sulci, 
was evident (Figure 4.2). Whilst the CLN6 affected cerebral cortex was more severely shrunken 
overall, the CLN5 affected frontal lobe, medial and rostral to the pseudosylvian sulcus, was 
discernibly more atrophied than that in the CLN6 affected brain. In contrast to the marked cerebral 
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atrophy, the cerebellum and subcortical structures of both genotypes retained normal appearance, 
even at 24 months. 
 
 
4.3.2 Regional atrophy and cortical thinning  
The unifying pathological hallmark of NCL is severe neurodegeneration. In order to quantify this, Nissl 
stained sections from CLN5 and CLN6 diseased sheep brains were analysed for neuronal 
cytoarchitecture and by measurement of cortical thickness, to compare spatiotemporal changes with 
disease progression (Figure 4.3). Distinct neuronal laminae were evident across the normal cortical 
mantle (Figure 4.4), with pronounced thickening of the normal cortical layers over time to reach 
maturity by 12 months (Figure 4.5). In contrast, the NCL affected ovine cerebral cortices never 
attained full maturity; instead regionally specific cortical thinning and neurodegeneration 
commenced. Preceding or coinciding with the neuronal loss was perturbation of the 
cytoarchitectonic layers and the progressive appearance of clusters of densely packed cellular 
aggregates at the layer I/II boundary throughout the affected cerebral cortex of both genotypes. 
Control sheep brains did not contain these cellular aggregates, except in the entorhinal cortex. In all 
Figure 4.2   Lateral view of the normal 
and affected sheep brain 
Perfused brains from A. a 19.4 month 
old normal Coopworth sheep, B. a 
19.2 month old CLN5 affected 
Borderdale and C. a 19.3 month old 
CLN6 affected South Hampshire. Note 
the marked atrophy of the diseased 
cerebral hemispheres and the relative 
sparing of the cerebella. Brain weights 
were 99, 74.86 and 60.75 g 
respectively. The suprasylvian sulcus 
(▲), pseudosylvian sulcus (■), parietal 
(Par), occipital (Occ) and frontal (Fr) 
lobes are indicated. 
 
 
A. 
C. 
B. 
▲▲▲▲ 
Par 
Occ 
Fr 
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affected cortical regions, the neuronal atrophy was more pronounced in the upper layers (II-III) with 
the lower cortical layers (V-VI) better preserved, especially the lamina V pyramidal cells.  
It was previously reported that the cytoarchitecture of the cerebellum, hippocampus and all cortical 
regions of the CLN6 affected brains appear normal at birth (Oswald et al., 2005; Kay et al., 2006). 
However, even by the earliest age in the current study (2 months), loss of layer definition was 
observed in the CLN6 affected primary visual and parieto-occipital regions with aggregation of cells at 
the I/II laminar boundary (Figure 4.4). These degenerative changes spread from the visual and 
parieto-occipital cortices to the somatosensory cortex at 6 months, reaching the motor cortex by 12 
months, and the entire cortical mantle by 18 months, corroborating the findings of Oswald et al 
(2005). Cortical thickness measurements demonstrated that the rate of active thinning differed 
between the regions but followed a similar pattern (Figure 4.5), to the cytoarchitectural changes 
albeit delayed. The visual and parieto-occipital regions were affected most and earliest (from 2 
months). The thickness of the CLN6 affected somatosensory cortex increased comparatively normally 
up to 9 months, delayed atrophy commenced in the entorhinal and frontal cortices from 12 months, 
and the motor cortex was relatively spared until 18 months of age. By 24 months, significant atrophy 
was seen across the CLN6 affected cerebral cortex with the primary visual, entorhinal, and primary 
motor areas reduced to 37%, 56%, and 61% of the respective normal thicknesses. 
The CLN5 affected brain was also normal in appearance at birth, except for a mild disturbance in the 
laminar architecture and small cellular clusters at the layer I/II interface of the primary visual cortex. 
The same clusters and loss of layer definition reached the parieto-occipital and somatosensory CLN5 
cortices by 4 months of age. Degenerative changes in the CLN5 entorhinal, frontal association and 
motor cortices were detected from 6 - 9 months, some 3 - 6 months earlier than in the CLN6 affected 
brain. However, despite the earlier cortical laminar reorganisation in the CLN5 brain, the affected 
brains of both genotypes reached the same pathological endpoint at 24 months of age with obvious 
layer I/II cellular aggregates and few cortical neurons remaining (Figure 4.4). 
As in the CLN6 model, active thinning in the CLN5 affected brain became apparent at different ages 
in different cortical regions. There was a near linear decline in the visual, parieto-occipital and 
somatosensory cortices from birth. Atrophy became apparent in the frontal cortex from 9 months 
and was not apparent in the entorhinal and motor cortex until 15 months (Figure 4.5). The 
neurodegenerative cascade began earlier in most regions of the CLN5 affected brain than in the CLN6 
affected brain, however, despite this earlier onset of atrophy, cortical thickness measurements from 
CLN5 and CLN6 affected sheep brains converged, and were very similar by 24 months (Figure 4.5).  
The major point of difference was seen in the cortices of the frontal lobe. At 24 months there was an 
11% greater reduction in the thickness of the CLN5 frontal association cortex compared to that of the 
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CLN6 brain (P  0.0001). Additionally the motor cortex of the CLN5 affected sheep brain shrank 
dramatically from 15 months of age to be 59% that of normal thickness by 18 months, a 20% greater 
reduction than in the same region in an age-matched CLN6 affected animals. This discrepancy was 
still statistically significant (P = 0.0006) at 24 months when the CLN5 and CLN6 motor cortex 
thicknesses were reduced to 54% and 61% of normal respectively (Figure 4.4). 
Progressive atrophic changes in the cortical grey matter were accompanied by white matter tract 
changes. Occipital white matter loss with disease progression was macroscopically overt (Figure 4.3). 
The thickness of the corpus callosum in normal brains increased to plateau at 1323  30 μm (n = 7) by 
18 - 24 months, whereas it remained relatively unchanged in NCL affected sheep throughout 
postnatal development (CLN6 affected 724  30 μm (n = 5); CLN5 affected 756  18 μm (n = 8)).   
The subcortical structures were remarkably preserved in sharp contrast to the gross atrophy of the 
cortex in both ovine disease models. Nissl staining revealed no overt depletion of cells in the affected 
thalamic nuclei, colliculi or striatum and neuronal populations in these resembled those seen in 
control sections. Cerebellar cortical thickness was also relatively constant from birth to 24 months in 
normal (513   5 μm; n = 10), CLN5 affected (511   5 μm; n = 18) and CLN6 affected (495  7 μm; n = 
5) sheep brains, demonstrating the relative sparing of the cerebellum in ovine CLN5 and CLN6 NCLs 
(Figure 4.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3     Progressive cortical atrophy in CLN5 and CLN6 affected sheep  
Nissl stained sagittal sections (Level 5) show gross atrophy of the cerebral cortex in CLN5 and CLN6 
affected sheep at 12 months, which is more pronounced at 24 months, especially in the visual cortex. 
The vulnerability of the motor cortex is also highlighted in CLN5 affected sheep. In contrast, the 
cerebellum is relatively spared in both disease models. 
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Figure 4.4    Microscopic comparison of CLN5 and CLN6 affected cortices 
A. Nissl staining revealed pronounced atrophy that began first, and was most 
advanced, in the visual cortex of both NCL affected sheep models. B. Earlier 
degenerative and atrophic changes were evident in the CLN5 affected motor cortex 
than in the CLN6 affected sheep brain. Upper arrows mark the layer I/II boundary, 
the middle arrows indicate layer IV, and the lower arrows mark the layer VI/WM 
boundary. Scale bar represents 500 m. 
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Figure 4.5  Quantitative 
assessment of the cortical 
thinning in CLN5 and CLN6 
affected sheep brains   
Cortical thickness 
measurements from Nissl 
stained brain sections 
revealed progressive 
thinning of the affected 
cortical mantle, but at 
various rates in different 
cortical regions. Compared 
with age-matched controls 
(blue), significant atrophy 
was first evident in the 
primary visual cortex in 
both disease models from 
2 to 4 months of age and 
subsequently observed in 
the parieto-occipital and 
somatosensory cortices at 
4 to 6 months. Earlier 
declines in the cortical 
thicknesses of most 
regions were evident in 
CLN5 affected brains 
(green) compared with the 
CLN6 affected brains (red).  
However in most regions, 
measurements converged 
for both genotypes by 24 
months of age. At this age, 
only the CLN5 affected 
frontal association and 
motor cortices were 
statistically thinner than 
the same CLN6 affected 
regions (P  0.001). Results 
are means of at least 25 
measurements. Standard 
errors for each point are 
not displayed but were 
within 0.5 – 5.2% of the 
means. Due to the 
progressive nature of the 
disease, only the first ages 
from which difference 
between control and 
affected thicknesses 
become significant are 
indicated (** P  0.05, *** 
P  0.001). 
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4.3.3 Progressive glial activation 
Because glial activation is proposed to play a central role in the pathogenesis of NCL, the glial cell 
response was assessed over disease progression by immunohistochemistry, using glial fibrillary acidic 
protein (GFAP) as an astrocytic marker and by GSB4 lectin histochemistry to detect microglia. 
Similarly to findings in CLN6 affected sheep, a prominent early response was detected with each of 
these markers in the CLN5 ovine model, which was at first restricted to individual laminae in the 
same cortical regions initially undergoing neurodegeneration, but which subsequently spread to 
involve all cortical laminae and subcortical regions (Figure 4.6 - Figure 4.11). Neither activated 
astrocytes nor microglia were detected in the cerebellum of either ovine NCL model, even at 
advanced disease. 
4.3.3.1    Regional astrocytosis 
Low-level GFAP reactivity was limited to protoplasmic astrocytes in lamina I adjacent to the pial 
surface or distributed evenly within the grey matter laminae)in the control brains at all ages (Figure 
4.7). These had short, highly branched processes. More intense GFAP immunopositivity was seen in 
the white matter of control sheep, due to the presence of quiescent astrocytes along the white 
matter tracts. These either exhibited the typical stellate morphology or were associated with the 
capillary vasculature. In marked contrast, discrete foci of reactive hypertrophic astrocytes were 
present as early as birth in the pre-symptomatic CLN5 affected brains. Similarly to observations in 
perinatal CLN6 affected sheep (Oswald et al., 2005; Kay et al., 2006), this upregulation of GFAP 
immunoreactivity in the CLN5 affected brains was initially regionalised to the first areas to undergo 
neurodegeneration (the visual and parieto-occipital cortices), with significantly more activation in the 
superficial laminae (II and III) than the lower cortical layers (P  0.005). A distinct band of 
hypertrophied activated astrocytes formed initially in these laminae. With age, reactive glia spread to 
form a dense network in affected brains of both genotypes throughout laminae II - VI as more 
cortical and subcortical regions became involved. 
Quantitative thresholding image analysis demonstrated progressive astrocytosis occurring within the 
cortex of affected sheep of both genotypes (Figure 4.8). Whilst significant increases in GFAP 
immunoreactivity were most pronounced in the primary visual cortex of both disease models, there 
were some regional differences between them. Temporal plots of the percentage of GFAP 
immunopositivity showed subcortical regions and the visual and parieto-occipital cortices were 
largely uniformly affected between the two disease models. However staining intensity in the CLN5 
affected motor cortex increased earlier than in the same region in the CLN6 affected brains (Figure 
4.7). A band of hypertrophied astrocytes in laminae II-III of the CLN5 affected motor cortex was 
revealed at 6 months, whilst sparse activated cells were present only in the molecular layer I of the 
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age-matched CLN6 brain. Even at end-stage disease (24 months) GFAP immunoreactivity was 
considerably greater in the CLN5 than in the CLN6 affected motor cortex. 
Figure 4.8 reveals an increase in GFAP immunoreactivity in the caudate nucleus and the lateral 
geniculate nucleus with age, which was representative of other subcortical structures. In particular, 
hypertrophic astrocytes were seen both macroscopically and microscopically in the CLN5 and CLN6 
affected thalamus from 12 months of age (Figure 4.6). However this progressive activation of 
subcortical astrocytes was considerably more delayed than in the cortex with far fewer cells involved. 
Of interest too, the affected white matter was intensely stained at birth, but this dramatically 
declined with disease progression before increasing again at end-stage disease (Figure 4.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6     Comparative astrocytosis during ovine NCL disease progression 
GFAP stained sagittal sections (Level 4/5) showing widespread and progressive activation of 
astrocytes in the NCL affected sheep brains with age. Note the increased activation in the CLN5 
affected brain at 6 months and the delayed subcortical involvement in both ovine disease models. 
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Figure 4.7    GFAP expression in 
the CLN5 and CLN6 affected 
visual and motor cortices 
Increasing astrocytosis (upper 
image) was revealed in the 
affected brains of both 
genotypes, spreading from 
initial specific foci in the upper 
cortical layers (lower image) to 
form a dense glial network 
across all cortical layers with 
disease progression. Note the 
earlier astroglial involvement 
(dark staining) in the CLN5 
affected cortex, especially seen 
at higher magnification (lower 
boxes). Scale bars represent 
500 m (upper) and 50 m 
(lower). 
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Figure 4.8     Astrocytic activation in the CLN5 and CLN6 affected sheep brain 
Quantitative thresholding image analysis of GFAP immunostaining in upper (I-III) and lower (IV-VI) laminae of different brain cortices and subcortical brain regions 
of control and CLN5 and CLN6 affected sheep of different ages. Results are expressed as the mean percentage areas that stained above a threshold value for at 
least 10 fields, showing the standard error of the mean (vertical bars). No astrocytic activation was found in the cerebellum of either ovine disease model. 6
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4.3.3.2    Microglial activation  
The GSB4 lectin, also referred to as I-B4, acts as a common neuroinflammatory marker in the brain, 
labelling vascular endothelia, as well as perivascular macrophages and activated (amoeboid) 
microglial cell populations (Streit, 1990). GSB4 staining followed a similar pattern to GFAP 
immunostaining, being markedly increased in the cortical grey matter of both CLN5 and CLN6 
affected brains compared with controls (Figure 4.9), with initial foci of activated microglia in the 
upper laminae (II-III) of the parieto-occipital and visual cortices. These foci were detected in the CLN5 
neocortex as early as birth and in the CLN6 affected brain by 2 months. As the disease progressed, 
the numbers of activated cells and clusters increased to form a conspicuous band in these cortical 
regions of the CLN5 affected brain by 6 months and in the CLN6 affected brain by 9 months, with 
subsequent activation in the somatosensory, entorhinal and motor cortices in both disease models. 
This microglial activation spread to the deeper laminae with time, particularly to VI and the white 
matter/grey matter boundary of both disease models. From 12 months of age all CLN5 affected 
cortical layers contained intensely stained cells, whilst these were not evident in the CLN6 affected 
brain until 18 months. Compared with the weakly stained and highly ramified microglia in the cortex 
of control sheep, many of the microglia in the CLN5 and CLN6 deficient sheep displayed enlarged 
soma with short thickened processes, typical of an amoeboid or brain macrophage-like morphology 
(Figure 4.10).  
These trends were consolidated by quantification of GSB4 staining. Thresholding image analysis of 
GSB4 staining revealed activated microglia first in the visual and parieto-occipital cortices, and later 
in the motor cortex in both disease models (Figure 4.11). However activation in all cortical regions of 
CLN5 affected brains began before that in CLN6 affected brains, and was considerably greater. Strong 
GSB4 reactivity in controls was evident only in the neonatal white matter. 
Progressive activation of subcortical nuclei was delayed compared with the cortical activation. On a 
gross level, there was some staining of GSB4-positive staining in subcortical regions of both the CLN5 
and CLN6 affected brain at 6 months (Figure 4.9) but this was not associated with cell bodies and was 
interpreted as neuropil staining of unattributed biological significance. By 12 months, activated 
microglia were present in the lateral geniculate nucleus and in other thalamic nuclei in both disease 
models. Initially activated cells in these regions were small but rounded with only weakly stained 
processes. By late to end-stage disease at 18 – 24 months they had morphed into activated brain 
macrophages, yet overall subcortical activation was minor compared with that in the affected 
cortices. 
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Figure 4.9    Comparative microgliosis during ovine NCL disease progression 
GSB4 stained sagittal sections (Level 4/5) showing widespread and progressive microglial activation 
in the NCL affected sheep brains with age. Note the greater activation in the CLN5 affected brain at 6 
months compared with that in the age-matched CLN6 affected brain. 
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Figure 4.10    Microgliosis 
in the CLN5 and CLN6 
affected visual and motor 
cortices 
GSB4 expression in the 
CLN5 and CLN6 affected 
visual and motor cortices 
(upper image) showing the 
increase in microglial 
activation with age, from 
initial hyper-trophic foci in 
the upper laminae II and III 
(lower image) which spread 
to encompass all cortical 
laminae. Brain 
macrophages were 
progressively noted in the 
affected brains of both 
genotypes at higher 
magnification (arrows, 
lower boxes). Note the 
earlier microgliosis (dark 
staining) in the CLN5 
affected cortex. Scale bars 
represent 500 m (upper) 
and 50 m (lower). 
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Figure 4.11    Microglial activation in the CLN5 and CLN6 affected sheep brains 
Quantitative thresholding image analysis of GSB4 staining across different cortices (laminae II-VI) of control and CLN5 and CLN6 affected sheep brains of different 
ages. Results are expressed as the mean percentage area that stained above a threshold value in at least 10 fields, showing the standard error of the mean  
(vertical bars). No microglial activation was found in the cerebellum of either ovine disease model. 
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4.3.4 Storage body accumulation  
Fluorescent lysosomal storage body accumulation is another hallmark of the NCLs. Punctate 
accumulation in different regions of affected brains was quantified by fluorescent microscopy and 
image analysis. In the initial disease stages, aggregates of fluorescent material were confined to cells 
with characteristic neuronal morphology in both disease models. These included neurons in the 
subcortical nuclei and across all laminae of the cerebral cortex, pyramidal cells of the hippocampus, 
and all Purkinje cells of the cerebellum. As the disease progressed, lysosomal storage appeared also 
in non-neuronal cells of both disease forms.  
Accumulation was revealed as early as birth in all regions analysed in the CLN5 affected sheep brain 
and became more pronounced with age (Figure 4.12). Age-matched newborn CLN6 brain sections 
were not available but prenatal accumulation has been reported for this form (Jolly et al., 1989), and 
at 12 days after birth (Oswald et al., 2005). Accumulation was evident at the earliest time-point of 2 
months in the current study. The earlier onset seen with the other neuropathological markers for the 
CLN5 sheep model did not reflect in the comparative storage body analyses. There was no significant 
difference between the two ovine disease models with respect to storage body onset and 
accumulation, which followed a near linear pattern in the neocortex from birth to end-stage disease 
(Figure 4.13).  
All subcortical regions analysed showed slower percentage increases in storage body accumulation 
than was observed in the cortex, apart from comparable, albeit delayed, cumulative responses 
detected in the cerebellum, hippocampus and the lateral geniculate nucleus of the thalamus (Figure 
4.13). By end-stage disease, storage material was universal throughout all grey and white matter 
regions. 
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Figure 4.12    Comparative storage body accumulation during ovine NCL disease progression 
Fluorescent (450-480 nm excitation, 490-530 nm emission) imaging of storage body accumulation in 
the parieto-occipital cortex of the CLN5 and CLN6 affected sheep brains compared with an 
unaffected control brain. Images are from 50 m cortical sections, hence the thickness of the section 
makes the punctate nature of the storage harder to see. Scale bar represents 50 m. 
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Figure 4.13    Accumulation of fluorescent storage bodies in CLN5 and CLN6 affected sheep 
B. Quantitative thresholding image analysis of storage body accumulation in different brain regions of CLN5 and CLN6 affected sheep compared with controls. 
Results are expressed as the average percentage area containing fluorescence above a threshold value in at least 10 fields, showing the standard error of the mean 
(vertical bars). Cortical values are means for all layers. 
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4.3.5 Neurogenesis 
The discovery of extended neurogenesis in the subventricular zone (SVZ) of CLN6 affected sheep 
suggested an intrinsic attempt at cell replacement within the diseased brain (Dihanich et al., 2009, 
2012). Consequently the extent of neurogenesis was explored in the CLN5 affected brains to verify if 
this was a disease-specific phenomenon, using an immunohistochemical marker for developing and 
migrating neurons, poly-sialated neural cell adhesion molecule (PSA-NCAM),. 
Markedly increased PSA-NCAM immunoreactivity was observed in both the CLN5 and CLN6 affected 
sheep brains along the entire rostro-caudal extent of the SVZ lining the lateral ventricle. Whilst SVZ 
neurogenesis was evident in the normal sheep brain, particularly in the early neonatal period, this 
was greatly enhanced in the CLN5 and CLN6 diseased brains. Intensely stained cells and fibres 
oriented tangentially to the ventricle, particularly at the rostral regions of the SVZ, formed a 
conspicuous band of endogenous neurogenesis in the affected sheep (Figure 4.14). As well as the 
normal migration of newly-generated neurons through the rostral migratory stream to the olfactory 
bulb, there was evidence of radial migration of these cells in the diseased brains, extending away 
from the SVZ along white matter tracts towards the deep laminar layers of the degenerating cortex 
(Figure 4.11A). Migratory PSA-NCAM positive cells, with intensely stained perikaryon and multiple 
dendritic processes, were detected through all cortical regions, particularly the upper laminae, in 
both the CLN5 and CLN6 affected brains. Here they formed densely packed clusters (or spheres) at 
the layer I/II boundary with fibrous dendritic processes. These were congruous with the developing 
cellular aggregates revealed in the diseased sheep cortex by Nissl staining (see Section 4.3.2). By 
comparison, in the adult normal brain, punctate staining was observed in sparse individual cells and 
along neuritic processes in the cortex but there were no clusters. 
Neurogenesis was particularly pronounced in the CLN5 affected brain at 6 months of age, much more 
so than in the CLN6 ovine model. There was considerable evidence of neurogenic activity in the SVZ 
and layer I/II PSA-NCAM-positive cellular aggregates were present across the entire CLN5 cortical 
mantle. In the CLN6 affected brain at the same age, these aggregates were mainly restricted to the 
occipital cortex, whilst elsewhere in the cortex they were similar in morphology to the control. From 
12 to 18 months, both disease models were identical in their presentation, resembling the 6 month 
CLN5 profile described above. Interestingly, at end-stage disease (24 months) very few cortical 
immunoreactive clusters were seen in the CLN5 affected brain, whilst dense spheres still existed in 
the CLN6 model. 
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Figure 4.14    Extended neurogenesis in the CLN5 and CLN6 affected sheep brain 
PSA-NCAM immunohistochemistry revealed a band of extended adult neurogenesis along the 
subventricular zone (SVZ) in affected sheep. A. As well as migrating through the usual rostral 
migratory stream (RMS) to the olfactory bulb, newly generated PSA-NCAM-positive cells and fibres 
could be seen radiating perpendicularly and tangentially from the 6 month CLN5 affected SVZ 
(arrowheads) along white matter tracts to the degenerating cortex. B. The neurogenic band and 
degenerating cortical regions are shown in an 18 month old CLN5 affected PSA-NCAM stained sheep 
brain section. C. Newly generated cells travelled along the SVZ and, once in the cortex, clustered at 
the layer I/II boundary. Scale bars represent 500 m in A,C (left and middle) and 50 m in C (right). 
 
4.3.6 Spatial expression of CLN5 and CLN6 in the sheep brain 
When developing therapies for genetic disorders, it is useful to know where the endogenous proteins 
are expressed. With this in mind, the expression patterns of these endogenous NCL proteins were 
explored using the recently developed novel sheep-specific polyclonal CLN5 and CLN6 antibodies 
(Hughes et al., 2014b). CLN6 reactivity was intrinsically weaker than that for CLN5. Nevertheless, 
CLN5 and CLN6 immunohistochemistry in the developing normal sheep brain resulted in a very 
similar, mainly neuronal, pattern of expression. Both endogenous CLN5 and CLN6 proteins were 
widely expressed throughout the brain during postnatal development, but were particularly evident 
in the cortical neurons, pyramidal cells of the hippocampus, periventricular epithelia and 
paraventricular thalamic cells, subcortical striatal and hypothalamic neurons as well as the cerebellar 
Purkinje cells (Figure 4.15). At a subcellular level, granular CLN5 and CLN6 immunostaining was 
predominantly localized to the neuronal cell soma, and along neurites of larger immunopositive cells. 
No expression was seen in the CLN5 affected sheep tissues with the CLN5 antibody nor in the CLN6 
affected tissues with the CLN6 antibody (Figure 4.15A, E insets). 
The strongest CLN5 and CLN6 immunoreactivities were detected in the hippocampus from birth to 
adulthood (Figure 4.15A,E-G). The most prominent expression was seen in the pyramidal cells in both 
CA3 and CA2 regions, the hilus and the granule cells of the dentate gyrus. In the sheep cerebral 
cortex, CLN5- and CLN6-positive cells were found across the cortical laminae II-VI, but were 
prominent in layers II-II and at the white matter/ gray matter boundary (Figure 4.15B). Both proteins 
were expressed in the Purkinje (PCL) and granular (GCL) cell layers of the cerebellum (Figure 4.15D). 
In the neonatal cerebellar cortex, weak endogenous CLN5 and CLN6 expression was observed in 
mitotically active cells of the external granular cell layer (EGL) but as the brain developed these cells 
migrated to populate the internal granular cell layer with subsequent loss of the EGL in the mature 
cerebellum. Additionally, an increase in immunoreactivity with both antibodies was detected in the 
molecular layer of the cerebellum, first seen at six months of age. 
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Figure 4.15    Expression of endogenous CLN5 and CLN6 proteins in the normal adult sheep brain 
Strong CLN5 immunostaining in hippocampal pyramidal cells (A), cortical neurons of laminae II-VI in the frontal lobe (B, inset C), cerebellar Purkinje cells (D), hilar 
(F) and CA3 cells (G) of the hippocampus, hypothalamic neurons (H) and the paraventricular cells of the thalamus (I). CLN6 expression (boxed) was considerably 
weaker but was co-localised to the same cell populations, as seen in the hippocampus (E) and paraventricular thalamic cells (J). Insets on A and E demonstrate the 
lack of CLN5 and CLN6 expression in the hippocampus of CLN5 and CLN6 affected brains respectively. Scale bars represent 500 m in A,B,E and 100 m in C,D,F-J. 
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4.4 Discussion 
This work provides the first detailed description of progressive pathological changes in the CNS of 
Borderdale CLN5 affected sheep. Despite the very different genotypes and subcellular localisation of 
the defective proteins, it was surprising that similar neuropathological themes emerged for both 
CLN5 and CLN6 affected sheep, including the cortical regionality of neurodegeneration and atrophy, 
together with early and localised microglial activation, pronounced hypertrophy of astrocytes, brain-
wide storage body accumulation and enhanced neurogenesis. The data serve to highlight the 
similarities of these two ovine models, whilst also showing that despite having pathological 
endpoints that resemble one another, these are reached by pathogenic cascades that differ between 
NCL subtypes. 
4.4.1 Common themes in ovine NCL pathogenesis 
4.4.1.1 Progressive neuropathological phenotype in the cortex 
The NCLs are traditionally characterised by the near-ubiquitous accumulation of protein in lysosome-
derived storage bodies and profound neurodegeneration, with severe resultant brain atrophy (Mole 
et al., 2011). The common assumption was that the storage body accumulation caused the 
characteristic neuropathology, but this idea no longer seems plausible (Palmer et al., 2013; Palmer 
2015). Instead a central role for disease associated neuroinflammation has been proposed. That 
neuroinflammation actually precedes neurodegeneration was first established in the CLN6 ovine 
model (Oswald et al., 2005; Kay et al., 2006) and has subsequently been reported in murine NCLs 
(Pontikis et al., 2005; Kielar et al., 2007; Partanen et al., 2008; Macauley et al., 2009; von Schantz et 
al., 2009; Kuronen et al., 2012; Schmiedt et al., 2012; Morgan et al., 2013). The current study extends 
these observations to include the CLN5 ovine model. 
Proliferating perivascular macrophages and activated astrocytes were detected in the CLN6 affected 
sheep brain as early as 20 and 40 days before birth (Kay et al., 2006). These progress to discrete foci 
of reactive hypertrophic astrocytes and activated microglia in CLN6 affected cortical regions at birth, 
and were also seen in the pre-symptomatic CLN5 affected neonatal cortex in the current study. They 
were initially localised to the superficial laminae (II and III) of the affected visual and parieto-occipital 
sheep cortices. However, their presence did not appear to disturb neuronal development overtly, 
with cerebellar and cortical laminae in both ovine models well-defined at birth (this study; Kay et al., 
2006). The gross anatomy and brain weight increases in the perinatal ovine NCL brain also suggest 
that the affected brain of both genotypes follows a relatively normal developmental path until 4 
months of age (Table 4.2). 
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With time, a progressive process of dysregulated glial activation becomes established. Consistently in 
both ovine disease models, reactive changes spread in a regionally specific manner from the visual, 
parieto-occipital and somatosensory cortices to the frontal association cortex, before spreading 
progressively across the cortical mantle and then into subcortical regions with maturation (Figure 
4.8). Later neurodegeneration followed gliosis in the same regional and temporal order in both the 
CLN5 and CLN6 affected sheep brains and, as in human NCLs (Cooper et al., 2006; Cooper, 2010), 
cortical regions were foremost (Figure 4.3). This ordered primacy of neuroinflammation over 
neurodegeneration in NCL supports the theory that activated glia serve as sensitive predictors of 
subsequent neuronal dysfunction or loss (Raivich et al., 1999; Streit, 2000, 2002). Each cortical region 
in affected sheep demonstrated a similar sequence of glial activation, from initial superficial foci to 
later involvement of successively deeper cortical laminae. The cortical regions first targeted and most 
affected by the glial activation, namely the parieto-occipital and visual cortices, were also those later 
associated with the onset of phenotypic symptomology. 
The early activation of glia in ovine NCL pathogenesis would suggest it is not solely a response to 
neuronal insult (this study; Oswald et al., 2005; Kay et al., 2006). Prominent glial activation has been 
reported as a common sequelae in many neuropathic LSDs, including Gaucher disease, GM1 and 
GM2 gangliosidosis, Niemann-Pick type C, Sandhoff disease and mucopolysaccharidoses I , IIIA and 
IIIB (Wada et al., 2000; Baudry et al., 2003; Jeyakumar et al., 2003; Ohmi et al., 2003; Farfel-Becker et 
al., 2011; Wilkinson et al., 2012). It is usually interpreted as a protective response to 
neurodegeneration. Healthy glia are in a quiescent resting state. On CNS insult, by an event such as 
neurodegeneration, damaged/dying neurons release molecular cues which trigger astrocytic 
hypertrophy and activation (Rama Rao & Kielian, 2015; Thundyil & Lim, 2015). Astroglial dysfunction 
can affect neuronal survival through the loss of neurotrophic support and critical homeostatic 
function, as well contributing to neuroinflammatory processes through robust chemokine secretion 
(Bosch & Kielian, 2015; Rama Rao & Kielian, 2015). Similarly on CNS disruption, microglia, the 
principal neuroinflammatory cells in the CNS parenchyma, undergo morphological transformation to 
amoeboid brain macrophages. These recognise and remove damaged neurons by phagocytosis whilst 
concurrently secreting pro-inflammatory cytokines and activating an innate immune response 
(Ransohoff & Perry, 2009; Schwartz & Shecter, 2010). Whilst acute neuroinflammation is typically 
self-limiting, collective evidence indicates persistent inflammation can itself elicit neuronal damage 
(Raivich et al., 1999; Streit et al., 2004; Lyman et al., 2014; Lee & MacLean, 2015), likely to further 
perpetuate the inflammatory cycle and progressive CNS pathology seen in NCL. 
It is still unclear what causes the initial activation in the NCLs. A molecular dissection of the 
neuroinflammatory cascade in ovine CLN6 revealed that the process was complex, and despite 
differential regulation of a number of genes, no causal initiators of neuroinflammation were 
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recognised (Chen, 2016). In collaboration with colleagues at the University of Sydney, a 
transcriptomic approach is planned on ovine CLN5 and CLN6 CNS tissues to compare gene expression 
in pre-clinical disease stages with the aim of identifying early targets for effective therapeutic drug 
interventions. 
The NCLs are also pathologically typified by the intracellular accumulation of punctate fluorescent 
storage bodies (Mole et al., 2005). Sparse storage material was apparent at birth in both affected 
sheep models (this study; Oswald et al., 2005; Kay et al., 2006), accumulating through the brain with 
disease progression but the distribution was neither focal nor did it correlate temporally or spatially 
with glial activation or neurodegeneration. Whilst cortical accumulation of storage material was 
near-linear (Figure 4.13), storage burden was spread across all laminae of the affected cortex. 
Despite large amounts of lysosomal storage in the soma of the Purkinje cells at end-stage ovine CLN5 
and CLN6 disease, there was no indication of atrophy or neuroinflammation in the cerebellum in the 
current study. This observation is not novel, but is consistent with previous findings in the CLN6 
sheep model that neurodegeneration and storage body accumulation are independent 
manifestations of the genetic lesion (Mayhew et al., 1989; Jolly et al., 1989; Palmer et al., 2002; 
Oswald et al., 2005, 2008; Kay et al., 2011). 
An important question for therapy is when does the pathogenic cascade become fatally damaging to 
neurons? Atrophy of the cerebral cortex in ovine NCL is not uniform but instead follows the same 
delayed pattern as glial activation, and both of these pathological events occur well before the 
animals become symptomatic. Consistent with the advanced symptomology and more rapid course 
of ovine CLN5 (Chapter 6), the onset of neuropathology was earlier in all analysed regions of the 
CLN5 affected brain than in ovine CLN6 brain regions. Measurable increases in glial markers and 
declines in cortical thickness could be seen from early perinatal stages in the CLN5 parietal and 
occipital lobes, with the frontal association cortex affected from 9 months of age (during early- to 
mid-stage disease) and generalised neuronal loss and atrophy across the cortical mantle observed by 
15 months of age. The early targeting of the visual and parieto-occipital cortices was also seen in the 
CLN6 ovine model, however atrophy was delayed until 9 months of age in the somatosensory cortex, 
the frontal association and entorhinal cortices until mid-stage disease at 12 months and the motor 
cortex was not affected until late in disease progression at 18 months of age. The CLN6 
measurements corroborated well with those of Oswald et al. (2005), and extended those findings to 
show very delayed, albeit significant, atrophy in the CLN6 motor cortex at terminal disease.  
Quantitative measures of atrophy and glial activation demonstrated the greater involvement of the 
frontal lobe in the ovine CLN5 disease. At end-stage disease, cortical thickness measurements for 
both genotypes converged for all regions, except the primary motor and frontal association cortices 
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(Figure 4.5). These two regions were macroscopically more atrophied in the CLN5 affected brains 
than in the CLN6 affected brains (Figure 4.4). In mammalian anatomy, the frontal association cortex 
is located in the prefrontal cortex, which has been implicated in executive function and complex 
cognitive behaviour (Yang & Raine, 2009). Although sheep have not been shown to have the 
equivalent of a human prefrontal cortex, rodents do (Dalley et al., 2004), hence it seems logical that 
sheep would too as they are capable of performing tasks that require this brain region (Morton & 
Avanzo, 2011). The frontal lobe also contains the primary motor cortex, which generates neural 
impulses that control the execution of movement. Atrophy in these regions correlates with the 
declining motor, proprioceptive and cognitive function seen with disease progression in the CLN5 
Borderdale sheep (Chapter 6). Motor deficits particularly manifest with stiffness in the legs and hind-
limb paralysis much earlier and more abundantly in the CLN5 affected sheep than in CLN6 affected 
sheep (Chapter 6).  
Given the earlier atrophic changes in the CLN5 affected sheep brain, one would expect this to 
manifest in the brain mass data as well. This was not the case. The CLN5 affected brain mass was 
greater at all time points, only converging with the CLN6 affected brain mass at terminal disease. This 
may be rationalised by the smaller size of the of the CLN6 South Hampshire sheep, which are smaller 
in stature, and of the fact that the CLN6 flock is longer established, and despite some out-breeding, 
have been maintained by heterozygous ewe/ homozygous affected ram crosses for over forty years. 
Collated results from this model include historical and newly collected data points. The CLN5 
Borderdale flock was established more recently, through homozygous out-breeding with another 
large sheep breed (Coopworth), which likely influences the overall mature size of the sheep and their 
brains. 
By end-stage ovine NCL disease at 22- 24 months of age, relatively few cortical neurons were left and 
overall atrophy was similar in both models. Consistent with findings in human NCL autopsy tissue and 
other model species, selective neuronal populations were lost. Neurons within laminae II and III were 
preferentially lost from both the CLN5 and CLN6 affected neocortices (Figure 4.4). Previous reports 
have described the loss of specific gamma amino-butyric acid (GABA)-ergic interneurons in human 
and murine NCLs, as well as in the CLN6 sheep model (Williams et al., 1977; Braak & Goebel, 1979; 
Cooper et al., 1999; Mitchison et al., 1999; Oswald et al., 2001, 2008; Bible et al., 2004; Pontikis et 
al., 2004; Tyynelä et al., 2004; Kielar et al., 2007). The interneuron loss seen in the CLN6 affected 
sheep brain follows the pattern of glial activation (Oswald et al., 2008), whereas Kay et al (2011) 
showed that the specific loss of gonadotrophin-releasing hormone (GnRH) secreting neurons of the 
hypothalamus was not associated with glial activation or storage body accumulation. This suggests 
cellular location and connectivity, rather than phenotype, are important determinants of neuronal 
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survival in ovine CLN6.  A future examination of interneuron survival in the CLN5 model would 
confirm if this was general to ovine NCL. 
Neuroinflammation is also purported to both enhance and suppress neurogenesis. Inflammatory 
factors released during acute inflammation are postulated to stimulate neurogenesis, whereas those 
released by extended, chronic uncontrolled inflammation reportedly create an environment which is 
more detrimental to neurogenesis (Whitney et al., 2009). This correlates well with the marked 
increase in adult neurogenesis evident in the CLN6 sheep model (Dihanich et al., 2009, 2012) and 
demonstrated in the current study in CLN5 affected sheep brains (Figure 4.14). An equivalent 
neurogenic capacity was detected in the hippocampus, cerebellum and subventricular zone (SVZ) of 
control and CLN5 affected neonatal brains. This showed an age-related decline in the control brains. 
However neurogenesis continued in the affected brains and did not appear to be ‘turned off’. As 
early as 6 months of age, newly-generated neural progenitor cells could be seen migrating on the 
usual rostral migratory stream destined for the olfactory bulb, but also radially along white matter 
tracts towards the affected cortical regions undergoing neurodegeneration (Figure 4.14A). Large 
spherical aggregates were observed at the lamina I/II interphase in the degenerating cortex. These 
have been shown to contain both immature and mature neuronal cells but not glial cells in CLN6 
affected sheep tissue (Dihanich et al., 2009). Their progressive appearance also became apparent 
after Nissl staining of the affected ovine cortical tissue (Figure 4.4). Equivalent aggregates have been 
reported in human CLN6 autopsied cortical tissue but not in any cortical regions of the CLN6 mouse 
model, even at advanced disease stages (Dihanich et al., 2012). There have been no previous reports 
of this phenomenon in human or murine CLN5 tissue. 
Neuroinflammation and neuronal death have been reported to trigger upregulated neurogenesis in 
other models of brain injury and neurodegenerative disease (Magavi et al., 2000; Arvidsson et al., 
2002; Curtis et al., 2003, 2005; Winner et al., 2011). Multiple steps are involved, including 
proliferation, migration, differentiation, survival and integration of the newly formed neurons into 
the CNS circuitry (Ming & Song, 2005). It is not clear what factors signal the observed cellular 
proliferation and migration in the ovine NCL brain, but it may be that the local micro-environment in 
the diseased brain resembles conditions seen during development and this is sufficient to maintain 
ongoing neurogenesis. Regardless, the increase evidenced in the current study was insufficient to 
compensate for the progressive cell loss observed in NCL. Moreover, neurogenesis in the CLN5 
affected sheep was significantly reduced at advanced disease, which may be because of the chronic 
detrimental effects induced by the chronic duration of the neuroinflammation. 
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4.3.1.5 Interconnectivity and delayed subcortical neuropathology 
No overt neuropathology was detected in the ovine NCL cerebellum during the study. The gross 
morphology of the cerebella in both ovine disease models remained unaltered during the disease 
and the size of the affected cerebella approximated normal (Figure 4.3). End-stage MRI studies on 
the affected sheep corroborated this structural finding (Amorim et al., 2015; Sawiak et al., 2015). This 
contrasts with the characteristic cerebellar pathology reported in human CLN5 and CLN6. Cerebella 
from human CLN6 patients may be normal or show some atrophy (Peña et al., 2001; Cannelli et al., 
2009), but it has been reported that the cerebellum in human CLN5 cases is severely atrophied, with 
an almost complete depletion of cerebellar granule and Purkinje cells observed post mortem 
(Tyynelä et al., 1997; Goebel et al., 1999; Haltia, 2003). Brain imaging of human CLN5 patients reveals 
atrophy of the cerebellum to be the most striking abnormality (Autti et al., 1992), yet only dilated 
cerebellar sulci without gross degeneration is seen in MRI or CT studies of a canine Border collie 
CLN5 model (Koie et al., 2004; Mizukami et al., 2012). Only mild cerebellar atrophy has been 
reported for Devon cattle with a naturally occurring CLN5 NCL (Jolly et al., 1992). The reason why 
cerebellar pathology does not manifest in ovine NCL, particularly CLN5, is unclear. The sheep in the 
current study did not die from the disease, being euthanised for humane reasons. It may be that the 
degenerative effects of the disease that manifest initially in the cerebral cortex of the ovine NCLs 
were simply delayed in the cerebellum and sheep did not live long enough to exhibit cerebellar 
pathology.  
The effect of the disease on the thalamus is more contentious. Whilst the main pathological target in 
multiple forms of NCL is the cortex (Haltia, 2003; Palmer et al., 2013), there is evidence that the 
thalamus is affected earlier in the disease progression than the cortex in murine models of CLN1, 2, 
3, 6, 8 and 10 (Pontikis et al., 2004, 2005; Weimer et al., 2006; Kielar et al., 2007; Partanen et al., 
2008; Kuronen et al., 2012). In contrast though, neuronal loss in the cortex preceded that in the 
thalamus in the CLN5 knock-out mouse (von Schantz et al., 2009). MRI studies on humans show 
decreased T2 intensity in the thalamus at the time of diagnosis in a Costa Rican CLN6 patient (Peña et 
al., 2001) and in some CLN5 cases (Holmberg et al., 2000) whilst an almost complete loss of thalamic 
neurons has been reported in post mortem human CLN5 brain tissue at end-stage disease (Tynnelä et 
al., 1997).  
The thalamus represents a structure that harbours high levels of neural interconnectivity. Every 
sensory CNS system (with the exception of olfactory) includes a thalamic nucleus that receives 
sensory signals and relays them through thalamocortical projections to the associated primary 
cortical region. Reciprocal corticothalamic fibres then relay the processed feedback information to 
the respective thalamic nuclei, in a process termed ‘top-down’ processing (Rauschecker, 1998; 
Granger & Hearn, 2007). For instance, in the visual system, sensory input from the retina is sent to 
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the lateral geniculate nucleus (LGN) of the thalamus, which in turn projects to the visual cortex of the 
occipital lobe. In turn, the LGN receives strong feedback connections from the primary visual cortex 
(Cudeiro & Sillito, 2006; Sillito et al., 2006).  
The current study is consistent with others of ovine NCL that showed that subcortical (including 
thalamic) degeneration was limited to very late in the disease progression at most (Mayhew et al., 
1985; Oswald et al., 2005, 2008; Kay et al., 2011). Whilst sparse activated microglia and astrocytes 
were first evident from 12 months of age in the affected sheep thalami, this was significantly delayed 
compared with the cortical reactive changes which originated in the visual and parieto-occipital 
cortex. Only at late stage disease were GFAP and GSB4 expression levels upregulated in the 
reciprocal LGN (Figure 4.8 and Figure 4.11). Nissl staining in the current study revealed no obvious 
qualitative changes in the subcortical or thalamic architecture and although MRI scans of CLN5 and 
CLN6 sheep reported some subcortical atrophy (Amorim et al., 2015; Sawiak et al., 2015), these 
imaging studies were performed at end-stage disease, when the entire brain was atrophied. Kay et 
al. (2011) found the cross-sectional area of the CLN6 affected thalamus was reduced by only about 
5%. The gross normality of the thalamus in the ovine NCLs compared with that in murine models 
would suggest that the pathogenic pathways may be species-specific (Kay et al., 2011) and any 
disruption in the thalamocortical network in affected sheep would result from the cortical 
degeneration rather than vice versa. 
Interestingly, the cortical laminae targeted in CLN5 and CLN6 NCL seem to differ between species. 
Layer V neuron vulnerability has been reported for human and murine CLN6 (Elleder et al., 1997) 
whilst the laminar loss of neurons in human CLN5 is targeted to laminae III and V (Tyynelä et al., 
1997) and to laminae IV-VI in CLN5 knock-out mice (von Schantz et al., 2009). As neurons within the 
individual cortical laminae are morphologically unique, with specific axonal projections to different 
CNS regions, one might expect neuronal cell loss within each lamina to produce distinct phenotypes. 
For instance, commissural and associative neurons reside within the laminae II and III which are most 
affected in the ovine NCLs. These neurons have projections across the midline to the contralateral 
hemisphere or to other ipsilateral cortical locations respectively (Greig et al., 2013). Potentially their 
loss could have significant consequences on inter-hemispheric and intracortical co-ordination of 
neuronal activity. The deeper neuronal laminae V and VI contain pyramidal and multiform neurons 
which mainly send efferent projections to subcortical structures, such as the basal ganglia and 
thalamus. Loss of these neurons would likely disrupt the reciprocal interconnections between the 
cortex and subcortex. 
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4.4.2 Spatial expression of endogenous CLN5 and CLN6 in the sheep brain 
Detection of sites of endogenous protein expression are important when designing therapies for 
genetic disorders, however the availability and/or generation of high quality antibodies to the NCL 
proteins has always been problematic. Neither the ovine CLN5 nor CLN6 proteins were amenable to 
production in bacteria, Escerichia coli, whilst recombinant protein expression in mammalian cells 
lines yielded only small quantities of purified protein (unpublished PhD observations, Janet Xu, 
Lincoln University). Sheep-specific CLN5 and CLN6 antibodies were recently developed with 
collaborators at the University of Otago and the current study set out to characterise endogenous 
protein expression in the normal sheep brain using them. Immunohistochemical staining with the 
CLN5 antibody was particularly successful, whilst the CLN6 antibody had weaker immunopositivity 
and had to be used at a much higher concentration.  
Spatial co-expression of both proteins was detected throughout the brain but the most prominent 
expression was seen in the hippocampal formation, hypothalamus, cerebral cortex and the 
developing cerebellum. This recapitulates the gene and/or protein expression patterns previously 
shown for CLN2 (Fabritius et al., 2014), CLN3 (Luiro et al., 2001; Fabritius et al., 2014), CLN5 
(Holmberg et al., 2004; Fabritius et al., 2014), CLN6 (Thelen et al., 2012) and CLN8 (Passantino et al., 
2013) in the murine brain. Expression of the CLN5 and CLN6 proteins appears to be developmentally 
regulated. Although this was not quantified, they did correlate with regions of active neurogenesis in 
the sheep brain, supporting a hypothesized role in embryonic neurogenesis and the development of 
neural networks (Fabritius et al., 2014). These neurogenic sites include the SVZ, hippocampus and 
cerebellum. In the normal sheep hippocampus, the pyramidal cells in both CA3 and CA2 subfields of 
Ammon’s horn, the hilus and the granule cells of the dentate gyrus were strongly immunoreactive 
with both antibodies. Stronger expression was seen in the ovine CA3 subfield than in CA1 (Figure 
4.15A). This correlated with CLN5 immunohistochemical findings in the mouse brain (Holmberg et al., 
2004; Fabritius et al., 2014) but contrasted with those detected in CLN6 mice by in situ hybridization 
(Thelen et al., 2012), where higher CLN6 expression was observed in the CA1 region.  
CLN5- and CLN6-positive cells in the normal sheep brain were typically neuronal in morphology. 
Collaborative studies at the University of Otago showed that CLN5 immunoreactivity in normal sheep 
brain sections co-localised with a neuronal marker (NeuN) and GABAergic interneuron markers, 
calretinin and parvalbumin (unpublished Summer Studentship observations, Kristina McIntyre, 2014). 
Whilst a quantitative PCR study by Holmberg et al. (2004) demonstrated murine CLN5 mRNA 
expression in glial cell cultures, the ovine CLN5 protein was not detected in astrocytes by co-
localisation in sheep brain tissue (Kristina McIntyre, 2014). 
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A correlation between NCL protein expression and the distinct laminar neurodegeneration and 
astrocytic activation seen in ovine NCL does not seem likely. Both proteins are expressed across 
cortical laminae II-VI, particularly in II-III. These are the same laminae that show early upregulation of 
astrocytosis and microgliosis but then are progressively lost in the affected sheep brain. However, 
although strong CLN5 and CLN6 expression is observed in the hippocampus and cerebellum, neither 
of these structures exhibit significant atrophy or neuroinflammation in ovine NCL.  
Taken together, the CLN5 and CLN6 co-expression findings from the current study suggest that 
expression of the NCL genes is cross-regulated and that the gene products operate together in a 
common pathway to cause a similar clinical phenotype.  
4.4.3 Implications for clinical therapy 
Whilst the mechanisms that underlie selective neuronal vulnerability in NCL have not yet been fully 
elucidated, targeted therapies may be beneficial for this disorder. As NCLs are primarily 
neurodegenerative diseases and endogenous CLN5 and CLN6 expression is predominantly in neurons 
and interneurons (Figure 4.15), neurotrophic gene therapies which replace the mutated gene 
product with a functional protein are likely to be most effective. Therapy can be directed to the 
regions most affected by the disease, namely the cortex, or more widespread to allow global 
correction. Such treatments will be explored in greater detail in the following chapters of this thesis 
but the general thought is that greater therapeutic efficacy will be achieved if delivered early in the 
disease process (Cabrera-Salazar et al., 2007). As evident above, there is an ideal pre-clinical 
therapeutic window during which an ordered neuroinflammatory cascade and a neurogenic ‘self-
repair’ response are underway but neurodegeneration and brain atrophy is negligible. For these 
ovine NCLs, this would be in the first four months of life. Realistically though, as definitive diagnosis 
of NCL can take from months to several years (Batten Disease Family Association UK), most human 
patients will have developed symptoms before any treatment is initiated. Affected sheep at 6 – 14 
months of age thus represent ideal early- to mid-stage disease models. Although neuropathology and 
clinical symptoms are established, gene therapies at this stage may be able to halt further disease 
progression.  
A further therapeutically relevant approach is targeted towards the extended yet spatially limited 
endogenous neurogenesis along the SVZ and within the cerebral cortex of CLN5 and CLN6 affected 
sheep. Although cell proliferation is upregulated in the diseased brain, the newly generated cells will 
carry the same genetic defect and hence any attempt at self-repair will inevitably fail. Yet if some of 
these neurogenic cells could be corrected early in the disease by gene therapy, it may be sufficient to 
halt disease pathology before it becomes irreversible. Intracerebroventricular administration during 
early stages of disease, of viral vectors expressing the corrective NCL gene, may be able to cross the 
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ependymal cell barrier resulting in transduction of cells in the SVZ, from which neurons are 
generated before migrating to their final destination in the brain parenchyma. This could facilitate 
widespread dissemination of transduced neurons throughout the CNS, allowing treatment of the 
global brain defects of NCL. Equally for NCL subtypes with soluble protein deficits (e.g. CLN1, 2, 5 and 
10), corrected ependymal cells could secrete the missing protein into the CSF circulation for uptake 
by other protein-deficient cells. 
Evidence presented in this study and by others (Oswald et al., 2005; Kay et al., 2006) of early 
activation of glial cells highlights their central role in NCL pathogenesis. As a chronic inflammatory 
response can be detrimental to both neuronal survival and neurogenesis (Raivich et al., 1999; Stoll & 
Jander, 1999; Streit et al., 2004; Whitney et al., 2009; Lyman et al., 2014; Lee & MacLean, 2015), 
early suppression of inflammation may be an important treatment strategy. The chronic oral 
administration of an anti-inflammatory drug, minocycline, alone to pre-clinical CLN6 affected sheep 
did not have any neuropathological benefits or prevent the clinical course of the disease (Kay and 
Palmer 2013). Anti-inflammatory neuroprotection may have a better effect in the treatment of the 
NCLs when given in combination with other therapies which correct the genetic defect (see Section 
8.3.4). 
4.5 Conclusion 
Given the different class and subcellular location of the defective proteins in the ovine CLN5 and 
CLN6 models, the phenotypic similarities between the two forms were remarkable. In both, cortical 
neurodegeneration is presaged by dense glial activation and these neuropathological events display 
regional selectivity. The parieto-occipital and visual cortices were first affected pre-clinically in both 
CLN5 and CLN6 disease models, with subsequent reactive and atrophic changes spreading to the 
somatosensory and entorhinal cortices during early- to mid-stage disease, and reaching the frontal 
association and motor cortices later in the disease process. Consistent with the advanced onset of 
clinical disease, the reactive and neurodegenerative changes were more pronounced earlier in the 
CLN5 Borderdale sheep brain. However sub-cortical involvement only occurs very late in the disease 
progression in both sheep models. By end-stage disease, NCL affected sheep brains weigh only 54% 
to 58% of a normal brain, with most of the atrophy involving the cerebral cortex in which few 
neurons remain. Concurrent with the progressive neuroinflammation and neurodegeneration in 
ovine NCL, extended yet spatially limited endogenous neurogenesis occurs along the SVZ and within 
the cerebral cortex of affected CLN5 and CLN6 sheep. While this self-repairing mechanism may be 
effective in maintaining neuronal functionality at early and mid-stages of the disease, it fails at more 
advanced phases. 
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The current assumption for NCL therapies, particularly gene therapy, is a need for global repair of 
neurons. However the regionality and selectivity of neuron loss suggest that targeted therapeutics 
might prove most effective. If delivered early in the disease process, therapies could either be 
directed to at-risk cells or to the neural progenitor cell in the SVZ, aiming to preserve the beneficial 
effects of enhanced neurogenesis and taking advantage of the latent potential of the diseased brain 
to orchestrate a self-repair response. 
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determined by the capsid serotype (Zincarelli et al., 2008). Several AAV serotypes (e.g. AAV1, 5, 9, 
rh10) mediate widespread transduction of the CNS in animal model systems (Burger et al., 2004; 
Cearley & Wolfe, 2006; Markakis et al., 2010; Swain et al., 2014) yet only AAV1 has been tested in 
the sheep brain, targeting short interfering RNA to the hypothalamus in a gene knockdown approach 
(Dufourny et al., 2008). 
Much interest has centered on AAV serotype 9 for CNS-directed gene transfer, due to its proven 
spread and efficiency of transduction, and predominant neuronal tropism (Foust et al., 2009; Gray et 
al., 2013; Samaranch et al., 2013; Swain et al., 2014). It has been shown to undergo efficient axonal 
transport within the brain (Cearley & Wolfe, 2006) and crosses the blood-brain barrier (BBB) to 
transduce neurons and glia within the brain and spinal cord (Foust et al., 2009; Gray et al., 2011). 
With clinical translation in mind, determining the optimal route of administration and the scalability 
from rodent models to larger animal species is essential. This proof-of-concept study set out to 
determine the effectiveness of AAV9 as a gene transfer vector in the normal sheep brain and how 
two distinct delivery routes affected transduction patterns of this vector. More specifically, it was 
questioned whether transduction of the brain and spinal cord parenchyma would be better achieved 
via direct parenchymal injections or by intracerebroventricular (ICV) infusion of sheep. Based on 
previous studies it was hypothesized that intraparenchymal (IP) administration of AAV9 expressing 
an enhanced green fluorescent marker protein (eGFP, hereafter termed GFP) gene driven by a 
ubiquitous promoter would result in a more focal distribution of the vector in the ovine brain, 
whereas a more global transduction may be achieved by direct ICV delivery. If so, widespread 
improvement in neuropathology may be achieved by AAV9-mediated ICV delivery of disease-
modifying transgenes into large mammalian brains, suggesting an effective treatment route for the 
neurodegenerative pathology seen in some human lysosomal storage diseases. 
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5.2 Materials and methods 
5.2.1 Viral vector 
Recombinant adeno-associated viral vector, serotype 9, expressing enhanced green fluorescent 
protein, (AAV9.CB7.Cl.eGFP.WPRE.rBG), was purchased from the vector core at the University of 
Pennsylvania (cat # AV-9-PV1963; viral titre 3.6 x 1013 viral genomes (vg)/ mL, Philadelphia, PA, USA). 
The vector genome encoded AAV2 inverted terminal repeats (ITRs) flanking a transcription unit 
containing GFP under the control of the CAGS promoter (CB7 promoter with chicken beta-actin 
intron (CI)) and pseudotyped with AAV9 capsid proteins. The importation and use of the recombinant 
AAV9 vector was approved by the New Zealand Environmental Protection Authority (Permits 
GMC100166 and GMD004899). 
5.2.2 In vivo viral injections 
Three healthy 9-month old Coopworth sheep (Ovis aries) were anaesthetised and prepared for 
neurosurgery as described in Section 3.2.2. Two sheep received unilateral parenchymal injections of 
25 μl (containing 9 x 1011 vg) of AAV9-GFP into three sites. Co-ordinates for parenchymal structures 
were (from bregma): for the primary visual (occipital) cortex, 6 , 8 and 8 mm caudal to bregma, left of 
midline, and ventral to the pial surface respectively, for the thalamus -8, 8 and 27 mm and for the 
parietal cortex -8, 8 and 8 mm. The same drill hole was used for the thalamic and parietal injections 
but the needle was directed 10° rostral for the latter to avoid following the same needle track. For 
each injection, 2 μl of viral vector was infused over 30 seconds, the needle withdrawn 0.5 mm, and 
the process repeated until the full volume was discharged. The needle was left in position for a 
further 3 minutes before slow retraction. A third sheep received bilateral ICV injections of 450 μl 
AAV9-GFP (containing 1.62 x 1013 vg) infused at a rate of 0.1 mL/ min. 
Treated animals were housed indoors, fed a mixed ration of chaffed lucerne and pelletised sheep 
feed concentrate (see Section 3.1.1). They were monitored daily for any adverse symptoms. 
5.2.3 Tissue collection and immunohistochemistry 
Procedures were performed as described in Section 3.7. Animals were euthanized and the brains 
perfusion-fixed in situ 4 weeks after AAV9 administration. Spinal cord samples (50 – 100 mm in 
length) were also collected from the lumbar, thoracic and cervical regions, fixed in 10% formalin for 5 
days and then processed with the brains (Section 3.7). Serial sagittal brain sections and coronal spinal 
cord samples (50 μm), cut on a freezing sliding microtome (MICROM International, Walldorf, 
Germany), were stored in cryoprotectant in 96-well plates at -20°C. 
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GFP immunohistochemistry was performed as previously described (Linterman et al., 2011). In brief, 
floating sections were pre-incubated in 1% H2O2 , 30 min, blocked with 10% normal goat serum (Life 
Technologies, Carlsbad, CA, USA) in 0.3% Triton X-100 in phosphate-buffered saline (PBS), 2 h, 
followed by overnight incubation at 4°C with a rabbit polyclonal anti-GFP antibody (1:20,000; 
#ab290; Abcam, Cambridge, MA, USA), preblocked on normal sheep brains to remove non-specific 
antibodies. Immunoreactivity was detected with biotinylated goat anti-rabbit IgG (1:1000; B7389; 
Sigma-Aldrich, Castle Hill, NSW, Australia), 2 h, followed by ExtrAvidin peroxidase (1:1000; E2886; 
Sigma- Aldrich), 2 h, and staining with 0.5 mg ml-1 3, 3’-diaminobenzadine (DAB; D5637; Sigma-
Aldrich) and 0.01% H2O2 in PBS. Sections were mounted in 0.5% gelatine and 0.05% chromium 
potassium sulphate on glass slides, air dried, dehydrated with 100% ethanol, cleared with xylene and 
coverslips mounted with DPX (BDH, Poole, England). No staining was observed in any negative 
control sections in which either the primary or secondary antibodies were omitted. 
Parallel series of sections were double-labelled with GFP and either glial fibrillary acidic protein, GFAP 
(1:1000; DAKO Z0334; Carpinteria, CA, USA) or the fluorescent Nissl dye, NeuroTrace (1:150; Life 
Technologies N21482) as markers of transduced glial cells and neurons, respectively (Section 3.8, 
Linterman et al., 2011). Fluorescent sections were mounted in 0.5% gelatine and 0.05% chromium 
potassium sulphate on glass slides, air dried, coverslipped using glycerol and imaged on a Zeiss 
LSM710 confocal microscope. 
A standard Nissl (cresyl violet) counterstain, and GFAP or biotinylated α-D galactose specific 
isoelectin I-B4 from Griffonia simplicifolia (1;500; GSB4; Vector Laboratories, Peterborough, UK) 
immunohistochemistry (see Section 3.8), was performed on adjacent sections around the injection 
sites, which were examined for signs of injection-related pathology. 
5.3 Results 
Sheep showed no adverse effects to the surgery, recovery from anaesthesia was uneventful and all 
resumed normal eating within 12 h. Rectal temperatures, growth rates, body condition and 
behaviour remained normal during the subsequent four-week observation period, after which the 
sheep were euthanized. Expression of GFP in the CNS was then compared for the two delivery routes 
using immunohistochemistry (Figure 5.1). 
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5.3.1 ICV delivery of AAV9-GFP mediates widespread CNS transduction 
GFP immunohistochemistry one-month post-ICV AAV9 delivery revealed widespread transduction in 
each hemisphere (Figure 5.1A,C), indicative of effective viral transport within the circulating CSF and 
vector penetration from the CNS surface to deeper regions. The broad transgene distribution 
extended through all cortical lobes and respective white matter tracts. Large clusters of GFP-positive 
cells were visible through most cortical laminae, particularly the layer V projection neurons of the 
occipital, parietal and frontal lobes (Figure 5.2A-C), extending up to 600 μm along multiple dendritic 
and axonal processes. Hilar, dentate gyrus and CA3 cells of the hippocampus were intensely stained 
as were cuboidal ependymal cells lining the lateral ventricle, extending right through to the rostral 
ventricular pole in all mediolateral sections analysed (Figure 5.2E). Additionally, scattered transduced 
subependymal cells were observed, at least 350 μm from the ventricular surface.  
Subcortical GFP expression was more diffuse, although a band of stained puncta was evident in the 
superficial grey layers of the thalamus (Figure 5.2G) and the rostral and caudal colliculi. Clusters of 
immunopositive cells were present in the more superficial thalamic nuclei and the hypothalamus 
(Figure 5.2H) but transduction in the caudate nucleus and striatum was limited to the ventral surface 
regions. Transduction favoured cells of neuronal morphology, including olfactory bulb neurons and 
cerebellar Purkinje cells whose dendritic trees ramified in a single plane into the molecular layer 
(Figure 5.2F, J). Occasional transduced protoplasmic astrocytes were seen in the grey matter of the 
occipital cortex (Figure 5.2K). 
GFP-positive cells were also seen along the extent of the spinal cord, from cervical to lumbar 
segments (Figure 5.3A). Transduced cell types ranged from interneurons of the intermediate spinal 
grey matter, scattered stellate cells in the ventral funiculi, columnar ependymal cells lining the CSF-
filled central canal to the uni-, bi- and multipolar sensory neurons of the dorsal horn and ventral horn 
motor neurons with large (25 - 40 μm) diameter somata (Figure 5.3B). GFP was expressed along the 
thickened branched processes of the sensory neurons and the long thin extensions of the motor 
neurons, up to 350 μm from the cell soma.  
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Figure 5.3    Robust transduction of the sheep spinal cord after ICV AAV9-GFP administration 
Robust transduction of the spinal cord was also evident one month after delivery of 1.62 x 1013 vg of 
AAV9-GFP into the lateral cerebral ventricles. A. Low-magnification images of cervical, thoracic, and 
lumbar spinal cord revealed the presence of GFP-positive cells at all levels. B.  A representative image 
of a lumbar spinal cord section, with high-magnification of the boxed areas showing immunopositive 
sensory and motor neurons of the dorsal and ventral horns respectively as well as transduced stellate 
cells in the ventral funiculi. Scale bar represents 0.2 cm in A, 200 m in B and insets 100 m.  
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5.3.2 IP delivery of AAV9-GFP results in localised and distal transduction 
Immunohistochemistry a month after IP injection of AAV9-GFP revealed the highest density of GFP-
positive cells proximal to the injection sites (Figure 5.1B), and some distal targeting (arrowheads). 
Dense GFP neuropil immunoreactivity was observed along the needle tracks in the occipital and 
parietal lobe cortical grey matter (Figure 5.4A,C), but declined further away from the centre of 
injection (Figure 5.4B). Lateral spread from the needle tracts was considerable, with GFP-positive 
soma spanning an area up to 12 mm rostrocaudal and 18 mm mediolateral from the injection 
column, indicating diffusion through the parenchyma. Injection into the thalamus, the largest relay 
centre for both sensory and motor modalities, resulted in robust transgene expression through most 
thalamic nuclei (Figure 5.4J) and distribution to motor and sensory cortical regions distal from the 
injection sites. AAV9 transduced a heterogeneous population of neurons, with immunopositive bi- 
and multipolar neurons, including the layer V projection neurons of the ipsilateral frontal association 
and motor cortices (Figure 5.4D,E). Neuronal somata were intensely stained, with GFP expression 
through the axonal hillock extending up to 500 μm along axonal and dendritic extensions. Cuboidal 
ependymal cells were transduced through multiple layers (Figure 5.4L), but not along the full extent 
of the ventricular surface. The cortical columnar delivery stratagem was designed to inject vector 
into the subventricular zone (SVZ) at its greatest depth but to avoid leakage into the ventricle. 
Transduced ependyma were therefore located near the base of the cortical injection sites, and 
sporadic GFP-positive subependymal cells with multiple processes extending vertically into the SVZ 
were evident. Very few hippocampal cells were transduced (less than five GFP-positive somata per 
field analysed). 
There was modest AAV9 transduction in the non-injected hemisphere, typically concentrated in 
homotopic regions contralateral to the injection sites such as the parieto-occipital cortex and the 
thalamic ventricular surfaces (Figure 5.4F), but extending to sporadically transduced cells in the grey 
matter of the frontal association and motor cortices. Notably GFP-positive cells were detected in the 
non-injected hemisphere over 20 mm mediolateral from the closest injection site, suggesting antero- 
and/or retrograde transport of the protein or vector through axons or dendrites. 
Examination of the sub-cortical regions of the IP injected brains revealed transduced olfactory bulb 
neurons (Figure 5.4G), striatal cells (Figure 5.4H), Purkinje cells of the cerebellum (Figure 5.4K) and 
caudal brainstem cells, which also indicated long-distance axonal transport of the AAV9 vector or 
protein.  
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5.3.3 Both ICV and IP delivery of AAV9-GFP result in predominantly neurotropism 
AAV9 tropism was assessed in representative brain sections labelled with antibodies against GFP and 
cell specific phenotypic markers. GFP expression was strongest in cells with neuronal morphology, 
confirmed by confocal colocalisation of the neuronal marker NeuroTrace and GFP (Figure 5.5A,B). 
Multipolar NeuroTrace-positive neurons expressed GFP throughout spheroid cell somata and over 
300 m along multiple dendritic and axonal processes. Although scattered astrocytic profiles were 
seen using histochemical staining (Figure 5.2K), these were not detected using confocal co-labelling 
with GFAP antibodies (Figure 5.5C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5    Dominant neurotropism of the AAV9-GFP vector in the healthy adult sheep brain                                     
Representative images of brain sections stained with antibodies against GFP, A-B, Nissl, NeuroTrace 
(neurons) or C. GFAP (an astrocytic marker). Both ICV and IP infusion resulted in preferential 
neuronal transduction and low transduction of astrocytes. Scale bar represents 50 μm.  
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5.3.4 IP delivery of AAV9-GFP triggers an inflammatory response 
Examination of GFAP, GSB4 (a microglial marker) and GFP/Nissl counterstained sheep sections 
indicated no signs of inflammation or other pathology in the ICV injected hemispheres and the GFP-
expressing cells retained healthy morphologies typical of their type (Figure 5.6A,C,E). Gliosis was not 
evident and no adverse effects were detected within the vasculature. Elongated flattened GSB4- 
positive perivascular cells were observed, as they were in non-injected control brains.  
Conversely, a localised lymphocytic inflammatory and focal glial response was evident around the 
needle tracks in the IP injected sheep. This was confirmed by GSB4 and GFAP immunohistochemistry, 
which revealed activated astroglia and microglia, possessing large soma and thickened retracted 
processes, in the parenchymal regions of highest transduction (Figure 5.6B,D) but typical quiescent 
ramified glial cells throughout the rest of the brain. Perivascular cuffs of macrophages and microglial 
infiltrates were observed in the white matter at the cortical IP injection sites (Figure 5.6F) 
accompanied by an incipient reactive astrocytosis. There was no indication of a brain-wide immune 
response or cell death resulting from these IP injections or in regions with high GFP expression 
mediated through retrograde vector transport. 
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Figure 5.6   Differential inflammatory responses following ICV and IP injection of AAV9-GFP  
Sagittal sheep brain sections were stained against A,B an astrocytic marker (GFAP), C,D a microglial 
marker (GSB4) and E,F GFP with Nissl (cresyl violet) counterstain. No neuroinflammatory response 
was found one-month after ICV administration (A,C,E) whereas inflammatory marker reactivity and 
perivascular cuffing was apparent in the IP-injected brains (B,D,F) particularly near the cortical 
injection sites. The reactive astrocytosis evident at the occipital injection site and adjacent gyrus in 
the IP-injected brain (B) was not seen in the distal cortical regions. Activated microglia were localized 
to the white matter tracts in close proximity to the intracortical injection sites (D). No perivascular 
infiltration or luminal pathology was observed in the blood vessels after ICV delivery (E) however 
localized perivascular inflammatory foci were seen in the transduced cortical white matter (asterisks) 
on IP infusion (F). Scale bar represents 100 μm for A,B,E,F and 500 μm for C,D.   
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5.4 Discussion 
This study aimed to test the ability of AAV9 to transduce neurons in the normal sheep brain by direct 
stereotactic delivery into the brain parenchyma or into the CSF of healthy, juvenile sheep. Vector 
administration by both routes was safe and well tolerated, with stable GFP expression evident one 
month post-injection. AAV9 injections into the sheep brains resulted in strong robust predominantly 
neuronal transduction. After IP delivery, this was localised with some distal targeting by diffusion and 
axonal transport but was much more widespread through the CNS after ICV administration, including 
the spinal cord (Figure 5.1). The neuronal preference with minimal tropism for astrocytes following 
either delivery route is similar to that seen in other animal models. Strong neuronal transduction has 
been observed after both ICV and IP delivery of AAV9-GFP into the dog brain (Haurigot et al., 2013; 
Swain et al., 2014), cortical neurons were specifically targeted after IP injections into mice (Aschauer 
et al., 2013) and striatal AAV9 injection into non-human primates resulted in a high tropism for 
neuronal cells, with low transduction of astrocytes (Masamizu et al., 2011). 
Previously direct brain parenchymal injections of AAV vectors have been extensively explored in 
animals and extended into clinical trials for patients affected by neuropathic LSDs, such as Canavan 
disease (Janson et al., 2002; Leone et al., 2012), late infantile neuronal ceroid lipofuscinosis (Crystal 
et al., 2004; Worgall et al., 2008), mucopolysaccharidosis types IIIA (Tardieu et al., 2014) and 
metachromatic leukodystrophy (Zerah et al., 2015). Naturally occurring ovine models of other LSDs 
exist and represent ideal pre-clinical models to test the efficacy and long-term safety of gene 
therapy, and also validating other translational delivery approaches. However the use of AAV vectors 
in the sheep brain has not been previously documented but, consistent with findings in non-human 
primates and dogs (Masamizu et al., 2011; Swain et al., 2014), unilateral IP injections of AAV9 in this 
ovine study result in focal transduction, with greater diffusion through the brain parenchyma than 
was reported for lentiviral vectors (Linterman et al., 2011). The vector doses given to sheep were 
comparable to those used in human clinical trials (Crystal et al., 2004). There was evidence of 
neuronal transport of AAV9 along neural projections, with distal targeting of layer V projection 
neurons of the ipsilateral frontal association and motor cortices (Figure 5.4), and scattered clusters of 
transduced cells in the uninjected hemisphere. This is consistent with previous studies in mice, dogs 
and non-human primates which indicate AAV9 undergoes anterograde and/or retrograde axonal 
transport with  spread of the transgene product along specific interconnected CNS pathways and to 
the contralateral hemisphere through axonal tracts (Cearley & Wolfe, 2006, 2007; Masamizu et al., 
2011; Castle et al., 2014; Swain et al., 2014). Additionally Purkinje cells of the cerebellum and caudal 
brainstem cells were transduced, a finding not observed in the hind-brain of dogs injected 
intraparenchymally with AAV9-GFP (Swain et al., 2014). 
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In the current study, three parenchymal sites were targeted. Sheep and human brains are too large 
and complex to attempt repair of the whole brain as viral spread from IP-directed gene therapy is 
relatively limited, therefore careful targeting of selected regions and cell types is required for this 
approach to be successful. The thalamus represents a structure that harbours high levels of neural 
interconnectivity. It receives afferent input from many CNS structures and relays this information 
through corticothalamic projections to the cortex, from which it also receives reciprocal sensory 
signals. Thus widespread distribution of lysosomal enzymes through the mammalian CNS may be 
achieved via axonal retrograde transport by targeted correction of the thalamus. Evidence to support 
this comes from widespread enzyme distribution from the CNS and eye after targeted thalamic 
injections with AAV vectors in adult GM1- gangliosidosis mice (Baek et al., 2010) and cats (McCurdy 
et al., 2014). The distal targeting of AAV9-GFP to the ipsilateral ovine motor and frontal cortex seen 
in the current study may be attributed to the IP thalamic injection. Cortical injections into the sheep 
parietal and occipital lobes specifically targeted the ependyma and subependymal cells of the 
subventricular zone (SVZ), in an approach explored in sheep with lentiviral-mediated gene transfer 
(Linterman et al., 2011). The rationale behind choosing these parenchymal sites is that specific 
direction of the injection locale to the subventricular zone (SVZ) could correct the resident neural 
progenitor cells (NPCs) in this region, providing an in situ stem cell repair therapy. The robust focal 
transduction detected after IP delivery of AAV9 vector to the sheep brain demonstrates that 
stereotactic injections in sheep can target smaller neuronal populations with distinct functions. 
The intraparenchymal approach is ideal for gene therapies targeted to selected cell populations or 
specific anatomical circuitry, such as in Parkinson’s disease, or specific anatomical regions where 
neuropathology is localized. However many neurogenetic disorders require wide-scale CNS 
transduction which is more difficult and less practical to achieve by IP injection, as shown here and 
by others (Foust et al., 2009; Fu et al., 2011; Hinderer et al., 2014). Scaling up the dose requires 
greater injection volumes and more injection sites. Additionally there was evidence of a focal 
immune response at the IP injection sites (Figure 5.6), which may be against the viral capsid or the 
transgene product itself, or following mechanical trauma associated with the needle insertion and/or 
the volume injected. Despite evidence for naturally occurring antibodies to AAV9 in sheep (Tellez et 
al., 2013), a humoral immune response to the capsid seems unlikely in this scenario as no obvious 
clinical problems have occurred in sheep undergoing long-term combined ICV/IP AAV therapeutic 
treatment (see Chapter 6 and Chapter 7). AAV9-mediated CNS expression of non-self proteins, 
including GFP, has been reported to induce neuroinflammation and neurotoxicity in rat and non-
human primate brains after IP and intra-CSF delivery (Ciesielska et al., 2013; Samaranch et al., 2014). 
For patients with null mutations in the endogenous gene or those previously exposed to AAV 
serotypes, a non-self transgene response could become a problem in gene therapy (Mingozzi & High, 
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2013), regardless of delivery mechanism. A similar gauge needle was used in the ICV delivery without 
an immune response, indicating that the volume of fluid injected may be the sole cause of the 
localised inflammation after IP injection. How long this immune response persists is yet to be 
determined.  
Intracerebroventricular injection of AAV into the CSF represents an alternative approach to 
transduce the brain. Initial attempts with AAV serotypes 2, 4 and 5 in mice and mammalian brains 
were thwarted, albeit with successful transduction of ependymal cells lining the ventricles, as there 
was limited or no penetration of the deep brain parenchyma from the CSF spaces and a lack of 
neuronal transduction without the systemic addition of adjuvants, such as mannitol (Ghodsi et al., 
1999; Davidson et al., 2000; Liu et al., 2005b; Fu et al., 2003). In contrast, this study shows that direct 
ICV injection into the lateral ventricles is an effective method for AAV9-mediated transduction of the 
sheep CNS, resulting in comprehensive and strong transduction of the CNS (Figure 5.2), and no 
significant neuroinflammatory response at the dose used (Figure 5.6). Ependymal cells were targeted 
but GFP expression was detected throughout the CNS. A similar result was seen through the central 
and peripheral nervous systems following ICV delivery and a titre-matched dose of AAV9-GFP vector 
into dogs (Haurigot et al., 2013). This contrasts a lack of widespread transduction following ICV 
injection into the rat (Gray et al., 2013), which may relate to the smaller size of the rodent CNS 
highlighting the translational limitations of these models. Recombinant protein expression in mice 
was restricted to upper spinal cord segments following direct ICV delivery in a previous study 
(Storkebaum et al., 2005), whereas ICV infusion of AAV9 results in strong transduction of the sensory 
and motor neuron pools throughout the ovine spinal cord. This is consistent with observations 
following intra-CSF delivery to cats, pigs, dogs and non-human primates (Bevan et al., 2011; Federici 
et al., 2012; Samaranch et al., 2012, 2013; Haurigot et al., 2013; Bucher et al., 2014) and systemic 
delivery in mice, cats and non-human primates (Duque et al., 2009; Bevan et al., 2011).  
As mentioned, the efficacy of AAV9 transduction by alternative intra-CSF (intrathecal or 
intracisternal) delivery routes has been studied in other models systems. Doses in the range of 1010 - 
1012 vg/ kg were sufficient to mediate widespread spinal cord expression but only variable brain 
parenchymal transduction. From a neuroanatomical point of view, ICV delivery should be effective 
for brain-directed genetic correction than other intra-CSF delivery routes. The CSF is produced 
through dialysis of the capillary blood by epithelial cells of the choroid plexus. These plexi lie adjacent 
to the ependymal cells lining the lateral ventricles and the roof of the third and fourth ventricles. 
Widespread parenchymal correction can be achieved by ICV directed AAV9 gene transfer but this 
route also offers the opportunity for targeted transduction of the ependymal cells lining the 
ventricle, with resultant secretion of the transgene product into the CSF and hence an ongoing global 
protein delivery mechanism. Freshly made CSF flows from the lateral ventricles via the foramen of 
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Monro into the third ventricle, and then into the fourth ventricle via the cerebral aqueduct in the 
brainstem. From there, it passes into the cisterna magnum and subarachnoid space, bathing the 
brain and spinal cord, before being returned to the circulation via the arachnoid villi. One might 
expect less vector would be available to target the brain and ventricular system after intracisternal, 
and especially intrathecal, delivery than by the ICV route, although this direct comparison has yet to 
be examined in sheep. Interestingly, there was no evidence of transduced cells in the brain, not even 
the ventricular ependyma, after injection of lentiviral vectors into the cisterna magnum of sheep 
(Linterman et al., 2011). In dogs, delivery of 2 x 1013 vg AAV9-GFP resulted in slightly greater GFP 
expression and vector distribution in the brain, spinal cord and peripheral nervous system after ICV 
delivery than through the intracisternal route (Haurigot et al., 2013). Limited distribution through the 
CNS has been achieved by the lumbar intrathecal approach. Preclinical data in pigs show vector 
penetration was restricted to the injection site after lumbar delivery and required three consecutive 
bolus injections into the cervical, thoracic and lumbar regions to achieve widespread spinal cord 
transduction (Federici et al., 2012). Moreover, intracisternal and intrathecal routes also resulted in 
contradictory tropism observations. For example, intracisternal injection of AAV9 resulted in both 
neuronal and astrocytic transduction in cats (Bucher et al., 2014) whereas cisterna magna delivery to 
non-human primates resulted in greater transduction of fibrous and protoplasmic astrocytes than of 
neurons (Samaranch et al., 2012). 
In terms of clinical translation and practicality, lumbar intrathecal delivery is a relatively low risk 
procedure and the most clinically applicable however, with inefficient penetration of the CNS, it may 
be futile. Whilst cisternal entry is a routine procedure in veterinary medicine, it is not as practicable 
in paediatric clinical medicine because of the smaller size of the human cisterna magna and its close 
proximity to the vital cardiac, respiratory and vasomotor centres of the medulla (Haurigot et al., 
2013; Hinderer et al., 2014). Surgical ICV delivery on the other hand is relatively straight-forward; 
ventriculosotomy being a routine diagnostic and therapeutic neurosurgical procedure in humans 
with more than 24, 000 procedures performed in the United States annually (Rosenbaum et al., 
2014).  
A third option, systemic intravenous (IV) injection of AAV9 vectors, is minimally invasive and offers 
global transgene delivery, however much larger vector doses would be required. For example doses 
of more than 1014 vg of AAV9 (in a maximum volume of 10 mL) were utilized in macaques (Bevan et 
al., 2011) with 1015 vg predicted for adult human treatment (Samaranch et al., 2012). With systemic 
IV delivery, the vector circulates through the entire body so is not restricted to the CNS and 
transduction of peripheral organs can occur. This can result in a loss of vector, off-target side effects 
and the increased risk of an immune response (Zincarelli et al., 2008; Xie et al., 2011). High titres of 
neutralising antibodies may block transduction of the target or peripheral tissues after IV delivery, 
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with a resultant lack of efficacy (Gray et al., 2011; Samaranch et al., 2012). Vector neurotropism after 
IV delivery is also reported to vary with age at injection. Peripheral, systemic injection of murine 
neonates resulted in widespread neuronal transduction, whilst adult mice exhibited a preferential 
astroglial tropism (Foust et al., 2009). AAV9 also targeted glial cells predominantly after intravascular 
administration to adult monkeys (Bevan et al., 2011; Samaranch et al., 2012). This age-dependent 
viral tropism has not been reported following ICV delivery, so the reduced vector dose and wide 
dissemination make it an advantageous alternative for neuronal transduction. 
5.5 Conclusion 
In summary, proof of therapeutic concept for AAV9-mediated transduction has been established in a 
sheep model following ICV or IP administration. Neurotropic global transgene expression was 
achieved by ICV delivery with no evidence of vector or procedural neuroinflammation or toxicity 
indicating that this route of administration may be simpler and more effective than multiple 
intraparenchymal injections. Recently, the ICV approach has proven efficacious in correcting somatic 
and neuropathology in diverse LSD animal models, with favourable phenotypic outcomes after AAV9 
administration in MPS-IIIA and IIIB mice (Haurigot et al., 2013; Ribera et al., 2015), and AAV2 in a 
canine model of CLN2 NCL (Katz et al., 2015). Concurrent studies with AAV9-mediated ICV delivery of 
corrective genes to ovine models of CLN5 and CLN6 NCL show protection from pathologic phenotype 
and behavioural dysfunction (Chapter 6 and Chapter 7 in this thesis). Clinical development of the ICV 
route as a therapeutic approach is underway. 
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efficacious results in the CNS of numerous murine and large animal models (Burger et al., 2004; 
Sondhi et al., 2005; Baek et al., 2010; Haurigot et al., 2013) and an excellent safety profile in non-
human primate and initial human studies (Markakis et al., 2010; Bartus et al., 2013; Gray et al., 2013; 
Tardieu et al., 2014). Of the AAV serotypes, AAV9 has been used increasingly in the treatment of 
neurodegenerative disorders because of its efficient targeting of the brain when introduced into the 
parenchyma, systemic circulation or cerebrospinal fluid (CSF) (reviewed by Dayton et al., 2012). AAV9 
has also been shown to mediate neurotropic gene delivery to the sheep brain after both IP and intra-
CSF delivery (Chapter 5). 
Promising results achieved with direct delivery of AAV vectors to the brain parenchyma in animal 
models (Hackett et al., 2005; Sondhi et al., 2005, 2007, 2012; Passini et al., 2006) have been 
extended to human clinical trials for late infantile NCL patients caused by mutations in the CLN2 gene 
(see Section 1.6.4). However limited distribution from the point of injections required vector 
administration at multiple sites (Worgall et al., 2008) and specific surgical procedures (Souweidane et 
al., 2010), suggesting other vectors and delivery routes should be explored. Large disease-relevant 
animal models, such as sheep, serve as a valuable translational tool in which to test and expedite 
these approaches to the clinic. 
The current study was instigated to test and compare the safety and efficacy of AAV9- and lentiviral 
vector-mediated delivery of ovine CLN5 in a naturally occuring CLN5 NCL model in New Zealand 
Borderdale sheep. Affected sheep have a c.571+1G>A splice site mutation in the CLN5 gene (Frugier 
et al., 2008), which results in the loss of function of an uncharacterised soluble lysosomal 
glycoprotein in human patients (Holmberg et al., 2004; Sleat et al., 2005, 2006). The ovine model 
recapitulates many of the clinical and neuropathological features of the human disease, including 
visual loss, progressive neurodegeneration and storage body accumulation (Jolly et al., 2002; Frugier 
et al., 2008). Clinical progression is remarkably stereotypical. Affected sheep initially develop visual 
loss at 10 - 11 months of age, with progressive neurodegeneration, reaching a humane endpoint 
typically before 22 months of age. It was hypothesised that pre-symptomatic viral-mediated gene 
transfer with the corrective CLN5 transgene would attenuate the natural disease progression in CLN5 
affected sheep. If so, this would provide some hope in the search for a treatment for this and other 
soluble forms of NCL.  
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6.2 Materials and methods 
6.2.1 Study design 
CLN5 affected Borderdale sheep received lentiviral- or AAV9-mediated gene therapy between 2.1 - 
3.5 months of age, prior to the onset of neurological disease signs.  Viral vectors were delivered 
bilaterally into the cerebral lateral ventricles (intracerebroventricular; ICV) and to two 
intraparenchymal (IP) (cortical) sites which have been shown to degenerate significantly in the 
affected sheep. Clinical, cognitive and behavioural tests were developed, in conjunction with 
quantitative CNS imaging techniques, to assess disease progression and monitor therapeutic 
correction longitudinally. 
The study endpoint was initially defined as 18 months of age, equivalent to an advanced disease 
state in untreated affected sheep, at which age the treated sheep were to be euthanized and 
collected tissues evaluated for any pathological amelioration. Once it became apparent that the 
treatment was functionally efficacious, the study was continued and has not yet reached its final 
endpoint. Table 6.1 summarises the study design.  
6.2.2 Animals 
Borderdale sheep within the CLN5 research flock were bred, maintained and diagnosed at birth as 
described in Section 3.1(Frugier et al., 2008). Cohorts of homozygous affected (CLN5-/-; n = 4) and 
clinically normal heterozygous (CLN5+/-; n = 4) sheep were maintained under normal pastural 
conditions at the Research Farm, Lincoln University, and acted as untreated affected and normal 
controls. An additional six pre-symptomatic CLN5-/- sheep were weaned early, at 1.5  0.1 (lentiviral 
cohort) or  2.2  0.2 (AAV cohort) months of age, housed indoors and fed initally on calf start-mix 
(Reliance Feeds, Rolleston, New Zealand), chaffed lucerne and a pelletised lucerne feed concentrate 
(see Section 3.1.1) prior to in vivo gene injection therapy at 2.1 to 3.5 months of age. There was one 
sibling pair in the study (1105/13 and 1106/13), with one in each treatment cohort (Table 6.1). In 
November 2015, the New Zealand Environmental Protection Agency (EPA) indoor housing 
restrictions for the AAV9-treated sheep were relaxed and these animals were permitted to move to 
outdoor pasture for the remainder of the trial. One animal remains alive at 33 months of age in May 
2016. Two sheep included in the gene therapy study (1106/13 and 1117/13) were ram lambs that 
had been castrated by elastration prior to 1 month of age. Pretherapy, the CLN5 genotype was 
reconfirmed  from genomic DNA isolated from venous blood and this was repeated by an 
independent evaluator every six months and/or at post mortem. 
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6.2.3 Viral vectors 
The ovine CLN5 coding sequence (GenBank accession number NM_001082595; Frugier et al., 2008) 
was amplified at Lincoln University by a hybrid polymerase chain reaction using CLN5-specific primers 
on sheep cDNA (unpublished PhD findings, Janet Boyu Xu, Lincoln University). The full length CDS was 
cloned into a pCR4 plasmid (Invitrogen, Carlsbad, CA, USA) and sent to the Otago Viral Vector Facility, 
University of Otago for sub-cloning and generation of lentiviral (LV) and recombinant AAV (serotype 
9; AAV9) viral vectors expressing ovine CLN5, under the control of the myeloid sarcoma virus U3 
element as described (see Section 3.2.1). Functional viral titres for the LV-MND-CLN5 (hereafter 
referred to as LV-CLN5) were 1.1 x 1010 transducing units (TU)/mL.  Genomic titres for AAV9-MND-
CLN5 (hereafter AAV9-CLN5) were 2.85 x 1012 ssDNA viral genomes (vg)/mL. 
6.2.4 In vivo viral injections 
The stereotactic surgical procedures are described in Section 3.2.2. LV-CLN5 or AAV9-CLN5 vectors 
were injected bilaterally into the occipital and parietal cortices, and into the lateral cerebral 
ventricles of pre-symptomatic CLN5-/- sheep.  One cohort of sheep (n = 3, mean age 2.2  0.1 
months) each received a total dose of 3.6 x 109 TU of LV-CLN5 (110 μl per ventricle; 26 μl per 
parenchymal site; vector titre 1.1 x 1010 TU/ml) through four 3 mm holes made in the skull at the 
following co-ordinates (in mm) relative to bregma: occipital cortex, anterior-posterior (AP) -4, 
mediolateral (ML) 7, dorsoventral (DV) -11 (from the meninges/pial surface); parietal cortex, AP +7, 
ML 7, DV -11.   
The second cohort (n = 3, mean age 3.2  0.2 months) each received a total dose of 3.1 x 1012 vg of 
AAV9-CLN5 (500 μl per ventricle; 25 μl per parenchymal site; vector titre 3.1 x 1012 vg/ml). To 
accommodate for brain growth due to their older age at injection, co-ordinates were revised for this 
cohort to: occipital cortex, AP -6, ML 8, DV -12; parietal cortex, AP +8, ML 8, DV -12.  
6.2.5 In vivo monitoring 
Protocols were established for longitudinal in vivo assessment of therapeutic efficacy. Treated sheep 
were monitored at monthly intervals for a period of 24 months, from 3.9 months of age, and 
compared with age-matched cohorts of untreated CLN5-/- and CLN5+/- sheep. A number of 
behavioural, cognitive and neurological parameters were determined and quantitative CNS imaging 
carried out as described in Sections 3.3– 3.6.  
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Table 6.1    Treatment groups and clinical assessment at post mortem (or trial completion) 
Sheep Genotype Treatment* Gender† Age 
(months) 
Cause of death‡ Clinical 
score 
Clinical description Seizures Brain weight 
(g) § 
1103/13 CLN5+/- - M 18.4 - 5 Normal - - 
1118/13 CLN5+/- - M 19 - 5 Normal - - 
1121/13 CLN5+/- - M 18.7 - 5 Normal - - 
1128/13 CLN5-/- - M 27 Completion of trial 5 Normal - - 
1107/13 CLN5-/- - M 16.9 Completion of trial 1 Advanced disease, blind - 75.77 
1114/13 CLN5-/- - M 18.3 Completion of trial 2 Mild clinical disease, blind - 74.31 
1115/13 CLN5-/- - M 18.8 Completion of trial 1 Advanced disease, blind + 61.03 
1116/13 CLN5-/- - M 17 Completion of trial 1 Advanced disease, blind + 76.54 
1106/13 CLN5-/- LV-MND-CLN5 W 26.9 Completion of trial 3 Loss of vision only - 87.5 
1117/13 CLN5-/- LV-MND-CLN5 W 27.0 Completion of trial 3 Loss of vision only - 92.9 
1126/13 CLN5-/- LV-MND-CLN5 F 27.1 Completion of trial 3 Loss of vision only - 84 
1105/13 CLN5-/- AAV9-MND-CLN5 F 27.1 Completion of trial 3 Mild visual deficits only - 88.5 
1109/13 CLN5-/- AAV9-MND-CLN5 F 33+ Alive 5 Loss of vision only - - 
1120/13 CLN5-/- AAV9-MND-CLN5 F 26.4 Completion of trial 3 Loss of vision only - 71 
* LV, lentiviral vector; AAV9, adeno-associated viral vector serotype 9; MND (myeloproliferative sarcoma virus enhancer, negative control region deleted, dl587rev primer-binding 
site substituted) promoter 
† M, male; F, female; W, wether (castrated male) 
‡ Sheep were euthanized at clinical humane endpoint or trial completion. AAV9-CLN5 injected sheep 1109/13 is still alive at 33 months of age in May 2016, with the only clinical 
sign being loss of vision 
§ Fresh brain weight values for untreated animals; post-fixation brain weights for treated animals (boxed) 
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6.3 Results 
Six CLN5-/- Borderdale sheep were treated, before the average age of clinical disease onset, by 
bilateral intracerebroventricular (ICV) and intraparenchymal (IP) injections with lentiviral or AAV9  
vectors expressing ovine CLN5 under the control of a constitutive viral MND. Because sufficient 
affected ewe lambs were not available, two castrated ram lambs were included in the lentiviral 
cohort. All of the animals treated with either vector showed functional efficacy for two years after a 
single neurosurgical gene transfer session. Five of the treated sheep were euthanised at around 27 
months of age, when the only clinical sign of disease was a delayed visual deficit, thus exceeding the 
normal life expectancy of ~22 months for untreated CLN5-/- sheep. Neuropathological analyses from 
these animals are outside the scope of this thesis but are underway. One AAV9-CLN5 treated animal 
(1109/13) remains alive at 33 months of age, albeit with visual loss but is otherwise phenotypically 
indistinguishable from heterozygous controls. This ewe in maintained on outdoor pasture, interacting 
well with its untreated flockmates and is in excellent condition. The loss of vision is only detectable 
when it is physically isolated from the flock, travelling down a straight lane-way, whereby it will 
collide with fences. Within the field or within the flock, this deficit is not apparent. Any systemic 
manifestation will be monitored in this sheep over its extended lifespan resulting from its improved 
neurological function. 
6.3.1 Confirmation of genotype 
Affected animals were identified by reverse transcription PCR and sequencing of the c.571+1G>A 
splice site mutation at birth and a fortnight prior to gene transfer surgery (Frugier et al., 2008) 
(Figure 6.1). Genotype analyses on serial blood samples collected every six months revealed a 
consistent homozygous result for the mutant allele (CLN5-/-) over the life span of all treated animals., 
showing that no inadvertant animal substitutions had taken place nor was there an integration of the 
viral vector cargo into the host cell genome.  
6.3.1.1 Safety and tolerability of LV-CLN5 and AAV9-CLN5 administration in sheep 
All six sheep recovered well from surgery, despite their young age and within 90 minutes post-
anaesthesia were standing up and eating. General safety was assessed in the three week observation 
period after vector administration. Rectal temperatures, pulse rates and respiratory rates remained 
normal during this time and no overt behavioural changes or clinical signs of an immune response 
occurred.  
Over the course of the study, only one adverse event was reported. An AAV9-CLN5 treated ewe 
(1120/13) had a recurrent vaginal prolapse, first seen at 5.7 months of age (2.9 months post-
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surgery), which required suturing but with full recovery. This incident was not directly attributable to 
the vector, anaesthesia, surgical or administration procedure per se but rather to the housing 
constraints and resultant long-term concentrate feeding of the sheep. No other adverse clinical or 
biochemical events were observed. 
 
 
 
 
 
 
 
 
Figure 6.1     Confirmation of the affected genotype in the six gene therapy sheep subjects 
CLN5-/- status was verified in the treated animals using PCR and sequencing (Frugier et al., 2008). 
Representative chromatographs show the c.571+1G>A (*) substitution in all six animals, confirming 
their CLN5 homozygosity. 
 
 
  
* * * 
* * * 
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6.3.1.2 Growth rate 
Treated sheep continued to gain weight during the course of the study. Direct live weight 
comparisons were not possible between the treated and untreated cohorts, as untreated control 
sheep were maintained on pasture whilst treated sheep received a daily feed ration indoors. 
However linear regression of increases in live weight of the treated sheep and CLN5 heterozygous 
and affected animals from a previous trial, similarly housed and rationed, agreed, revealing 
comparable growth rates for all three genotype groups (3.0 kg/ month for CLN5+/-, 2.37 kg/ month 
for untreated CLN5-/- and 2.43 kg/ month for treated CLN5-/- sheep) (Figure 6.2). 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2     Mean live weight increases following viral-mediated CLN5 gene transfer in sheep 
Changes in the mean (± SEM) live weights of the treated CLN5 deficient (CLN5-/-, n = 6) sheep during 
the course of the experiment, compared with untreated CLN5 heterozygous (CLN5+/-, n = 6) and 
CLN5-/- (n = 6) sheep housed and fed similarly on a separate indoor trial. Animals in both trials were 
housed indoors and received a daily maintenance ration of lucerne pellets, chaffed lucerne and hay. 
Composite live weights were plotted for the LV-CLN5 and AAV9-CLN5 treated sheep as there was no 
significant difference between the two treatment groups.   denote the time of treatment for LV-
CLN5 and AAV9-CLN5 respectively.  
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6.3.2 In vivo assessment of therapeutic efficacy 
6.3.2.1 Clinical staging of ovine CLN5 
To assess any long-term clinical benefit in treated CLN5-/- sheep robustly, it was first necessary to 
characterise the natural disease history in untreated CLN5-/- sheep. Criteria were established for 
assessing neurological, behavioural, motor and visual function in the treatment groups and untreated 
Borderdale controls, based on historical observations on NCL ovine models (Westlake et al., 1985; 
Cook et al., 2002; Jolly et al., 2002). A clinical rating scale (Table 3.1, see Section 3.3), encompassing 
the multifocal nature of this disease, was developed to assess deviation from healthy function. 
Clinical rating scores (CRS) decreased from 5 (normal function) to 0 (progressive disease with 
spontaneous manifest seizures) as animals became more debilitated from the disease. Routine 
physical and neurological examinations were performed monthly, with concurrent open- and closed-
field behavioural observation, beginning on average at 3.9 months of age. 
As expected for a recessive disease, CLN5 heterozygous sheep were phenotypically normal 
throughout this study, with no functional deficits and consistently scored 5 on the rating scale (Figure 
6.3). In contrast, stereotypical disease progression began at 5.7  0.3 months of age in untreated 
CLN5-/- sheep. Manifestations included walking with their heads held low, crouching and/or baulking 
with occasional stumbling when in shadows, passing through gateways or negotiating steps (CRS 4). 
From 10.9  0.2 months of age all untreated CLN5-/- animals were functionally blind (CRS 3), with an 
asymmetric reduction or bilateral absence in menace (blink) response, loss of visual tracking and 
decreased acoustic startle. Affected sheep at this age shared a diminished herding instinct and 
tended to self-segregate, grazing alone in the field. Clinical symptoms progressed with deterioration 
of cranial nerve reflexes, motor, behavioural and cognitive (reduced mentation, increased 
somnolence) deficits by 14.2  1.8 months (CRS 2). Motor and proprioceptive dysfunction was 
evidenced by ataxia which was more severe in the pelvic limbs, stumbling, dragging of the feet, and 
intermittent episodes of localised muscle tremors particularly of the ears, eyelids, lips, and hind 
limbs. Behavioural changes from this age included a reduced awareness of surroundings, repetitive 
actions, such as aimless circling and teeth grinding, and feeding abnormalities, including dribbling 
and inefficient or sham eating. Affected CLN5 sheep in the advanced disease phase (15.2  1.1 
months, CRS 1) demonstrated low mentation, extended periods of somnolence, non-responsiveness 
to a variety of stimuli; including loud noise, pushing, flashing light and human presence, and loss of 
body condition with or without manifest seizure activity. Tetanic spasms, elicited by stress or 
handling, began in one CLN5 affected animal at 13.2 months. However there was significant 
individual variation in onset and severity with another of the affected animals not showing inducible 
manifest seizures, even at advanced disease at 18 months of age.   
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A. 
Score Clinical phenotype Clinical status * Age (months) 
5 Normal Normal <5.7  0.3 
4 Pre-clinical Low head carriage 
Propensity to crouch, baulk and stumble 
5.7  0.3 
3 Blind Head tilt/stargazing 
Visual deficits 
Decreased or lost menace (blink) response 
Reduced herding 
10.9 ± 0.2 
2 Overt/neurological Behavioural, cognitive and proprioceptive deficits 
Decreased startle to auditory stimuli 
Wide stance 
14.2 ± 1.8 
1 Advanced Progressive disease 
+/- induced tetanic seizures 
15.2 ± 1.1 
0 Terminal Spontaneous tetanic seizures Not observed 
  *   Onset of inducible mild tremors in individual sheep began as early as 13.2 months; Spontaneous convulsive 
seizures have not been observed in any CLN5-/- sheep, even in animals carefully nursed to 24 months of age.   
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3   Attenuation of stereotypical clinical progression following viral-mediated CLN5 delivery 
Sheep were scored monthly after treatment using a clinical rating scale based on the natural course 
of disease progression in ovine NCL models. A. Ages of symptom onset are shown for untreated 
CLN5-/- sheep, with initial deficits at 5.7  0.3 months of age. B. Composite clinical rating scores for 
CLN5+/- control (n = 4), untreated CLN5-/- (n = 4) and treated CLN5-/- sheep (n = 3 in each vector 
cohort). Treated sheep were clinically normal until 20.5  0.6 months of age (LV cohort) and 24.1  
1.5 months of age (AAV9 cohort), when late-onset visual deficits developed. No further neurological 
decline was observed. All data are shown as the mean  SEM (vertical bars).   denote the time of 
treatment for LV-CLN5 and AAV9-CLN5 respectively, * marks the age from which differences 
between the treatment groups and untreated CLN5-/- sheep become significant (P < 0.05). 
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6.3.2.2 Clinical status in treated CLN5-/- sheep 
The quality of life for treated CLN5-/- sheep was dramatically improved compared with untreated 
CLN5-/- animals. No overt disease onset or progression was documented for any of the treated sheep 
apart from a much delayed loss of vision relative to untreated affected controls. At the initial pre-
determined study endpoint of 18 months of age, all of the treated sheep remained alive with no 
overt disease onset and negligible neurological signs. At this point, there was no discernible 
difference in therapeutic benefit between the LV and AAV9 cohorts, whose composite clinical rating 
scores were 4.7 ( 0.3) and 5.0 ( 0.0) respectively. The delineation from normal observed at this age 
in the LV cohort arose from one animal (1106/13), which developed a distinctive, yet non-
attributable, head tilt at 17.2 months of age, that progressed to a myoclonic head jerk (dyskinesia) in 
photopic conditions by 18.5 months with complete loss of vision and reflex function by 19 months, 
but with no other stereotypical behaviour. In contrast, by 17.2 months of age, untreated CLN5-/- 
sheep obtained a score of only 1.25 ( 0.2) on the rating scale, with three out of four animals 
showing advanced disease, including subtle tremors to whole-body handling and/or stress induced 
seizures, which defined their humane endpoint. Graphical review of the fitted curves at 18 months 
(Figure 6.3) revealed treated sheep were clinically indistinguishable from the heterozygote controls, 
such that the 16-month post-treatment experimental endpoint was suspended and the trial duration 
was extended. 
Funduscopic examination at ~18 months of age, conducted by an independent veterinary 
ophthalmologist, revealed tapetal hyperreflectivity and severe generalised blood vessel attenuation 
in the clinically blind untreated CLN5-/- animals, compared with CLN5+/- controls, whilst treated 
sheep had intermediary indicators of retinal damage yet retained visual functionality. Despite signs 
of retinal pathology, the onset of blindness was significantly delayed (P < 0.0001) in the treated 
animals compared with untreated CLN5 deficient sheep that were functionally blind by 10.9  0.2 
months. Blindness developed in the other two animals in the lentiviral cohort by 21 months of age, 
whilst two of the three AAV9-treated animals began to lose vision from 22 months, with complete 
loss by 2 years of age. The AAV9-treated sheep that is still alive, 1109/13, did not show visual deficits 
until 27 months of age.  
6.3.2.3 Maze testing as a biomarker of functional correction 
The impact of LV-CLN5 and AAV9-CLN5 vector administration on vision, cognitive function and 
general locomotor activity was assessed monthly by closed-field maze testing. Time taken to traverse 
the maze was recorded, as was any time spent in the error zone, a cul-de-sac which deviated from 
the correct path through the maze (Figure 6.4). A simple maze rating scale was developed to describe 
each sheep’s passage through the maze (Figure 6.5). At baseline (3.9 months of age) there was no 
significant difference between the mean traverse times of the cohorts but at all subsequent testing 
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intervals, the untreated CLN5-/- sheep were significantly slower at passing through the maze than 
the treated and heterozygous control sheep (Figure 6.4A). Untreated sheep showed a progressive 
navigational decline through the maze, with a propensity to stumble initially, and later a reduced 
awareness of their surroundings, behavioural phenotype and increased error scores (Figure 6.4 – 
6.5). When induced to enter the maze by gentle pushing, affected sheep would move in a guarded 
manner with a tendency to circle. Under photopic conditions, untreated CLN5-/- sheep shied away 
from shadows and became increasingly unable to negotiate the ramp which led onto the maze 
testing arena without assistance. Despite functional blindness from 10.9  0.2 months, untreated 
affected sheep were generally able to negotiate the maze for another few months and notably they 
did not tend to hit any of the obstacles but rather would pull up short and fail to find a way around. 
However by 16 months of age, they were so severely affected as to be akinesic. This defined the 
humane endpoint for this test.  
In contrast, delivery of either LV-CLN5 or AAV9-CLN5 to preclinical CLN5 deficient lambs reversed the 
cognitive dysfunction, with no discernible difference in performance between the treated sheep and 
healthy heterozygous control sheep for some months after untreated CLN5-/- sheep reached the end 
stage of disease (Figure 6.4- 6.5). Treated sheep walked or ran through the maze with their heads 
held high, scarcely pausing yet avoiding the obstacles and error zone and mean transit times were 
significantly faster than those of the heterozygotes at some time points. From 23 and 25 months 
respectively, the LV-treated and then AAV9-treated sheep began to show the effects of their delayed 
visual loss, colliding with obstacles, often with force, as they ran through the maze (Figure 6.5) and 
the testing was hence terminated for humane reasons. 
Nevertheless, treated sheep in both vector cohorts prior to euthanasia were neurologically sound. At 
27 months of age, they were alert and responsive to their environment and auditory cues. They 
interacted with farm staff and each other both inside and during their outdoor testing times, through 
vocalisation and physical contact, and immediately detected the presence of foreign sheep or 
humans. Clinically, they were indistinguishable from heterozygous controls whilst grazing in the open 
field, with no evidence of the stereotypical wide stance, manifest hindlimb paresis or localised 
tremors seen in the overt neurological and advanced disease stages of CLN5 ovine NCL.  
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A. 
Score Maze assessment  Age (months) 
5 Traverse with no problems < 4.3 ± 1.8 
4 Traverse with small pauses 4.3 ± 1.8 
3 Traverse but with obvious behavioural phenotype (+/- hits obstacles) 7.2 ± 2.4 
2 Traverse with or without pauses but misses entry 12.9 ± 0.9 
1 Traverse with errors 14.4 ± 1.4 
0 Fail - requires assistance to traverse 15.7 ± 0.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5   Prolonged visual acuity and maze navigational ability after viral-mediated CLN5 delivery 
A. Sheep were scored for every passage through a closed-field maze at monthly intervals, with scores 
ranging from 5 (normal traverse) to 0 (failure to traverse without assistance). Ages of onset for each 
stage are shown for untreated CLN5-/- sheep. Initial phenotypic deficits were observed from 7.2  
2.4 months of age. These included low head carriage, crouching, baulking, stumbling or ‘self-
spooking’ at obstacles. B. Composite scores for the four cohorts showing that CLN5+/- sheep 
traversed the maze with no or small pauses, consistently scoring 5 whilst untreated CLN5-/- found 
the maze progressively harder to traverse without errors or assistance. In contrast, sheep in the LV 
and AAV treatment cohorts traversed the maze as normal until 23 and 25 months of age respectively, 
when late-onset visual deficits began to affect their performance. All data are expressed as the mean 
 SEM; n = 3 - 4 animals per group, 2 runs per animal at each timepoint,   denote the time of 
treatment for LV-CLN5 and AAV9-CLN5 respectively. 
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6.3.2.4 Disease progression assessed by CNS imaging 
The characteristic brain atrophy that defines NCL was monitored by longitudinal computed 
tomography (CT) scanning. Intracranial volumes were used as an in vivo measure of brain atrophy 
and hence disease progression. Scans were performed every second or third month on treated 
animals from 5 months of age and the rates of change compared against longitudinal data previously 
recorded from untreated CLN5 deficient and heterozygous sheep (Figure 6.6A,B). At three months of 
age, the mean intracranial volumes were similar for untreated CLN5-/- and CLN5+/- animals but with 
time, these became disparate with affected animals losing about 0.7 mL/month of intracranial 
volume compared with a heterozygote gain of 0.7 mL/month. Three-dimensional reconstructions of 
the cranium and ventricles demonstrated a marked regional atrophy in the diseased brain, 
particularly in the occipital and parietal cortices, with secondary ventricular enlargement, widening 
subarachnoid CSF spaces and sulcal prominence (Figure 6.6– 6.8). By contrast, the cerebellum was 
similarly sized in CLN5 deficient and heterozygous animals, with well-preserved morphology.  
The cranial volume loss and ventricular enlargement seen in sheep with CLN5 disease was attenuated 
in the treated animals (Figure 6.6A,B), intracranial volume and three-dimensional measurements 
being within the ranges recorded for heterozygous controls. This phenomenon was observed in all 
subjects, regardless of vector. Although mean intracranial volume increases were calculated as 0.5 
mL/month and 0.2 mL/month respectively for the LV and AAV9 treated cohorts, this difference only 
reached statistical significance (P < 0.04) at 27 months of age. The initial cranial volumes and 
subsequent rates of change varied dramatically between individuals, with increases of between 3.8 
mL (1105/13) and 13.6 mL (1117/13) from 5 to 27 months of age. One AAV9-CLN5 treated animal 
(1120/13) exhibited a volumetric plateau, with a consistent cranial volume of 96.1  0.2 mL over 
most of the study period, until 19 months when the intracranial volume began to decline at 
0.5mL/month. This animal also had the lightest brain at post mortem of all the treated animals (Table 
6.1). 
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Figure 6.6    Attenuation of intracranial volume loss after viral-mediated CLN5 delivery  
A. Shown is longitudinal intracranial volume data for untreated CLN5+/- and CLN5-/- control sheep 
against LV (unfilled markers) and AAV9 (filled markers) treated sheep. Thin blue (CLN5+/-) and green 
(untreated CLN5-/-) lines represent historic individual volume changes over time; thick blue and 
green lines indicate respective volumetric trend lines. All treated CLN5-/- sheep demonstrated 
intracranial plateaux or growth over time, but not the atrophic loss seen in untreated CLN5-/- 
animals. B. Normalised intracranial volume trajectories further demonstrate the functional efficacy 
of gene therapy in CLN5 deficient sheep. Volumes were normalised to compensate for the 
differences in intracranial volumes at baseline.   denote the time of treatment for LV-CLN5 and 
AAV9-CLN5 respectively. 
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Figure 6.8   Retention of intracranial volume after CLN5 delivery 
Representative three-dimensional models of intracranial volumes from an 18 month old CLN5+/- 
control sheep (left), a 17 month old untreated CLN5-/- sheep (middle), and a 27 month old LV-
treated CLN5-/- sheep (right) reconstructed from axial CT slices. Note the pronounced atrophic 
targeting of the cerebral cortex with relative sparing of the cerebellum in the untreated CLN5 
deficient brain. In comparison, the gross anatomy of the treated brains is indiscernible from a healthy 
CLN5+/- control. The treated animal was blind but otherwise clinically normal at the time of imaging. 
Images were prepared by Katharina Russell (Lincoln University) as part of her PhD study. 
 
Magnetic resonance imaging (MRI) confirmed the CT findings. MRI images of treated sheep at 25 
months of age showed that the overall brain structure and architecture was normal (Figure 6.9), with 
no obvious degenerative changes. Together the CNS imaging showed that the stereotypical brain 
atrophy and ventricular enlargement is ameliorated in treated sheep and the brain white and grey 
matter structures are preserved after gene therapy. 
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Figure 6.9    Normalisation of sheep brain structure after viral-mediated CLN5 delivery  
Representative MRI (T2) sections in the horizontal (top) and coronal (bottom) views of a typical 16 month unaffected control and CLN6 affected sheep, compared 
with 25 month old CLN5 affected sheep which have received AAV9 (1105/13) and lentiviral (1106/13) mediated CLN6 gene therapy. Profound atrophy is apparent 
in the untreated affected sheep cortex (upper arrow), as is prominent ventricular enlargement (middle arrow) and cranial thickening (lower arrow). Treatment 
with either lentiviral or AAV9 vectors expressing ovine CLN5 normalised the brain structure and protected against atrophy. Scale bar represents 1 cm.  
Abbreviations: CB cerebellum, CN caudate nucleus, HC hippocampus, LV lateral ventricle, OC occipital cortex, Th thalamus. 
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6.4 Discussion 
Like most neuropathic lysosomal storage diseases resulting in premature death, the NCLs lack 
effective therapies beyond supportive treatment. Promising results have been achieved with direct 
delivery of AAV vectors to the brain parenchyma in CLN2 rodent and non-human primate models 
(Hackett et al., 2005; Sondhi et al., 2005, 2007, 2012; Passini et al., 2006). These have been extended 
to human clinical trials (Crystal et al., 2004; Worgall et al., 2008) however no treatment options or 
clinical testing are available for NCL patients bearing the CLN5 mutation. Studies assessing the safety 
and efficacy of CLN5 gene therapy in large animal models of the disease are critical for potential 
clinical development of this strategy. To this end, results from the experiments described in this 
chapter document sustained functional and structural efficacy in pre-symptomatically treated CLN5 
sheep via two different gene delivery platforms, lentiviral and AAV9 vectors carrying the therapeutic 
ovine CLN5 gene, through just four burr holes in a single neurosurgical procedure lasting less than 90 
minutes. 
CLN5 affected lambs were weaned early and treatment was administered at 2.2 – 3.2 months, before 
the onset of clinical signs. Two years post-administration, five of the six treated sheep were 
euthanised at 27 months of age, exceeding the typical humane endpoint for untreated CLN5 
deficient animals of 22 months of age. Surprisingly clinical outcomes were similar for both of the viral 
vector platforms tested; lentiviruses, currently in use in human clinical trials for a number of LSDS 
and neurodegenerative diseases (Cavazzana-Calvo et al., 2000; Biffi et al., 2013; Palfi et al., 2014), 
and AAV9, a newer AAV serotype which has shown promise in the treatment of neuropathic LSDs (Fu 
et al., 2011; Ribera et al., 2015; Walia et al., 2015). The treated sheep were disease-free, apart from 
delayed-onset visual deficits. They benefitted from a profound improvement in quality of life, 
preservation of cognitive and neurological function, and normalisation of intracranial volume and 
brain structure, compared to untreated animals.  
Longitudinal studies of non-invasive biomarkers were used to assess the efficacy of lentiviral and 
AAV-based therapeutics in sheep in vivo. Monthly neurological examination and clinical scoring using 
a sheep-specific rating scale revealed the long-lasting functional efficacy of treatment, treated 
animals being clinically indistinguishable from untreated heterozygous controls until 20.5  0.6 
months and 24.1  1.5 months for the lentiviral and AAV9 cohorts respectively, when they begin to 
show effects of their visual deficits (Figure 6.3). Aside from this loss of vision, at 27 months of age 
treated sheep were still highly interactive with their environment. They showed a willingness to 
engage with new stimuli (e.g. environmental enrichment items, including chains hanging from the 
ceiling, balls, plastic bottles or chewing bars in pens which were introduced to prevent oral 
stereotypies) and developed strong social attachments within their cohort and with animal care 
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personnel. In contrast, signs of clinical dysfunction in untreated CLN5 affected sheep developed 
progressively from 5.7 months of age. They were functionally blind by 11 months, isolated and in an 
advanced diseased state with differing degrees of inducible seizure activity by 14 - 16 months and 
were euthanized for humane reasons between 16.9 and 18.8 months of age. 
Photopic behavioural maze testing was able to detect cognitive decline early in the course of NCL in 
affected sheep as well as the functional efficacy of viral-mediated gene transfer. Assessments in a 
relatively simple maze were highly informative. As the clinical signs of the disease developed, 
traverse and error times for the untreated CLN5 deficient sheep became significantly greater than for 
heterozygous and treated sheep and the testing was terminated when they became too akinesic to 
participate (Figure 6.4). Longitudinal subjective grading of sheep through the maze (Figure 6.5) 
provided graphical plots that mirrored the clinical rating data. Treated sheep retained the ability to 
navigate the maze well after this point and regularly outperformed the clinically normal 
heterozygotes with respect to maze passage and times taken.  
Maze testing has been used previously in sheep for a number of different applications (Peirce et al., 
2001; Shamir et al., 2010; Hunter et al., 2015; McBride et al., 2015), including the assessment of 
efficacy of intraocular AAV5 gene therapy in an ovine model of achromatopsia (Banin et al., 2015) as 
well as in ovine spatial learning and memory studies (Lee et al., 2006). These published maze studies 
and the current study rely on the natural flocking instinct of sheep, using conspecifics in the goal area 
to motivate movement through the maze. Under normal circumstances sheep have a strong 
compulsion to flock, particularly when they are wary (Lynch et al., 1992; King et al., 2012). However 
the Biosafety Level 2 containment that was required in the current study required treated sheep to 
be housed indoors in individual pens and this resulted in behavioural adaptation. Treated sheep 
became habituated to frequent human contact and handling, developing strong social bonds with 
animal care personnel, and losing their wariness. Sheep are gregarious by nature, requiring contact 
with other sheep to maintain well-being and normative physiology (Reinhardt & Reinhardt, 2002). 
Despite having uninterrupted visual, auditory, olfactory and tactile contact with their neighbours, 
treated sheep showed a reduction in their natural flocking behaviour – a phenomenon that has 
previously been reported in sheep held in confinement in small groups for several weeks (Fell et al., 
1991; Degabriele & Fell, 2001). Food therefore had to be used as a further motivator for the maze 
testing, which may explain the faster traverse times seen with the treated animals. Additionally, 
because of the progressive debilitating nature of CLN5 NCL, it was not possible to blind investigators 
to the treatment status of the sheep during this in vivo testing. To limit observer bias, all subjective 
measurements (clinical rating scores, maze and behavioural assessments) were performed by two 
independent investigators, either at the time of testing or from retrospective video analysis and 
scores were then averaged. 
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CNS imaging (CT and MRI data) provided objective in vivo clinical measures of CNS atrophy in 
untreated CLN5 deficient sheep whilst demonstrating structural integrity in treated brains. 
Computed tomography (CT) images were generated by passing an x-ray beam through the skull and 
measuring the attenuation of the x-ray beam through the different tissues (e.g. brain, bone, CSF). 
Quantitative measurements of atrophy and ventricular dilatation are possible by this scanning 
technique. Longitudinal intracranial and ventricular volume estimates were obtained from a series of 
CT scans for each sheep using the Cavalieri principle (Graham Kay, personal communication) and, 
alongside three-dimensional (3D) reconstructions (Figure 6.8), served as excellent measures of 
disease progression. MRI scanning at the conclusion of the trial confirmed preservation of brain 
architecture following treatment (Figure 6.9). The typical cranial volume loss and ventricular 
enlargement seen in CLN5 disease was attenuated in the treated animals (Figure 6.6), that had 
volume measurements within range of heterozygous controls. On average, LV-treated and AAV-
treated sheep showed intracranial volume increases of 0.5 and 0.2 mL/month respectively over the 
study, in line with rates of change for untreated CLN5 heterozygous sheep of 0.6mL/month whilst 
untreated CLN5 affected sheep lost 0.4 mL/month. Because the initial cranial volumes and 
subsequent rates of change varied between individuals, baseline volumes were normalised for the 
two treatment groups. Doing this clarified the comparative longitudinal changes for each vector. LV-
treated animals maintained higher intracranial volumes than AAV9-treated ones through the study. 
This could be caused by a number of factors. Firstly there were two wethers in the LV cohort which 
would affect results if sexual dimorphism influences brain size. The larger brains and thus volumes of 
the LV-treated wethers was consistent with their larger body size. However a recent MRI study of 
healthy Merino sheep demonstrated that the volume of brain tissue did not differ between wethered 
rams and ewes (Nitzsche et al., 2015), conflicting with a report for humans which suggested that 
male brain volumes are typically larger than females (Allen et al., 2002; Lüders et al., 2002). Secondly, 
one animal in the AAV cohort (1120/13) had a plateau of intracranial volume from 5 to 19 months 
and, interestingly, lost 3.8 mL of intracranial volume in the last seven months of the trial (from 19 to 
26 months of age). At post mortem the brain of this individual was considerably lighter than that of 
other treated animals, being more comparable to advanced disease-stage untreated CLN5 deficient 
animals (Table 6.1). The cause of this late-stage decline in intracranial volume is yet to be determined 
but neuropathological analysis may be enlightening. 
Late-onset loss of vision was the only clinical sign presented by treated sheep from both vector 
treatment groups, with earlier deficits seen in the lentiviral cohort than in the AAV cohort. This visual 
loss experienced by the treated animals differed from that seen during natural disease progression. 
Despite being functionally blind by 10.9  0.2 months, the untreated CLN5 affected sheep did not 
collide with fences or obstacles, rather they pulled up short or failed to find a path through an 
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opening. Their menace reflexes were generally absent or reduced at this age but pupillary light 
reflexes were intact. Positive ERG traces could be recorded from similarly aged CLN5 affected animals 
in a later trial (unpublished PhD findings, Katharina Russell, Lincoln University), confirming retinal 
functionality and demonstrating that blindness is likely due to a visual cortex lesion at this age. 
Cortical (or central) blindness presents with partial or total loss of vision, however the eye and retina 
are normal (Cassin & Rubin, 2011). Such patients may be able to distinguish light/dark and shapes 
(Cummings & Trimble, 1995) which may explain why the affected sheep here could avoid collisions 
during early clinical disease. Post mortem neuropathological studies have confirmed significant 
neurodegeneration in the ovine CLN5 affected visual cortex by 9 months of age, with the cortical 
thickness of this region being reduced to half that of normal at this age (Chapter 5). Not until late in 
the CLN5 disease progression, when the cortical blindness is compounded with the retinal 
degeneration (measured by negative ERG responses), do CLN5 affected sheep actually hit obstacles. 
This has been noted whilst moving affected Borderdale sheep between paddocks over the past 
decade (Nadia Mitchell, personal observation). However, as delayed-onset visual deficits began in 
treated sheep from 21-22 months of age, they started to run directly into obstacles, often with force. 
They would collide with fences, even in a straight laneway. Funduscopic examination from 18 months 
on showed the anterior and posterior segments of the treated eyes were normal except for a mild 
vascular attenuation. Menace responses diminished from 21-22 months of age, whilst the pupillary 
light response was sluggish but retained. ERG measurements at a single timepoint (27 months) were 
unrecordable, indicating retinal dysfunction. This suggests the pathophysiological cascade causing 
the visual disturbances in the treated sheep is different from the progressive visual cortex 
abnormalities and later retinal degeneration seen in untreated CLN5 affected animals. Post mortem 
neuropathological studies of the brains and histological analysis of the eyes of treated sheep are 
underway to confirm this. 
This delayed visual loss seen in the treated sheep likely reflects insufficient retinal penetration by the 
CLN5 protein for prevention of degeneration after intracranial gene therapy. In fact, the retention of 
eyesight for so long after intracranial gene delivery was remarkable given that no intraocular therapy 
was attempted. Similar findings were recently published for a dog model of CLN2 NCL after ICV 
AAV2-mediated delivery of TPP1, which encodes the soluble lysosomal enzyme tripeptidyl peptidase 
1 (Katz et al., 2015). Like the sheep, diseased dogs had an extended lifespan after treatment, with 
protection from cognitive decline and delayed disease onset and progression. Visual abnormalities 
were also the first clinical signs in the treated dogs. Elevated levels of the recombinant TPP1 protein 
were detected throughout the brain parenchyma but not in the retinal pigmented epithelium or 
photoreceptor cells, indicating there was insufficient retinal penetration to preserve structure and 
function. Both the current study and the CLN2 dog findings suggest that adjunct ocular gene therapy 
may preserve vision in treated NCL patients for a longer time. 
 126 
Due to the successful correction of phenotype in the treated sheep, post mortem CLN5 expression 
and neuropathological studies, looking for pathological correction, were not possible during the 
timeframe of this doctoral study. Brain, spinal cord, eye and peripheral tissue samples collected from 
the five euthanised animals are being processed as part of a collaborative initiative with Prof. Jon 
Cooper (Kings College, London UK) in 2016. Thick (50 m) brain sections will be analysed for CLN5 
transgene expression, attenuation in neuropathology (neuronal loss, cortical atrophy, astrocytosis, 
microgliosis, storage) and any potential adverse events (inflammation, neurotoxicity). One can only 
theorise as to how and why the gene therapy was effective in the CLN5 sheep model. Based on 
previous findings in sheep (Chapter 5) (Linterman et al., 2011) and the literature (Liu et al., 2005a; 
Haurigot et al., 2013; Katz et al., 2015; Ribera et al., 2015), it is hypothesised that targeted ICV-
mediated delivery of lentiviral and/or AAV9 vector to the ependymal cells, lining the brain ventricular 
system, with resultant secretion of the CLN5 transgene product into the CSF circulation has acted as 
a useful global protein delivery mechanism in the treatment of CLN5 NCL. Additionally columnar IP 
injections may have corrected the resident neural progenitor cells (NPCs) of the subventricular zone 
(Linterman et al., 2015), shown to migrate radially to the degenerating cortex in the diseased CLN5 
sheep brain (Section 4.3.5), providing an alternative in situ stem cell repair therapy. 
In conjunction with neuropathological studies, vector biodistribution will be determined through the 
CNS and peripheral tissues by quantitative PCR with primers specific for ovine CLN5. Blood serum 
samples, collected through the study from pre-injection to time of sacrifice, will be tested 
commercially for the prevalence of neutralising antibodies against the injected capsid and transgene 
product. Given the degree of functional and structural efficacy seen in the treated animals, one 
would expect low serum anti-vector and anti-CLN5 titres, however it is possible a humoral response 
may explain the reduced duration of intracranial volume correction in the AAV9-treated animal 
1120/13. Eyes have also been collected from the treated sheep and sent to Massey University for 
expert pathological analysis. This is particularly pertinent given the differing aetiology of the 
blindness exhibited by the treated and untreated CLN5 deficient sheep.  
In November 2015, the New Zealand Environmental Protection Agency (EPA) determined that sheep 
injected with AAV vectors at Lincoln University were no longer to be regarded as new organisms 
(genetically modified) under the Hazardous Substances and New Organisms (HSNO) Act 1996. This 
has given clearance for the one remaining AAV9-treated animal, 1109/13, to be maintained on 
pasture outdoors under normal husbandry conditions with untreated sheep. As such, this ewe will be 
kept alive unless otherwise indicated to assess the long-term and systemic effects of AAV 
therapeutics in a CLN5 affected sheep. It will be interesting to see if any non-CNS pathology becomes 
clinical in this sheep. 
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The timing of therapeutic intervention is likely to be a very important factor when predicting 
outcomes in human patients. The vast majority of children are not diagnosed with NCL prior to 
symptom onset whereas in the present study CLN5 deficient sheep were treated pre-
symptomatically. Whilst there is evidence of regional reactive astrocytosis from birth in the pre-
symptomatic CLN5 affected brain, loss of cortical neurons and overt brain atrophy do not commence 
until later, from four and six months of age respectively (Chapter 5). Whilst viral-mediated delivery of 
gene therapy pre-symptomatically in this study has shown functional and structural efficacy, it is 
unlikely to be as efficacious at delaying clinical symptoms and pathology when administered later in 
the disease course. To test this in a more clinically relevant scenario, post-symptomatic gene transfer 
to CLN5 affected sheep will be evaluated. A trial comprising six CLN5 deficient sheep injected with 
AAV9-CLN5 at nine months of age is already underway and a further six affected sheep were injected 
at seven months of age in May 2016. Subretinal delivery of AAV9-CLN5 will also be attempted in the 
latter cohort as a means to target degeneration within the eyes (see Section 8.3.3).  
6.5 Conclusion 
The tolerance, safety and efficacy of lentiviral and AAV based therapeutics was tested in pre-clinical 
affected CLN5 deficient sheep. Diseased sheep, treated pre-symptomatically with a single 
administration of either lentiviral or recombinant adeno-associated virus expressing ovine CLN5, 
showed protection from stereotypical disease onset and progression, retention of cognitive function, 
sustained normalisation of brain structure and intracranial volume, and an extended lifespan. The 
only disease manifestation seen in the treated sheep was a very delayed-onset visual deficit. Post 
mortem analysis of the CLN5 treated sheep will determine the exactitudes by which the intracranial 
gene therapy was able to correct neuropathology. The robust pre-clinical data of the safety and long-
term biological efficacy of pre-clinical AAV- and LV-based gene therapy used here to treat the CNS 
pathology in the CLN5 sheep model is likely to expedite advancement of this methodology to the 
clinic. 
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Importantly for gene therapy studies, not all cells needed to be ‘corrected’ for disease amelioration 
to be achieved.  
Also propitious for CLN6 gene therapy was evidence of extended neurogenesis in the CLN6 affected 
sheep (Dihanich et al., 2009) (see Section 1.5.4). Immunohistochemistry revealed a prominent band 
of neurogenic cells and fibres along the subventricular zone (SVZ) of affected sheep brains, which 
migrate to form large clusters of newly generated neurons in the cortical laminae undergoing 
degeneration. This observation has since been confirmed in human CLN6 patients and has been 
proposed as an intrinsic attempt at cell replacement within the diseased brain (Dihanich et al., 2012). 
As such, the SVZ represents an accessible site for targeted viral-mediated gene correction of neural 
stem and progenitor cells. Intraparenchymal injection of lentiviral vectors into the SVZ has shown 
targeted transduction of the ependymal and subependymal cells along the extent of the ventricular 
surface in sheep (Linterman et al., 2011). Transduced cells included type B astrocytic cells, thought to 
be the bona fide adult neural stem cells (Doetsch et al., 1999), which have the ability to perform 
lifelong migration, differentiation and repopulation of functionally defined regions in the brain 
(Alvarez-Buylla & 2004; Lim & Alvarez-Buylla, 2014). If targeted early enough in the pathogenic 
cascade, whilst the rate of cell loss is still low and the microenvironment is still conducive to cell 
maturation and survival, corrected neuroblasts and their progeny could migrate rostrally, as well as 
radially to the outer cortex, allowing cross-correction of diseased neurons. 
There is likely to be a threshold minimum percentage of cells necessary to be corrected to observe 
functional amelioration and/or impede disease progression but it is anticipated that either 
widespread or specific targeting will benefit the gene therapy strategy for the CLN6 disease. Over the 
past 7 years, much effort within BARN has concentrated on optimising strategies to maximise 
delivery. On this basis, in vivo gene therapy was attempted on pre-symptomatic CLN6 affected sheep 
comparing the capability of AAV9 and lentiviral vector platforms to effectively deliver ovine CLN6 and 
prevent disease development in these sheep. Based on the findings described in Chapter 4 and the 
Linterman study (2011), it was hypothesised that the AAV9 vector would provide greater spread of 
transgenic protein through the CLN6 affected sheep brain, whilst targeting the migratory neural 
progenitor cells with the lentiviral vector could facilitate broad transduction within the diseased 
brain via migraton.  
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7.2 Materials and methods 
7.2.1 Study design 
Pre-symptomatic CLN6 affected sheep were treated with lentiviral or AAV vectors containing ovine 
CLN6 and then phenotypically compared with untreated CLN6 affected and clinically normal 
heterozygous controls (Table 7.1). On trial completion, post mortem CNS tissues from treated sheep 
were examined for evidence of disease amelioration, specifically looking for any attenuation in the 
cortical thinning and severe neurodegeneration, glial activation, and storage body accumulation 
documented for untreated CLN6 affected sheep (Chapter 4, Oswald et al., 2005). 
7.2.2 Animals 
South Hampshire sheep were bred, maintained and diagnosed at birth as described in Section 3.1 
(Tammen et al., 2006). Cohorts of CLN6 homozygous affected (CLN6-/-; n = 9) and clinically normal 
heterozygous (CLN6+/-; n = 3) sheep were maintained under normal pastural conditions at the 
Research Farm, Lincoln University, and acted as untreated affected and normal controls. An 
additional six pre-symptomatic CLN6-/- sheep were weaned early, at 1.8    0.1 months of age, and 
moved indoors prior to in vivo gene therapy at 3 to 4 months of age (see Section 3.1.1). There were 
two sibling pairs, with one pair in each treatment cohort (1001/13 and 1002/13; 1026/13 and 
1027/13). Pretherapy, the CLN6 genotype was reconfirmed from genomic DNA isolated from venous 
blood (see Section 3.1.2.2) and this was repeated by an independent evaluator every six months 
and/or at post mortem.   
7.2.3 Viral vectors 
The ovine CLN6 coding sequence (GenBank accession number NM_001040289; Tammen et al., 2006) 
was generated using the polymerase chain reaction with CLN6-specific primers on sheep cDNA by the 
author in 2005. The full-length CDS was cloned into a pcDNA3.1D TOPO plasmid (Invitrogen, 
Carlsbad, CA, USA) and sent to Otago University where lentiviral (LV) and recombinant AAV (serotype 
9; AAV9) viral vectors expressing ovine CLN6, under the control of the myeloid sarcoma virus U3 
element  were produced at the Otago Viral Vector Facility as described in Chapter 3 (Section 3.2.1). 
Functional viral titres for the LV-MND-CLN6 (hereafter referred to as LV-CLN6) ranged from 7.5 to 8.1 
x 109 TU/mL. Genomic titre for the AAV9-MND-CLN6 (hereafter AAV9-CLN6) vector was 2.36 x 1012 
ssDNA vg/mL. 
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Table 7.1    Treatment groups and clinical assessment at post mortem (or trial completion) 
Sheep Genotype Treatment* Gender† Age 
(months) 
Cause of death‡ Clinical 
score 
Clinical description Seizures Brain 
weight (g) ¶ 
1007/13 CLN6+/- - M 18.4 - 5 Normal - - 
1012/13 CLN6+/- - M 18.3 - 5 Normal - - 
1022/13 CLN6+/- - M 18.1 - 5 Normal - - 
1003/13 CLN6-/- - M 17.6 Completion of trial 2 Clinical disease, blind - 77 
1005/13 CLN6-/- - M 19.2 Completion of trial 1 Advanced disease, blind - 64.72 
1011/13 CLN6-/- - M 17.4 Completion of trial 2 Clinical disease, blind - 77.79 
1013/13 CLN6-/- - M 12.6 Disease-related 1 Advanced disease, blind - n.t. # 
1015/13 CLN6-/- - M 19 Completion of trial 1 Advanced disease, blind - 61.03 
1017/13 CLN6-/- - M 17.3 Completion of trial 1 Advanced disease, blind - 71.34 
1021/13 CLN6-/- - M 17.2 Completion of trial 1 Advanced disease, blind - 74.47 
1028/13 CLN6-/- - M 13.4 Misadventure 1 Advanced disease, blind + n.t. # 
1041/13 CLN6-/- - M 13.4 Indeterminable § 1 Advanced disease, blind + 51.4 
1001/13 CLN6-/- LV-MND-CLN6 F 16.7 Completion of trial 3 Clinical disease, blind - 67.32 
1002/13 CLN6-/- LV-MND-CLN6 F 14.8 Copper toxicosis 3.5 Onset of disease, losing vision - 66.8 
1004/13 CLN6-/- LV-MND-CLN6 F 14.1 Copper toxicosis 3 Onset of disease, losing vision - 66.22 
1025/13 CLN6-/- AAV9-MND-CLN6 F 13.8 Age-match for 1004/13 2.5 Clinical disease, blind - 69.34 
1026/13 CLN6-/- AAV9-MND-CLN6 F 16.2 Completion of trial 2 Advanced disease, blind - 63.14 
1027/13 CLN6-/- AAV9-MND-CLN6 F 26.2 Completion of trial  5 Normal - 84.9 
* LV lentiviral vector; AAV9 adeno-associated viral vector serotype 9; MND (myeloproliferative sarcoma virus enhancer, negative control region deleted, dl587rev primer-binding 
site substituted) promoter 
† M male; F female 
‡ Sheep were euthanised at a clinical humane endpoint or trial completion 
§ Presentation of symptoms similar to Listeriosis. A veterinary post mortem and examination of tissues by Gribbles Veterinary Pathology failed to confirm this diagnosis.   
   Death was likely attributable to advanced NCL 
¶ Fresh brain weight values for untreated animals; post-fixation brain weights for treated animals (boxed) 
# n.t not tested 
1025/13 was euthanised with clinical symptoms as an AAV9 age-match comparison to 1004/13 (LV)
1
31
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7.2.4 In vivo viral injections 
Pre-symptomatic CLN6-/- sheep received bilateral parenchymal (occipital and parietal cortices) and 
intracerebroventricular (ICV) injections as described in Section 3.2.2. For the lentiviral (LV) cohort, 
four 3 mm holes were made in each skull at the following co-ordinates (in mm) relative to bregma: 
occipital cortex, anterior-posterior (AP) -4, mediolateral (ML) 7, dorsoventral (DV) -11 (from the 
meninges/ pial surface); parietal cortex, AP +7, ML 7, DV -11. Each sheep (n = 3, aged 2.7 months) 
received a total dose of 2.3 x 109 TU of LV-CLN6 (110 μl per ventricle; 26 μl per parenchymal site). 
A month later, the second cohort (n = 3, aged 3.7 months) each received a total dose of 2.6 x 1012 vg 
of AAV9-CLN6 (500 μl per ventricle; 25 μl per parenchymal site). To accommodate brain growth due 
to their older age at injection, co-ordinates were revised for this cohort to: occipital cortex, AP -6, ML 
8, DV -12; parietal cortex, AP +8, ML 8, DV -12.  
7.2.5 In vivo monitoring 
Treated CLN6-/- sheep were monitored for in vivo assessment of therapeutic efficacy for a period of 
24 months, from 4.3 months of age, and compared with age-matched cohorts of untreated CLN6+/- 
and CLN6-/- sheep using the parameters and CNS imaging described in Sections 3.3– 3.6. 
7.2.6 Tissue collection and immunohistochemistry 
Injected animals were euthanised by exsanguination at 13.8 to 26.2 months of age, and the brains 
perfusion fixed as described in Section 3.8. Spinal cord and visceral tissue samples, including liver, 
lung, spleen, adrenal gland, bladder, oesophagus, pancreas, lymph nodes, kidney, gastrointestinal 
tract, skeletal and cardiac muscles were either snap-frozen in liquid nitrogen for retrospective RNA 
isolation and quantitative real-time PCR-based biodistribution studies or fixed in formyl saline, 
equilibrated in cryoprotectant, frozen at -80 °C, and sectioned at 50 μm (see Section 3.8). Eye globes 
were enucleated at post mortem, fixed in 10 % formalin for at least 2 h, and sent to Gribbles 
Veterinary Pathology (Christchurch, New Zealand) for post-fixation in Bouin’s solution (HT10132; 
Sigma-Aldrich, St. Louis, MO, USA) for 4 h, wax-embedding and sectioning at 5 µm. 
Brain hemispheres from the injected animals were analysed for CLN6 and CLN5 expression, cortical 
thickness and neuronal loss, neurogenesis, storage body accumulation and glial activation with 
different histological and immunostains (Section 3.9). 
 
 133 
7.3 Results 
CNS-directed gene therapy was performed on pre-clinical CLN6-/- animals at 2.7 (LV-CLN6; n = 3) and 
3.7 months of age (AAV9-CLN6; n = 3). Of the six animals treated, three were euthanised during the 
study period at 12 months post-treatment, whilst the remaining three survived to study completion. 
In vivo monitoring showed that five of the six treated sheep developed stereotypical CLN6 disease, 
which was confirmed by post mortem neuropathology studies. This group will hereafter be referred 
to as the unsuccessful treatment cohort. However, one AAV9-treated animal (1027/13) maintained 
phenotypic correction through the two year follow up period and was euthanised at 26.2 months of 
age to allow assessment of CLN6 transgene expression and neuropathological assessment of 
treatment-dependent modulation of lysosomal storage pathology, glial activation, and neuronal loss.  
7.3.1 Confirmation of genotype  
The genotype of each treated sheep was determined from restriction fragment length polymorphic 
analysis of a silent substitution in CLN6 exon 7 at birth and a fortnight prior to surgery (Figure 7.1) 
with confirmation by sequencing. A consistent homozygous result for the mutant allele (CLN6-/-) was 
observed from serial blood samples collected every 6 months over the life span of all treated 
animals. 
 
 
 
 
 
Figure 7.1   Confirmation of the affected genotype in the six gene therapy sheep subjects 
CLN6-/- status was verified in the six treated animals using the disease-associated A/G polymorphism 
(Tammen et al., 2006). Shown is a representative agarose gel of the affected banding pattern from 
the six treated CLN6-/- animals after Hae II digestion of a 251 bp PCR product from exon 7 of ovine 
CLN6 (refer to Figure 3.1). Lane 1 contains a size standard with 400, 300, 200 and 100 bp bands 
visible.   
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7.3.1.1 Safety and tolerability of LV-CLN6 and AAV9-CLN6 administration to sheep 
The neurosurgical CLN6 gene transfer procedure was well tolerated by the CLN6 deficient sheep. 
They had an uneventful post-operative course with no neurobehavioural changes, alteration in 
health status, or clinical signs of an immune response - as indicated by normal rectal temperatures. 
Over the course of the study, five adverse events were reported (Table 7.2). None of these were 
directly attributable to the vector, anaesthesia, surgical or administration procedure per se but most 
likely resulted from the housing constraints and resultant long-term concentrate feeding of the 
sheep. 
Table 7.2    Reported adverse events following viral-mediated CLN6 gene therapy in sheep 
Level of severity Number of events Description of event Outcome 
Serious 2 Copper toxicosis Fatal (euthanasia) 
Non-serious 1 Lip piercing Non-fatal, self-resolving 
 1 
1 
Contagious ecthyma 
Stereotypical behaviour 
Self-limiting 
Required intervention 
 
7.3.1.1.1 Chronic copper toxicosis 
The most serious adverse event was the development of fatal copper toxicoses in two of the 
lentiviral- injected sheep ~12 months post-treatment. The first sheep, 1004/13, presented with 
haematuria (haemoglobinuria), fever, anorexia and reduced activity. An initial veterinary diagnosis of 
urinary tract calculi was made. Although a 5 day course of intramuscular antibiotic (Alamycin 10, 
Norbrook NZ Ltd, Auckland New Zealand) and oral drenching with ammonium chloride (7 g per day) 
resolved the fever and haematuria, the sheep remained lethargic, with depression, loss of appetite 
and repetitive teeth grinding, indicative of ongoing pain. A decision was made to euthanise on 
humane grounds. A veterinary post mortem examination showed pathological changes typical of a 
haemolytic crisis. There was marked jaundice through all the tissues. The liver was swollen, with 
rounded edges and was pale yellow in appearance. The kidneys were enlarged with a dark ‘gun-
metal’ appearance. Histological examination of the liver by Gribbles Veterinary Pathology identified 
hepatocyte megalocytosis with mild multifocal apoptosis and cholestasis, compatible with chronic 
copper toxicity. Kidney lesions were consistent with haemoglobinuric nephrosis. The copper 
concentrations in the kidney confirmed this diagnosis, measuring 510 μmol/kg, well above the 
adequate healthy range for sheep of 0 – 157 μmol/kg. 
Three weeks later, a second sheep, 1002/13, presented with similar symptoms and was also 
euthanised. The pathology report confirmed chronic copper toxicity, with intravenous haemolysis 
detected and widespread apoptotic and mitotic hepatocytes indicative of progressive liver damage. 
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Trace copper concentrations in the kidney and liver again well exceeded the normal range (906 
μmol/kg and 5000 μmol/kg respectively; normal liver range 95 – 3000 μmol/kg).  
Extra supplementation was added to the diet. Ammonium molybdate (50 mg) and sodium 
thiosulphate (0.5 g) were added daily for three week-long periods as a preventative measure to 
reverse the copper overload. Copper levels in the concentrate lucerne pellet feed, lucerne chaff and 
hay chaff were found to be low; 9, 7 and 6 parts per million respectively (Gribbles Veterinary 
Pathology). Levels from the water supply to the sheep holding facility were found to be 2 parts per 
billion and below detection respectively in the two samples sites tested (Analytical Services, Lincoln 
University).  
Despite the introduction of supplementation to reduce copper absorption, the copper concentration 
in the livers of all of the other treated sheep were excessively high at euthanasia (>3000 μmol/kg), 
indicating this to be an ongoing problem for sheep maintained long-term indoors on lucerne-based 
concentrate feed. 
7.3.1.1.2 Other adverse events 
During the gene therapy trial, three other adverse incidents were reported. One sheep (1027/13) 
pierced its lip on the metal mesh surrounding its cage. Regular treatment with saline solution 
prevented infection and the piercing closed over within a month. Another sheep (1001/13) 
developed a large purulent papule on its upper lip, with no other systemic symptoms. This was 
identified as contagious ecthyma (Orf disease, scabby mouth), a pustular form of dermatitis. The 
animal was isolated, no further cases developed in the other similarly housed animals and the 
pustule self-resolved in 3 weeks. The third incident occurred early in the trial and involved 
stereotypic “wool biting” behaviour, with one animal (1002/13) pulling strands of wool from the 
fleece of her subordinate sibling (1001/13), who became substantially denuded in patches. 
Environmental enrichment was increased, including hanging chains from the ceiling, balls, plastic 
bottles or chewing bars in the pens, and these  were rotated biweekly to stimulate investigative 
behaviour. Long-strand fibre (chaffed hay) was also added to the diet, to increase the roughage 
content, with the resultant cessation of the behaviour. 
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7.3.1.2 Growth rate 
Despite injected sheep being weaned early and maintained indoors on a daily feed ration during the 
course of the trial, growth rates for treated sheep were steady (1.91 kg/month) and comparable with 
age-matched untreated CLN6-/- (1.46 kg/month) and CLN6+/- cohorts (2.25 kg/month) maintained 
on pasture (Figure 7.2). Rates were also consistent with those documented for animals similarly 
housed indoors on a long-term pharmaceutical trial, being 1.7 kg/month for CLN6-/- sheep and 2.1 
kg/month for CLN6+/- sheep (Kay & Palmer, 2013). 
 
 
 
 
 
 
 
 
Figure 7.2   Mean live weight increases following viral-mediated CLN6 gene transfer in sheep 
Mean live weight changes in outdoor housed untreated heterozygous (CLN6+/-) and CLN6 affected 
(CLN6-/-) cohorts reflect normal seasonal fluctuations, whilst treated CLN6-/- animals were weaned 
early at 1.8 months, housed indoors after their gene transfer neurosurgery ( LV-CLN6,  AAV9-
CLN6) and received a daily maintenance ration of feed, reflected in their steady weight gains. 
Composite live weights were plotted for the treated sheep as there was no significant difference 
between the two viral vector treatment groups. Vertical bars depict ±SEM. 
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7.3.2 In vivo assessment of gene therapy efficacy 
7.3.2.1  Clinical staging of ovine CLN6  
Determining the natural progression of disease was essential for evaluating therapeutic success in 
the gene therapy study. As in the CLN5 gene therapeutic study, sheep in the treatment and control 
cohorts were assessed for neurological, behavioural, motor and visual function based on an ovine-
specific clinical rating scale (Table 3.1, see Section 3.3). Clinical rating scores (CRS) decreased from 5 
(normal function) to 0 (progressive disease with spontaneous tetanic seizures, defined as the 
humane end-point) as animals became more debilitated from the disease. Routine monthly physical 
and neurological examinations were performed, with concurrent open- and closed-field behavioural 
observation, beginning on average at 4.3 months of age. 
CLN6 heterozygous sheep were clinically normal throughout the study period, consistently scoring 5 
on the rating scale (Figure 7.3) and exhibited no functional deficits. In comparison, clinical signs of 
CLN6 disease in homozygous affected (CLN6-/-) sheep developed slowly and progressively from 7  
0.9 months of age. They initially presented with low head carriage, which was especially apparent 
when they were passing through gates, races, a maze (see Section 7.3.2.4) and in shadows (CRS 4). 
From 9 months of age, individual sheep began to show visual deficits with an overt head tilt, thereby 
extending their visual field, and depressed visual reflexes, namely the menace (eye preservation), 
pupillary light and dazzle responses. By 10 to 12 months CLN6-/- sheep were smaller and had less 
condition than their heterozygous counterparts; this coincided with the onset of winter, when 
grazing was limited. Despite the difference in live weights at this timepoint, the subsequent growth 
rate of the CLN6-/- cohort mirrored that of the CLN6+/- cohort (Figure 7.2). From 12.6  1.0 months, 
all untreated CLN6  -/- sheep were functionally blind (CRS 3).  
An overt neurological disease phenotype (CRS 2) was detected in the remainder of the affected 
South Hampshire sheep from 15.4  1.0 months of age, with reduced mentation and spontaneous 
episodes of head nodding and facial twitches, particularly of the eyelids, ears and lips. There was 
however significant variation in the disease onset and progression in the CLN6-/- cohort. Three 
untreated CLN6-/- sheep died naturally, but prematurely with advanced disease symptoms, during 
the study (Table 7.1). 1013/12 died at 12.6 months, with disease-related pathology observed post 
mortem. Another animal (1028/13) developed stress-induced tremors at 12.7 months and died of 
misadventure (falling into a ditch) at 13.4 months. A second sheep (1041/13) also developed severe 
inducible tremors, with a circling tendency resembling encephalitic listeriosis, and was euthanised at 
13.4 months. Thus the sample size of the untreated CLN6-/- cohort decreased with age prior to trial 
completion.  
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After 17.2  0.8 months, CLN6-/- sheep exhibited progressively more obvious changes in sensation 
(blindness), mental state (behavioural changes), and posture or movement (motor deficits), termed 
the advanced disease state (CRS 1). Menace and dazzle responses were absent and pupillary reflexes 
were diminished. Affected sheep self-segregated from the flock, showed a reduced awareness of 
their surroundings and performed repetitive activities, such as inefficient or sham eating, aimless 
walking and compulsive circling in a confined space. Sheep showed a higher propensity to stumble, 
and when they stood still often adopted a wide stance with more manifest hindlimb paresis and 
localised tremors. Spontaneous seizure activity was not evident in the CLN6-/- cohort during this 
study, however this manifestation of the disease usually presents from 18 months of age and only 
occurs in a minority of the affected sheep (Palmer and Mitchell, personal observation). Despite 
affected South Hampshire sheep having lived up to 29 months with extensive nursing, all CLN6-/- 
sheep in this study were euthanised by 19.2 months for humane reasons with varying degrees of 
clinical disease (Table 7.1).  
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A.  
Score Clinical phenotype Clinical status * Age (months) 
5 Normal Normal <7.0  0.9 
4 Pre-clinical Low head carriage 
Propensity to crouch, baulk and stumble 
7.0  0.9 
3 Blind Head tilt/stargazing 
Visual deficits 
Decreased or lost menace (blink) response 
Reduced herding 
12.6 ± 1.0 
2 Overt/neurological Motor, cognitive and proprioceptive deficits 
Decreased startle to auditory stimuli 
Wide stance 
15.4 ± 1.0 
1 Advanced Progressive disease 
+/- induced tetanic seizures 
18.1 ± 0.9 
0 Terminal Spontaneous tetanic seizures Not observed 
* Onset of inducible mild tremors in individual sheep began as early as 12.7 months. Spontaneous convulsive 
seizures were not reported for the CLN6-/- sheep in this study but have been observed previously in the field in 
animals approaching or into their second year of life. 
 
 
 
Figure 7.3  Clinical progression of CLN6 deficient sheep following viral-mediated CLN6 gene transfer  
Treated sheep were followed for 24 months after treatment ( LV-CLN6, AAV9-CLN6) and 
monitored against disease progression in untreated CLN6-/- sheep.  A. Ages of symptom onset are 
shown for untreated CLN6-/- sheep (mean  SEM, n = 9). The scale is based on multi-focal 
neurological and motor defects, with initial behavioural deficits at 7  0.9 months of age. B. One 
animal (1027/13) responded robustly to the treatment showing clinical scores consistent with 
untreated CLN6+/- controls, whereas the remaining five treated animals responded less favourably, 
developing behavioural deficits from 12.7  0.6 months and loss of vision and other clinical 
symptoms from 14  0.8 months of age.  
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7.3.2.2 Clinical status in treated CLN6-/- sheep 
At baseline (4.3 months), no neurological abnormalities were detected in the study animals with all 
cohorts scoring 5 (Figure 7.3). The treated cohort could be divided into two groups: one animal 
(1027/13) responded so favourably to AAV9-CLN6 treatment that it was indistinguishable clinically 
from the untreated CLN6+/- cohort over the duration of the study whereas the same level of 
therapeutic efficacy was not achieved by the other five treated animals. At the pre-determined study 
endpoint of 18 months of age, sheep 1027/13 showed no clinical evidence of ovine NCL disease 
symptoms and, with a CRS of 5, the trial was extended to gain an insight into the persistence of 
efficacy. 
At 26.2 months of age (23.9 months post-treatment), 1027/13 was euthanised. The only 
clinicopathological indication of NCL detected in this animal was low level retinal damage, described 
below, which did not impact her visual functionality. Bilateral funduscopic examination at 18 months 
of age, conducted by an independent veterinary ophthalmologist, revealed a degree of tapetal 
hyperreflectivity and mild attenuation of the retinal vasculature in 1027/13 compared with untreated 
CLN6+/- controls. Electroretinography (ERG) and funduscopy performed on 1027/13 just prior to 
euthanasia corroborated this finding. ERG waveforms in both eyes of untreated CLN6-/- animals 
began to decrease from 12 - 15 months of age, becoming extinguished (flatline) in some individuals 
from 18 months (Katharina Russell, personal communication), confirming retinal dysfunction in the 
ovine model. However a- and b-waveforms were detected for 1027/13 at 26 months of age, although 
the amplitude of the a-wave was slightly reduced compared with fully sighted heterozygous controls 
(Figure 7.4). Only a single ERG episode was recorded for 1027/13, hence no longitudinal data are 
available. At this age, the menace response and pupillary light reflexes were still intact. Mild vascular 
attenuation was confirmed in the tapetal and non-tapetal fundus, but this was much less marked 
than in younger untreated CLN6-/- animals (Katharina Russell, personal communication). 
Although the other five treated CLN6-/- animals did not show the same degree of functional 
correction, disease onset was delayed in them by a few months on average (Figure 7.3). These sheep 
were clinically normal until 12.7  0.6 months of age, when they began to baulk at obstacles, 
shadows and their cohorts (CRS4). The presentation of a head tilt in some animals and reduced 
menace reflexes indicated the onset of visual deficits, with functional blindness reported at 14  0.8 
months (CRS 3). During this early-clinical stage, animals 1004/13 and 1002/13 were euthanised due 
to the cumulative effects of copper toxicity. A third sheep (1025/13) was also euthanised early, at 
13.8 months, because of overt clinical signs of NCL, which included blindness, confusion and circling. 
Animals 1001/13 and 1026/13 saw the trial to completion, but were functionally blind from 15.6 and 
12.6 months respectively, and developed an overt clinical phenotype prior to euthanasia. 
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Figure 7.4    Electroretinography (ERG) as an indicator of retinal damage  
A. Scotopic electroretinogram from the left fundus of an 18.8 month old CLN6+/- sheep with normal 
retinal function. A negative deflection (a-wave) and larger positive deflection (b-wave) can be seen.  
B. A flatline response, in the left fundus of a 18.3 month untreated CLN6-/- sheep, with complete 
ablation of the a- and b-waves, indicative of retinal dysfunction.  
C. A response, albeit with decreased a-wave amplitude, is detected from the left fundus of the 
treated CLN6-/- sheep, 1027/13, at 26.2 months of age, almost 24 months after AAV9-CLN6 delivery. 
This suggests CNS-directed gene therapy afforded sufficient protection to the retina to maintain 
vision and elicit an ERG response. Electroretinogram traces were provided by Katharina Russell (PhD 
student, Lincoln University). 
a-wave 
b-wave 
Normal ERG 
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7.3.2.4 Maze testing as a biomarker of functional correction 
Functional efficacy of CLN6 gene transfer was assessed monthly in a closed-field maze test (see 
Section 3.4). Total mean maze traverse times for the treatment groups and untreated CLN6-/- and 
CLN6+/- cohorts are shown in Figure 7.5A. There was no detectable difference between the four 
groups at baseline (4.3 months of age) but a significant (P < 0.05) treatment effect became apparent 
from 5.4 months as untreated CLN6-/- sheep took progressively more time to navigate the maze. 
Despite being functionally blind from 12.6  1 months, they were still able to traverse the maze 
without assistance until 15.4 months of age. Maze testing was abandoned for humane reasons for 
untreated CLN6-/- sheep from that timepoint because of generalised akinesia and the risk of stress-
induced tremor activity. Treated sheep could be divided into two groups: one AAV9-treated animal, 
1027/13, required less than 10 seconds on average to traverse the maze for most testing intervals, 
whereas the remainder of the LV- and AAV9-treated sheep (n = 5) did not show the same level of 
functional correction. This unsuccessful treatment cohort were initially faster through the maze than 
untreated controls, but from 9 months of age their mean transit times matched untreated 
heterozygotes and then they became increasingly slower.  
Figure 7.5B is a graphical plot of the mean error times per month. Although five of the nine untreated 
CLN6-/- sheep spent time in the error zone during the first testing episode, this was not an increasing 
trend. Heterozygous sheep never entered the error zone, a cul-de-sac which deviated from the 
correct path through the maze, instead running through the maze rapidly with few pauses. 
Subjective grading of each sheep’s individual negotiation of the maze demonstrated this, and also 
showed the increasing gap in performance and the developing behavioural phenotype in the 
untreated CLN6-/- sheep and the unsuccessful treatment cohort with time (Figure 7.6). Despite 
retaining visual acuity to 14  0.8 months, the unsuccessful treatment cohort demonstrated non-
quantifiable NCL phenotypic signs in the final testing sessions, including confusion and pacing back 
and forth in front of an obstacle, bleating and lowering the head in search of olfactory cues, similar to 
that seen earlier by untreated CLN6-/- sheep. 
In contrast, the AAV9-CLN6 treated sheep, 1027/13, was clinically indistinguishable from healthy 
heterozygous control sheep, showing no discernible difference in maze performance to them. It ran 
through the maze arena with its head held high, avoiding obstacles easily, showing no visual 
problems. It was alert and responsive to visual, auditory and environmental cues, such as wind, 
pasture, and food rewards, as well as wary of foreign humans or sheep. There was no evidence of the 
hindlimb ataxia, stereotypical wide stance or localised manifest tremors previously reported for 
untreated CLN6-/- sheep at end-stage disease (~24 months of age).  
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Figure 7.5    Performance in a close-field maze test after viral-mediated CLN6 delivery 
A. Mean traverse times for LV-CLN6 (n = 3) or AAV9-CLN6 (n = 3) treated CLN6-/- sheep were 
compared with unaffected CLN6+/- control (n = 3) and untreated CLN6-/- (n = 9) sheep over a period 
of almost 2 years. The performance of treated sheep was initially significantly better (P  0.05) than 
untreated CLN6-/- sheep but with time five of the treated animals began to take progressively longer 
to traverse the maze. However one AAV9-treated animal, 1027/13, maintained long-term functional 
correction, with significantly faster traverse times (P    0.05). 
B. Mean error times during maze passage for the groups in A recorded over the same period. Error 
times do not reflect the changes in performance as efficiently as the average traverse time plot. 
However the only animals to enter the error zone in the maze were the untreated CLN6-/- sheep and 
later the five sheep who did not respond so favourably to the viral-mediated CLN6 treatment.  
Data are shown as the mean + SEM (vertical bars); n = 3 - 4 animals per group, 2 runs per animal at 
each time point.  
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A. 
Score Maze assessment Age (months) 
5 Traverse with no problems < 5.7 ± 0.7 
4 Traverse with small pauses 5.7 ± 0.7 
3 Traverse but with obvious behavioural phenotype (+/- hits obstacles) 9.8 ± 1.1 
2 Traverse with or without pauses but misses entry 13.6 ± 0.7 
1 Traverse with errors 15.2 ± 0.4 
0 Fail - requires assistance to traverse Not seen 
 
 
 
 
 
 
 
 
 
 
Figure 7.6   Grading of maze navigational ability after viral-mediated CLN6 delivery 
Subjective grading of individual sheep traverses through a closed-field maze were performed at 
monthly intervals. A. Sheep were scored for every maze passage, with scores ranging from 5 (normal 
traverse) to 0 (failure to traverse without assistance). Ages of onset are shown for seven untreated 
CLN6-/- sheep. Initial phenotypic deficits were detected from 9.8  1.1 months of age and included 
low head carriage, crouching, baulking, stumbling or ‘self-spooking’ at obstacles. B. Composite scores 
for the four cohorts show that untreated CLN6+/- sheep traversed the maze with no or small pauses, 
consistently scoring 5 whilst untreated CLN6-/- found the maze progressively harder to traverse 
without errors or assistance. Five of the lentiviral or AAV9- treated sheep traversed the maze with 
only pauses until 13 months of age when they began to show a behavioural phenotype. The onset of 
visual deficits then began to affect their performance in line with the untreated CLN6-/- sheep. 
However, one AAV9-CLN6 treated sheep demonstrated prolonged visual acuity, maze navigational 
ability and cognitive function, being indistinguishable from untreated CLN6+/- controls at 26 months 
of age. All data are expressed as the mean  SEM (vertical bars); n = 3 - 9 animals per group, 2 runs 
per animal at each timepoint.   denotes the time of treatment for LV- and AAV9-CLN6 
respectively.  
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7.3.2.5 Disease progression assessed by CNS imaging 
Treated animals were CT scanned every two months, intracranial volumes determined and the rates 
of change calculated from the raw data. At the first scan at 5 months of age, the intracranial volume 
for treated sheep ranged from 84.1 to 89.0 mL (mean 86.4  0.8 mL; median 86.6 mL), exceeding the 
mean anticipated for an affected CLN6 animal of the same age (83.0 mL). However for five of the 
treated sheep, the measured rates of decline in volume after the first scan were faster than those 
seen from historical data for untreated CLN6-/- animals (Figure 7.7, Table 7.3). In contrast, the AAV9-
CLN6 treated animal (1027/13) demonstrated a positive rate of change over the study, equivalent to 
an increase in intracranial volume of 0.61 mL/month until 15 months of age, then plateauxed at 91 
mL. A similar plateau at >100 mL would be expected for a normal adult sheep, based on the 
literature (Nitzsche et al., 2015) and personal observation.  
Brain structure was also examined by MRI. A single imaging session performed on 1027/13 at 25 
months of age demonstrated long-term normalisation of the brain structure after AAV9-CLN6 gene 
transfer (Figure 7.8). Ventricles were of similar size to those of an untreated control animal and there 
was no evidence of the overt brain atrophy and cranial bone thickening seen in a much younger 
untreated affected animal.  
 
Figure 7.7    Prevention of brain atrophy in 1027/13 after AAV9-mediated CLN6 delivery 
Longitudinal changes in the intracranial volume profile of treated CLN6-/- sheep were compared with 
average volumetric changes observed in untreated control CLN6+/- and CLN6-/- animals in previous 
studies. Whilst five treated animals showed a decline in intracranial volume over time to mirror that 
seen in untreated CLN6 affected sheep, one AAV9-CLN6 treated sheep maintained volume for an 
extended period of time.   denote the time of treatment for LV-CLN6 and AAV9-CLN6 
respectively. 
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7.3.3 Post mortem analysis of CLN6 gene therapy efficacy 
Sheep treated with LV and AAV-CLN6 were euthanised for analysis of transgene expression and 
morphological assessment of neuropathology from 13.8 – 26.2 months of age. The two treated 
hemispheres were analysed individually. However, since no statistical significant differences were 
found, results are presented as an average of the two. 
7.3.5.1 CLN6 Transgene expression  
Vector-driven CLN6 expression and distribution was assessed in sagittal sections of the brain by 
immunohistochemical staining using the anti-sheep CLN6 antibody (Figure 7.9). Specificity has been 
demonstrated by the absence of staining in untreated CLN6-/- sheep tissue (Figure 4.15). In all 
treated sheep, clusters of CLN6-expressing cells were detected in multiple brain regions, particularly 
near the targetted parenchymal locations in the occipital and parietal cortices. There was intense, 
punctate staining of the periphery or the entire cell soma, and along proximal neuritic processes 
extending up to 150  µm. Transduced cells from both vectors were typically neuronal in morphology, 
although there was considerable heterogeneity with multi- and bipolar cells expressing CLN6. Some 
LV-transduced cells resembled protoplasmic astrocytes morphologically (Figure 7.9C). 
A high density of CLN6-positive cells was evident for up to 7 mm along the extent of the cortical 
needle tracks in the lentiviral-treated brains. Transduced cells were detected in the brain 
parenchyma up to 4 mm rostro-caudal and lateral to the injection sites as revealed by DAB staining. 
The circular spatial pattern of the staining appeared to reflect the 2 µl bolus and withdrawal nature 
of the injection strategy (Figure 7.9B). Cuboidal ependymal cells at the ventricular surface were also 
transduced along the entire rostro-caudal extent (Figure 7.9D). In one LV-treated animal (1004/13) 
transduced cells extended into the rostral migratory stream leading to the main olfactory bulb 
(Figure 7.9E). Occasional Purkinje cerebellar cells were also CLN6-positive but little CLN6 expression 
was detected elsewhere either cortically or subcortically.  
AAV9-mediated delivery of CLN6 resulted in a more widespread distribution of transduced cells, 
predominantly with neuronal morphology. Pockets of expression, through all cortical layers and 
spanning up to 6 mm, were noted near the two parenchymal injection sites. Additionally sporadic 
transduced cells were detected in the cerebellum, hipppocampus of all AAV-treated brains and in the 
striatum of 1027/13. No ependymal transduction was observed. A higher density of tranduced cells 
was apparent in 1027/13 than in the other two AAV9-treated sheep. 
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Figure 7.9    Lentiviral and AAV9-mediated CLN6 transfer to the CLN6 affected sheep brain 
DAB staining showing CLN6 positive transduced cells within the brain parenchyma of CLN6 affected 
sheep after lentiviral (LV) and AAV9-mediated CLN6 transfer. Potent lentiviral infection was restricted 
to the brain parenchyma proximal to the occipital (A) and parietel (B, inset C) cortex injection sites or 
along the entire rostro-caudal extent of the ependyma lining the lateral ventricle (D). Transduced 
cells were mainly neuronal in morphology with punctate staining through the cytosol and along 
neural extensions, although CLN6 was also expressed in astroglia. Immunopositive cells were also 
detected along the rostral migratory stream in one LV-treated animal (E, inset), and sparsely in the 
cerebellum (F). AAV9 delivery of CLN6 resulted in pockets of cortical expression (G, inset H) with 
greater intensity in 1027/13, the only animal to show functional and structural efficacy(J, inset I). 
Transduced cells were predominantly neuronal. Scale bar represents 500 m in A-B,G,J; 200 m in E; 
100 m in D,F,H,I; 50 m in C,E inset.  
A B C 
D E F 
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7.3.5.2 Neurodegeneration 
The impact of pre-clinical CLN6 gene therapy on neurodegeneration was analysed by measuring 
cortical thickness in Nissl stained sections. Measurements were made from the pia to the easily 
identifiable boundary between the white and grey matter in three cortical regions differentially 
affected by the disease. Individual hemispheres from the treated sheep brains were analysed in three 
groups against age-matched untreated CLN6-/- and CLN6+/- controls; three animals (1002/13, 
1004/13 and 1025/13) were compared with a 13.8 month old CLN6-/- control, and two animals 
(1001/13 and 1026/13) were assessed against 16 month old controls. The final surviving sheep 
(1027/13) was euthanised at a much later age and its brain histology was compared with 24 month 
old control brains (Figure 7.10). 
As expected, there was no apparent loss of neurons in the unaffected control brains, and the typical 
laminar distribution of cells was observed through all cortical regions. However marked atrophy was 
seen in all regions of the cerebral cortex of the CLN6 affected sheep brains, with associated neuronal 
loss and progressive thinning of the cortical layers (Figure 7.10, Table 7.4). This atrophy was most 
pronounced in the affected visual cortex, where the cortical thickness was reduced from 55 % at 13.8 
months to 37 % of normal by 24 months of age. Concurrently, individual layer boundaries became 
less discernible, with clusters of cellular aggregates observed at the layer I/II boundary throughout 
the affected cortical mantle but not in the control brain. 
Five of the treated brains, excluding 1027/13, displayed reduced definition of the cortical layers and 
very distinct layer I/II cellular clusters, similar to a 13.8 month old CLN6 affected brain (Figure 7.10, 
representative images). Cortical thickness measurements reinforced these findings (Table 7.4). Mean 
thicknesses for each cortical region examined (visual, motor and parieto-occipital) were not 
significantly different between these 5 treated sheep and an untreated 13.8 month old CLN6 affected 
brain. Although treated sheep measurements were significantly greater (P < 0.019) than an 
untreated 16 month old CLN6 affected sheep across all cortical regions, pre-clinical CLN6 gene 
transfer appeared to have no, or only a mild, neuroprotective effect in five of the six treated sheep. 
In comparison, a distinct laminar structure was seen across the cortical mantle of one AAV9-CLN6 
treated brain (1027/13), and no overt loss of neurons was observed although sporadic clusters were 
seen in the layer I/II boundary of the visual and parieto-occipital cortices. The cortical thicknesses 
were reduced compared with an untreated control brain, ranging from 94 % of normal thickness in 
the motor cortex, 76 % in the parieto-occipital cortex, to 70 % in the visual cortex. However all 
thicknesses were significantly greater than those of a 24 month old untreated CLN6-/- animal (P < 
0.0001) (Table 7.4, grey box), demonstrating some correction of disease-associated atrophy and 
neurodegeneration by AAV9-mediated delivery of CLN6 cDNA to the sheep CNS. 
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Figure 7.10    Qualitative assessment of neurodegeneration after lentiviral- and AAV9-mediated CLN6 gene transfer to preclinical CLN6 deficient sheep 
Nissl staining demonstrates progressive atrophy of the visual cortex in untreated CLN6 affected sheep, with associated disruption of the cortical cytoarchitecture 
and aggregation of cells at the lamina I/II boundary. The lentiviral treated (1001/13) and AAV9 treated (1026/13) brains, which are representative of other treated 
sheep (1002/13, 1004/13 and 1026/13), resemble a 13.8 month old untreated CLN6 affected brain, with dense cellular clusters and thinning of the cortex. In 
contrast, a more normal laminar distribution of cells and no clusters are evident in one AAV9-CLN6 treated sheep (1027/13). Although the cortical thickness of this 
animal was reduced compared with an untreated normal control, it was significantly greater than an untreated CLN6 deficient sheep brain of similar age (P < 
0.0001). Upper arrows mark the layer I/II boundary, middle arrows indicate the layer IV/V boundary whilst lower arrows denote the layer VI/white matter 
boundary. Scale bar represents 200 μm. 
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Table 7.4    Quantitative assessment of neurodegeneration after viral-mediated CLN6 gene transfer to preclinical CLN6 deficient sheep 
  Mean thickness of layers (μm  SEM)*    
Cortex 
(Layers I-VI) 
 
Affected 
Untreated 
13.8 m 
1025/13    
AAV-CLN6       
13.8 m 
1004/13       
LV-CLN6     
14.1 m 
1002/13       
LV-CLN6  
14.8 m  
Affected 
Untreated 
16 m 
1026/13 
AAV-CLN6 
16.2 m  
1001/13    
LV-CLN6 
16.7 m 
Normal                
Untreated          
16 m 
Affected 
Untreated 
24 m 
1027/13 
AAV-CLN6 
26.2 m 
Normal 
Untreated 
24.6 m 
Visual 912  12 981  18 908  16 942  19 802  32 906  19 1010  23 1668  56 621  37 1178  21 1694  43 
Parieto-occipital 1081  14 1050  17 1022  14 1016  16 889  28 965  19 1071  32 1772  39 614  20 1335  23 1765  34 
Motor 1539  13 1584  19 1549  23 1583  24 1485  31 1553  27 1564  23 1795  29 1109  44 1702  15 1806  44 
*25 measurements per cortical region 
1
51
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7.3.5.3 Glial activation 
Glial activation precedes neurodegeneration during pathogenesis in the ovine CLN6 model (Chapter 
4; Oswald et al., 2005) hence any amelioration in this response due to gene therapy was evaluated. 
Activation was assessed by immunohistochemistry using the astrocytic marker GFAP, and GSB4-lectin 
histochemistry to detect activated microglia in normal, CLN6 affected and treated brains. 
7.3.5.3.1 GFAP  
In the normal cerebral cortex, GFAP reactivity was predominantly detected in protoplasmic 
astrocytes, with short, fine highly branched processes that were distributed uniformly across all 
cortical layers and regions. Ramified fibrous astrocytes were detected along white matter tracts, 
often associated with the capillary vasculature, or at the pial surface with weakly labelled glial 
processes (Figure 7.11A). Conversely, a dense meshwork of hypertrophic astrocytes formed in the 
untreated CLN6 affected brains across the upper cortical layers (Figure 7.11A). Reactivity in the visual 
cortex was more pronounced compared with parieto-occipital and motor cortices.  
GFAP staining in the five unsuccessfully treated brains, excluding 1027/13, was similar to that in the 
brain from the untreated affected control animal. A dense glial meshwork was apparent in the upper 
cortical layers and immunoreactive astrocytes shared the same hypertrophic morphology with 
thickened intensely immunostained processes (Figure 7.11A). Quantitative threshold analysis of the 
intensity of GFAP immunoreactivity confirmed that the gene therapy had no effect on astrocytosis in 
these five animals (Figure 7.11B). Immunoreactivity across the cortical layers (I-VI) of the visual 
cortex was 22.8  1.5 % for the 16 month old untreated CLN6 affected animal and ranged from 19.2 
 0.9 % (1025/13) to 24.9  1.5 % (1002/13) for the treated sheep, indicative of a similar astrocytic 
response in these animals. No significant differences were observed between normal, untreated and 
treated CLN6 affected animals in subcortical or cerebellar regions. 
In contrast, there was a significant amelioration in disease-associated astrocytic activation in the 
AAV9-treated animal, 1027/13. White matter astrocytes were fibrous whereas astrocytes throughout 
the cortical grey matter in this animal were protoplasmic, being highly branched with numerous 
processes. Both astroglial morphologies resembled those seen in the untreated normal control brain 
(Figure 7.11A). Quantitative analysis revealed that the total immunoreactivity across the grey matter 
layers of the visual cortex was 2.6  0.5 % for 1027/13, which was not significantly different to the 
control brain (P = 0.017) but markedly less than that of a representative untreated CLN6 affected 
animal (27.8  0.2 %), P < 0.0001, (Figure 7.11B).  
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Figure 7.11    Effects of viral-mediated CLN6 gene transfer upon astrocytosis  
A. Immunostaining for GFAP reveals the extent of astrocytosis in the untreated normal control and CLN6 affected sheep visual cortices compared with those from 
CLN6 affected sheep treated pre-clinically with lentiviral- and AAV9-mediated CLN6 gene transfer. Compared with scattered protoplasmic astrocytes present 
throughout the normal sheep brain, widespread upregulation of astrocytosis was observed in the untreated CLN6 affected brain, where intensely stained 
astrocytes with thickened processes and hypertrophied cell soma formed a dense glial meshwork. Hypertrophic astrocytes were also seen in the five 
unsuccessfully treated brains (1001/13, 1002/13, 1004/13, 1025/13 and 1026/13), forming a prominent band in the upper cortical laminae. In contrast, one AAV9-
CLN6 treated sheep (1027/13) displayed GFAP-positive protoplasmic astrocytes, similar to the untreated control, with no evidence of astroglial activation. Note 
images of 1002/13 and 1025/13 are representative of the other lentiviral and AAV9 treated sheep. Scale bar represents 200 μm (upper) and 50 μm (lower). 
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 Figure 7.11    Effects of viral-mediated CLN6 gene transfer upon astrocytosis (cont.) 
B. A histogram of the mean area of immunoreactivity per field (%) obtained by thresholding image 
analysis of GFAP immunostaining in the visual cortex. These data confirm the progressive disease-
associated astrocytosis in the CLN6 affected visual cortex, as described previously (Oswald et al., 
2005) and show that lentiviral- (shaded) and AAV9- (white) mediated CLN6 gene transfer did not 
prevent astrocytic activation in five CLN6 affected sheep. However pre-clinical AAV9-CLN6 
administration significantly decreased the level of GFAP immunoreactivity in one treated animal, to 
levels similar to the untreated control sheep. **** P < 0.0001, one way ANOVA. Vertical bars 
represent + SEM. 
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7.3.5.3.2 GSB4  
Little staining was seen in the normal control brain with the neuroinflammatory marker, GSB4-lectin. 
GSB4 reactivity was limited to meningeal and flattened elongated perivascular macrophages with no 
parenchymal microglia detected in any cortical layer or region (Figure 7.12). In contrast, there was a 
marked and progressive increase in reactivity in the CLN6 affected brain, with intense staining in the 
grey matter and subcortical nuclei. Clusters of GSB4 positive microglia and brain macrophages, with 
hypertrophic cell bodies and retracted thickened processes, merged to form two conspicuous bands 
within layers II-III and V-VI of the parieto-occipital and visual cortices from 13.8 months (Figure 7.12). 
The width of these bands decreased with age as the cortex atrophied. Ramified microglia clustered at 
the white and grey matter boundaries, with strong staining in all white matter tracts.   
There was no indication that CLN6 gene therapy reduced microglial-related neuroinflammation in 
five of the treated sheep brains. Similar dense clusters of activated amoeboid microglia and 
hypertrophied cells, reminiscent of brain macrophages, were detected in the cortical grey matter and 
these were also concentrated into the two bands seen in the age-matched untreated CLN6 affected 
brains (Figure 7.12). The widths of the upper GSB4 positive band in three cortical regions (visual, 
motor and parieto-occipital) were not statistically different between the untreated and these treated 
brains (Table 7.5). Moreover, these five unsuccessfully treated animals had staining intensities within 
white matter tracts and subcortical nuclei comparable to those in the untreated CLN6 affected brain.  
Conversely, examination of the 26.2 month old AAV-CLN6 treated brain from animal 1027/13 
revealed a distinct lack of GSB4-positive cells in the cortical grey matter (Figure 7.12) which was 
indistinguishable from the untreated control cortex (Table 7.5, grey box).  
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Figure 7.12    Effects of viral-mediated CLN6 gene transfer upon microglial activation  
GSB4-lec tin histochemistry reveals the extent of microgliosis in the untreated normal control and CLN6 affected sheep visual cortices compared with those from 
CLN6 affected sheep treated pre-clinically with lentiviral- and AAV9-mediated CLN6 gene transfer. No reactivity was detected in the cortical grey matter of the 
normal sheep brain, whereas activated microglia were apparent throughout the affected visual cortex. Staining was particularly intense in the superficial laminae II 
- III and in deeper laminae V – VI, where prominent bands of reactivity were seen. GSB4 positive cells were ramified and clustered together or had hypertrophied 
cell bodies and thickened retracted processes, typical of brain macrophages. Comparable staining morphologies, intensities and distribution were observed in five 
of the treated brains (1001/13, 1002/13, 1004/13, 1025/13 and 1026/13), indicating viral-mediated CLN6 transfer had little therapeutic effect on microglial 
activation in these animals. In contrast, no GSB4-positive cells were detected in the cortical grey matter of one AAV9-CLN6 treated sheep (1027/13) indicating 
therapeutic inhibition of disease-associated microglial activation. Note images of 1002/13 and 1025/13 are representative of the other lentiviral and AAV9 treated 
sheep. Scale bar represents 200 μm (upper) and 50 μm (lower). 
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Table 7.5    Quantitation of microglial activation in the cortex after viral-mediated CLN6 gene transfer to preclinical CLN6 deficient sheep 
  Mean thickness of GSB-positive band width* (μm  SEM)†    
Cortex 
(Layers II-III) 
Affected 
Untreated 
13.8 m 
1025/13    
AAV-CLN6       
13.8 m 
1004/13       
LV-CLN6     
14.1 m 
1002/13       
LV-CLN6  
14.8 m  
Affected 
Untreated 
16 m 
1026/13 
AAV-CLN6 
16.2 m  
1001/13    
LV-CLN6 
16.7 m 
Normal                
Untreated          
16 m 
Affected 
Untreated 
24 m 
1027/13 ‡ 
AAV-CLN6 
26.2 m  
Normal 
Untreated 
24.6 m 
Visual 241  8 223  8 215  7 249  8 290  7 200  7 269  13 - 138  3 - - 
Parieto-occipital 285  8 297  5 283  3 277  5 313  8 267  9 262  7 - 151  8 - - 
Motor 232  9  185  7 225  7 249  6 240  12 200  8 202  7 - 165  8 - - 
* GSB4, biotinylated α-D-galactose-specific isolectin I-B4 from Griffonia simplicifolia (microglial marker) 
† 25 measurements per cortical region 
‡ No parenchymal microglia were detected in any cortical regions for this animal 
m = months 
 
1
57
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7.3.5.4 Storage body accumulation 
To assess the accumulation of storage bodies in the brain, sections from treated sheep were 
analysed for the presence of fluorescent storage material (Figure 7.13). No storage bodies were 
identified in the normal sheep brain. Conversely, punctate globular storage body deposits were 
densely packed into the cortical neurons and glial-like cells of the untreated CLN6 deficient sheep 
brain, as well as the perikarya of cerebellar Purkinje cells. Consistent with this observation, similar 
levels of storage material were also seen throughout neocortical, subcortical and cerebellar regions 
of five unsuccessfully treated CLN6 deficient sheep. However the AAV9-treated brain from animal 
1027/13 was phenotypically normal, with minimal storage body accumulation in all brain regions.  
A brief examination of thin (5 μm) wax-embedded sections of liver and mesenteric lymph node from 
this animal revealed some storage body accumulation in these tissues, confirming the CLN6-/- 
(affected) genotype. Not all hepatocytes or lymphatic cells had storage body accumulation, 
suggesting that the AAV9-mediated gene therapy was capable of correcting not only the lysosomal 
storage defect in the brain but also some of the peripheral pathology (Figure 7.14). 
 
 
 
 
 
 
Figure 7.13    Effects of viral-mediated CLN6 gene transfer upon storage body accumulation 
Fluorescent microscopy of storage material (450-490 nm excitation, 510 nm emission) in 50 m brain 
sections of normal, untreated and treated CLN6 affected cerebral cortex. Storage bodies are not 
present in the 16 month old normal sheep brain (A) but cytoplasmic inclusions are present 
peripherally in the age-matched CLN6 affected cell soma (B). A comparable distribution of 
fluorescent storage material was observed in all of the lentiviral-treated brains at 14 -16 months of 
age (C). Two of the three AAV9-CLN6 treated brains also showed no reduction in lysosomal storage 
burden at this same age (D). However storage body accumulation was significantly reduced in the 
third AAV9-treated animal (1027/13) at 26.2 months of age (E) when compared with the other 
treated brains and a 24 month old untreated CLN6 affected brain (F). A histogram of the mean area 
of fluorescence per field (%) obtained by thresholding image analyses in the visual cortices (G) 
confirms viral-mediated CLN6 transfer had little therapeutic effect on lysosomal storage in five of the 
treated animals but significantly reduced the storage burden in 1027/13, **** P < 0.0001, one way 
ANOVA. Vertical bars denote  SEM. Scale bar represents 50 m. 
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Figure 7.14    Evidence of peripheral storage body accumulation in 1027/13 
Thin 5 m sections of liver (left) and lymph node (right) from the AAV9-CLN6 treated sheep 1027/13 
confirmed the presence of storage material in some cells. Scale bar represents 50 m, and 25 m for 
insets. 
7.3.5.5 Injection related pathology 
For the unsuccessful treatment cohort, Nissl staining showed the site of injection in 6 out of 10 
hemispheres, but without any other noticeable neuropathological changes to the brain parenchyma. 
However staining with the neuroinflammatory markers, GFAP for astrocytes and GSB4 for 
macrophages and activated microglia, showed injection-site-specific infiltration. Obvious needle 
tracks with localised GFAP immunoreactvity and GSB4 reactivity in the vicinity of the injection area 
were detected over 11 months after vector administration. These correlated with the locales of 
greatest transgene expression.  
In contrast, no noticeable neuropathological changes were found in the successfully treated brain 
(1027/13), indicating the treatment in this animal did not induce damage to or an inflammatory 
response in the brain parenchyma.  
7.3.5.6 Eye pathology 
Histopathology of the retina from the successfully treated sheep (1027/13) was compared with that 
of untreated normal controls (Figure 7.15). Atrophy was apparent in the untreated CLN6 affected 
retina at 17 months, with compression of the outer retinal layers. There was degeneration of the 
photoreceptor layer, with particular dystrophy of the outer segments of the rods and cones, whilst 
the outer nucler layer was reduced to a double row of nuclei, reflecting loss of photoreceptor cell 
bodies. The bipolar cells of the inner nuclear layer appeared distended, as did the ganglion cells near 
the vitreal surface, however other retinal layers were attenuated.  
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Although the number of nuclei in both the inner and outer nuclear layers appeared reduced and less 
densely packed, the retina from 1027/13 more closely resembled the normal phenotype than that of 
an untreated affected sheep. There was little compression across the retina in this successfully 
treated animal and the inner and outer photoreceptor segments retained their uniformity. Despite 
some degenerative changes, the animal maintained its vision.  
 
 
 
 
 
 
Figure 7.15    Effect of AAV9-mediated CLN6 gene therapy on the retina 
Haematoxylin and eosin stained retinal sections from 17 month old CLN6 heterozygous control (left) 
and a CLN6 affected sheep (right), compared with that of a 26 month old CLN6 affected sheep 
(1027/13) which successfully responded to pre-clinical brain-directed CLN6 gene therapy (middle). 
The typical ovine retinal pattern was evident for the clinically normal heterozygous animal. The age-
matched CLN6 affected animal was functionally blind and histopathology shows degeneration of rod 
and cone photoreceptors in the affected OS and ONL (arrows). In contrast, AAV9-mediated delivery 
of CLN6 to a pre-symptomatic CLN6 affected lamb largely prevented this cell loss, attenuating the 
retinal atrophy and protecting against the onset of blindness. Some of the different retinal layers are 
marked: GCL ganglion cell layer; INL inner nuclear layer; ONL outer nuclear (photoreceptor cell body) 
layer; IS inner segment; OS outer segment; RPE retinal pigment epithelium. Scale bar represents 25 
μm. 
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7.4 Discussion 
Some forms of NCL present a greater therapeutic challenge than others. They result from defective, 
intracellular proteins (e.g. CLN3, CLN6, CLN7, CLN8)  that are not secreted and thus cannot benefit 
from extracellular cross-correction. There is suggestion that some of these proteins may regulate the 
secretion of other factors allowing cross-correction to still occur (Barry, 2011; Sondhi et al., 2014). 
The present study sought to test the impact of lentiviral (LV) and AAV9-mediated gene therapy in an 
ovine model of CLN6. Pre-clinical CNS administation of viral vectors expressing the ovine CLN6 cDNA 
prevented the CLN6 phenotype in one AAV9-treated animal, whilst the other five developed 
stereotypical disease. In the successfully treated animal, inhibition of the NCL neurobehavioural 
dysfunction and normalisation of brain structure was prolonged, lasting longer than 2 years. This is 
the first report of successful correction of neurobehavioural dysfunction and the pathologic 
phenotype in NCL caused by a defective CLN6  membrane protein. Importantly, NCL disease 
hallmarks such as neurodegeneration, glial activation and storage pathology were significantly 
attenuated and no neurotoxic or inflammatory responses associated with AAV9-driven CLN6 
expression were seen. 
7.4.1 Phenotypic assessment of CLN6 gene transfer 
On the basis of clinical disease symptoms and in vivo biomarkers of therapeutic efficacy, the six 
treated sheep could be split into two groups; five sheep showed a three month delay in clinical 
presentation but ultimately succumbed to the disease, whilst one AAV9-CLN6 treated animal 
(1027/13) displayed phenotypic correction, with a significantly improved quality of life and survival. 
In these experiments, untreated (heterozygous and CLN6 affected) and treated cohorts were 
assessed monthly by neurological examination and maze testing. From 7 months, a clear distinction 
could be made between CLN6 affected and heterozygous sheep, who were phenotypically normal. As 
anticipated based on the literature (Mayhew et al., 1985; Jolly et al., 1989) the diseased sheep began 
to show behavioural symptoms on examination and shortly thereafter in maze testing. They were 
functionally blind from 12 - 13 months of age and progressively declined as an overt neurological 
phenotype, with reduced mentation, disorientation, akinesia and hindlimb ataxia, became more 
established. Five of the treated sheep showed a similar decline, albeit delayed. They were clinically 
normal until 12 - 13 months, then began to show a stereotypical neurobehavioral phenotype. 
Functional blindness was established by 14  0.8 months, yet onset ranged from 12.6 months in an 
AAV9-treated individual to 15.6 months for a lentiviral-treated sheep. The adverse complications 
related to copper toxicity and indoor housing (see Section 8.2.4) prompted the premature euthanasia 
of three of the treated sheep prior to their reaching the akinesic disease state, however this was 
after it became apparent that therapeutic efficacy had not been fully realised. 
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In contrast, one AAV9-treated animal (1027/13) displayed remarkable functional and structural 
correction throughout the study. It was clinically indistinguishable from age-matched heterozygotes 
on neurological examination, in the open field and during maze-testing. It was alert and responsive 
to visual, auditory and tactile stimuli, including mirrors, environmental enrichment toys, claps, bleats, 
wind and loud noises, and developed a strong social attachment with animal care personnel and 
similarly treated Borderdale CLN5 cohorts. Despite ophthalmoscopic and ERG studies indicating some 
degenerative changes in the retina, there was no clinical evidence of visual deterioration. Neuro-
opthalmic reflexes were intact, including the menace response which was suggestive of a functioning 
visual cortex. 
CNS neuroimaging confirmed the structural functionality of the brain of 1027/13. MR imaging of the 
sheep brain is becoming more common as ovine models gain popularity in translational 
neuroscientific research (Amorim et al., 2015; Ella & Keller, 2015; Lee et al., 2015; Nitzsche et al., 
2015; Sawiak et al., 2015). An MRI performed on 1027/13 at 25 months of age showed none of the 
cortical atrophy or ventricular enlargement associated with ovine NCL (Figure 7.8). Only a single MRI 
session occurred  and voxel-based morphometry was not performed however the data could later be 
compared with that collected during a longitudinal MRI study in CLN6 South Hampshire sheep at 
end-stage disease (Sawiak et al., 2015). Intracranial brain volumes were calculated through the study 
from CT images. These demonstrated an initial steady increase for 1027/13 to plateau during 
adulthood at 91 mL. This equates to approximately 82 % of normal adult volume (Figure 7.7). CLN6 
affected sheep brains develop normally for the first 4 months of life, offering an ideal temporal 
window for optimum therapeutic efficacy, before commencing regionally specific neurodegeneration 
with concomitant cortical atrophy (Chapter 4, Oswald et al., 2005). Typically by 18 months of age, 
normal and affected intracranial volumes differ by at least 30 mL, with normal volumes exceeding 
100 mL and CLN6 affected volumes under 80 mL. Interestingly in this study, all treated sheep had 
intracranial volumes at baseline (5 months of age) above that expected for age-matched untreated 
CLN6 deficient animals. It may be that the treatment initially allowed normal growth of the brain but, 
as efficacy wore off from 5 months of age, volume loss and subsequent atrophic changes became 
evident in the five unsuccessfully treated sheep.  
7.4.2 Histological impact of CLN6 gene transfer 
The accumulation of fluorescent storage material within the lysosome, coupled with neuron loss and 
gliosis, characterises the NCLs, including those in sheep (Oswald et al., 2005; Mole et al., 2011). To 
show the definitive impact of treatment on phenotype, these post mortem neuropathological 
parameters were used as a measure of therapeutic efficacy. The five unsuccessfully treated sheep 
displayed little reduction in the pathological hallmarks of NCL previously reported for untreated 
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affected controls (Jolly et al., 1989; Oswald et al., 2001, 2005, 2008). Conversely, the AAV9-mediated 
expression of CLN6 in one sheep (1027/13) successfully resulted in widespread neuropathological 
correction. 
As described above, sheep received treatment at 2.7 (LV) or 3.7 (AAV9) months of age – a pre-clinical 
window of time deemed likely to be efficacious. Prenatal lysosomal storage has been reported in 
South Hampshire sheep (Jolly et al., 1989). Storage bodies are generalised, yet sparse, through the 
brain in the first few months of life, but they progressively accumulate (Chapter 4, Oswald et al., 
2005).  Reactive astrocytosis has been described in the CLN6 affected brain as early as 40 days before 
birth, whilst microglial activation is apparent at birth (Kay et al., 2006). Both precede 
neurodegeneration, which becomes regionally established in the early post-natal period (Chapter 4, 
Oswald et al., 2005), and the onset of clinical symptoms from 7  - 13 months (this study, Mayhew et 
al., 1985). Despite treatment early in the pathogenic cascade, the level of storage burden was not 
reduced for five out of six treated sheep. Nissl staining revealed densely packed cellular aggregates in 
the upper neocortex and a reduction in cortical thicknesses for these five treated animals (Figure 
7.10, Table 7.4). Comparable patterns of astrocytosis and gliosis were detected (Figure 7.11- Figure 
7.12), with widepread staining of brain macrophages, representative of end-stage microglial 
activation (Streit, 1990). Collectively these five animals displayed findings similar to those of affected 
controls, indicating that CLN6 gene transfer did not impact favourably on them for any extended 
period. 
However pre-clinical AAV9-CLN6 administration had a significant neuroprotective effect in one 
sheep, demonstrating significant neuropathological correction for NCL caused by a defective CLN6 
membrane protein for the first time. Post mortem analysis corroborated the CT volumetric data with 
the brain weight of 1027/13 at 26.2 months of age about 80 % of normal. Preliminary 
neuropathological analysis revealed a degree of cortical thinning in the brain of 1027/13, ranging 
from 94 % of normal thickness in the motor cortex to 70 % in the visual cortex. By comparison, 
cortical thicknesses in the best matched untreated CLN6 affected brain were 65 to 55 % of normal for 
the same regions at 24 months (Table 7.4). The laminar distribution of neurons was retained across 
the cortical mantle in 1027/13 and very few cellular aggregates were evident. There was a distinct 
lack of glial activation, even at 26.2 months of age, in contrast to affected animals in which 
astrocytosis and gliosis were profound well before this age (Figure 7.11 - Figure 7.12). Similarly 
minimal storage body accumulation was seen in the brain, however there was evidence of lysosomal 
storage  in some peripheral tissues, albeit significantly reduced (Figure 7.13). This suggests that 
either some, as yet unknown, form of cross-cell correction has occurred or there has been 
transduction of a significant proportion of cells. However when CLN6 expression within the treated 
brains was examined by immunohistochemistry with a sheep-specific CLN6 polyclonal antibody, only 
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a slight greater transduction of cells in 1027/13 was noted compared with the unsuccessfully treated 
animals (Figure 7.9).  
There was strong evidence for transduction of the ependyma lining the lateral ventricles in the LV-
treated brains, similar to that documented in sheep with the reporter green fluorescent protein 
(Linterman et al., 2011), and even in the rostral migratory stream of one animal (Figure 7.9) but 
apparently this was insufficient to provide therapeutic efficacy. Despite ependymal transduction in 
other animal models after AAV-mediated gene delivery to the ventricular system (Liu et al., 2005b; 
Haurigot et al., 2013; Katz et al., 2015; Ribera et al., 2015), this was not apparent in the AAV-treated 
brains in this study. Why therapeutic efficacy was seen in 1027/13 and not in the other treated sheep 
is still to be elucidated. Whilst immunohistochemistry suggested the level of CLN6 expression in the 
brain of 1027/13 was relatively limited, a biodistribution study in CNS and peripheral tissues will 
follow with detection at the mRNA level as this method may prove to be above the threshold for 
detection by immunohistochemical means. 
Studies in sheep and mice models of CLN6 and CLN3 respectively suggest these proteins may 
regulate the secretion of other factors allowing some level of cross-correction to occur (Barry, 2011; 
Sondhi et al., 2014). As described above, studies by Barry (2011) determined that the CLN6 defect is 
cell extrinsic and that the presence of unaffected normal cells had a corrective effect on 
neighbouring affected cells in chimeric sheep. Like CLN6, the CLN3 gene product is a hydrophobic, 
intracellular protein that is not secreted yet neonatal administration of an AAV serotype rh.10 vector 
expressing the human CLN3 cDNA to a Cln3∆ex7/8 knock-in mouse model of juvenile NCL resulted in 
partial correction of phenotype (Sondhi et al., 2014). Treated mice demonstrated safe, long-term 
expression of the CLN3 transgene with reduced storage material burden, decreased gliosis and some 
attentuation of neuronal loss after targeted injections into the hippocampus, striatum and 
cerebellum. Taken together with the results from the current study, it is envisaged that for NCL 
subtypes with defective intracellular proteins, correction of some cells can have a neuroprotective 
effect on adjacent uncorrected cells and this may be sufficient to correct phenotype. 
A particularly interesting observation from this study was the retention of eyesight in 1027/13. The 
retina was not normal (Figure 7.15) yet retained long-term functionality. This contrasted the late-
onset loss of vision in similarly treated CLN5 deficient animals (Chapter 6). Based on CSF circulation, it 
would be anticipiated that only the ganglion cells of the retina should take up either circulating 
vector at administration or some neurotrophic factor secreted into the CSF by corrected cells. This is 
due to their close proximity to the meninges ensheathing the optic nerve. CLN6 expression in the 
retina has not yet been performed but will provide information on the retinal transduction profile. 
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A number of factors still need to be determined, which may extend the success of future treatments 
to all animals. Firstly, the pathogenicity and cell toxicity of AAV9-CLN6 delivery has not been explored 
fully. There appears to be a mild change in density of Nissl stained cells in cortical regions of the 
successfully treated brain (1027/13) although quantification of the number of neurons and 
interneurons in specific brain regions will be required to confirm this. However Nissl staining 
revealed no alteration in tissue near or at the injection sites in the occipital and parietal cortices and 
negligible injection-related neuroinflammation was observed. This contrasted with the results from 
the unsuccessfully treated sheep, which had obvious needle tracks with localised GFAP 
immunoreactvity and GSB4 reactivity in the vicinity of the injection area over 11 months after vector 
administration. Similarly, whilst the immunogenicity of AAV vectors is low, there can be a high 
prevalence of neutralising antibodies (NAbs) against various AAV serotypes in human (Calcedo et al., 
2009; Boutin et al., 2010) and sheep (Rapti et al., 2012; Tellez et al., 2013) populations. Studies have 
shown that anti-AAV NAbs do not appear to affect focal brain parenchymal delivery of AAV vectors 
(Kaplitt et al., 2007), but transduction efficiency after delivery to the CSF is partially affected (Gray et 
al., 2011; Haurigot et al., 2013). Analysis of collected serum samples for any viral capsid-driven or 
CLN6-driven host immune response may be helpful in determining the potential to improve 
therapeutic outcome. 
7.5 Conclusion  
Under field conditions, CLN6 affected sheep are not expected to live beyond two years of age. Here 
data are presented that shows pre-clinical administration of an AAV9 viral vector encoding the 
therapeutic CLN6 transgene to CLN6 deficient sheep reverted the pathologic phenotype and 
prevented disease onset and behavioural dysfunction for over 26 months in one out of six treated 
animals. The longevity of the AAV9-mediated transgene expression was encouraging, given that CLN6 
NCL results from an intrinsic transmembrane protein deficiency. Some questions remain as to how 
this approach can be improved upon to correct all animals under treatment, paving the way for 
translation to therapy in the human clinic. 
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This was not the case. The pathogenic cascades were remarkably similar for CLN5 and CLN6 affected 
sheep (Table 8.1, Table 8.2). Focal astrocytosis and activation of microglia, the resident macrophages 
of the CNS, was evident from birth or in early perinatal stages in both models (this study; Oswald et 
al., 2005; Kay et al., 2006). Despite precocious glial activation being the earliest described 
manifestation of the disease, it is still unclear what causes the initial gliosis in NCL. Regardless, 
targeted suppression of neuroinflammation will likely be an important adjunct to any therapy (see 
Section 8.3.4).  
Markedly regional neuron loss and cerebral atrophy became detectable at 4 and 6 months of age for 
the CLN5 and CLN6 affected sheep respectively and followed the same pattern as the glial activation. 
Layer II-III neurons were specific and early targets of the disease (Figure 4.4). Cortical atrophy 
commenced and progressed faster in the primary visual and parieto-occipital regions than in other 
cortices and the development of pathology in subcortical structures was relatively delayed whilst the 
affected cerebellum was spared (Figure 4.5). 
The specific lysosomal storage of subunit c of mitochondrial ATP synthase was first identified in the 
CLN6 ovine model (Palmer et al., 1989; Fearnley et al., 1990) and subsequently in the majority of 
human forms of NCL (Palmer, 2015). Ovine CLN5 is also a subunit c storage disease (Jolly et al., 2002; 
Frugier et al., 2008) yet, unlike the selective regionality of neurodegeneration and 
neuroinflammation, fluorescent storage bodies were uniformly distributed throughout the diseased 
brains of both genotypes in the current study (Figure 4.13) and many neurons accumulated large 
amounts of storage material with no overt signs of degeneration. Thus despite its ubiquity, a 
causative role for storage body accumulation in neurodegeneration in ovine NCL is not plausible. 
Overt clinical signs of disease were not seen until at least 10 months of age in either ovine NCL 
model, well after neuropathology was established. The earlier onset of both neuroinflammation and 
neurodegeneration in the CLN5 model correlated with the earlier onset of clinical symptoms in the 
CLN5 sheep. The predominant involvement of the primary visual cortex in both disease models also is 
in agreement with the first overt clinical symptom, being visual failure in ovine NCL. The delayed 
motor and thalamic involvement in pathogenesis is likely to be responsible for the later presentation 
of manifest seizures and motor dexterity issues in the disease course. Interestingly, motor, 
proprioceptive and cognitive dysfunction are more pronounced in the CLN5 deficient sheep than in 
their CLN6 affected counterparts and this is reflected by the greater atrophy in the CLN5 frontal lobe 
(Figure 4.5). 
Concurrent with the neuronal loss was evidence of continued endogenous neurogenesis in the 
subventricular zone of both ovine NCL models (Figure 4.14). This suggests a regenerative response by 
the diseased brain early in the pathogenic cascade. It also represents a target site for therapeutic 
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correction of neural progenitor cells which could replace affected cells lost in neurodegeneration. 
Thus therapeutic interventions, such as gene transfer technologies, would likely be most efficacious if 
delivered early in the disease, before irreparable damage was done (see Section 8.2.1).  
Systematic neuropathological analyses, such as used in the current study, are simply not feasible in 
humans. Using established techniques, a spatio-temporal survey of the whole sheep brain is possible. 
Multiple comparisons can be made between brain regions within the same sagittal section, on 
adjacent sections or between genotypes. These are highly informative for the human disease, in 
which small non-specific post mortem brain biopsy samples are often all that is available. 
Additionally, a large number of unstained sections from control and CLN5 and CLN6 deficient brains 
have been catalogued and are available for future investigations. 
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Table 8.1    Summary of clinical and neuropathological changes in CLN5 Borderdale sheep 
Age * Mean brain 
weight (g) † 
Neuropathological findings Clinical phenotype 
Neuronal loss Astrocytosis Microgliosis Storage Neurogenesis  
E70 ~3.5 
Smooth surface 
 ND ND ND ND  
E90 ~14 g  ND ND ND ND  
E150 
Birth 
~55 g (55%) 
 
Normal 
except in V1 
Foci in laminae II/ 
III of V1 and POC 
Foci in laminae II/ 
III of V1 and POC 
Sparse, only 
neuronal cells 
SVZ, HC and CB Normal 
4 m ~ 82 g (89%) 
Peak brain 
weight 
V1, POC, S1 Laminae II/ III of 
V1 and POC 
Laminae II/ III of 
V1 and POC 
ND ND Normal 
6 m ~80 g (89%) 
Cortical atrophy 
first evident  
V1, POC, S1 Laminae II/ III of 
V1, POC and M1 
Laminae II/ III of 
V1, POC and M1 
Widespread, 
mainly 
neuronal 
Prominent in SVZ, 
cortical laminae II/III  
Preclinical: 
Low head carriage 
Propensity to baulk, crouch, stumble 
9 m ~78 g (85%) V1, POC, S1, 
FA 
Laminae II/ III of 
V1, POC and M1 
Laminae II/ III of 
V1, POC and M1 
ND ND  
10- 
11 m 
      Blind: 
Visual deficits, head tilt/stargazing 
Decreased or lost menace response, depressed 
PLR, dazzle response and ERG  
Reduced herding 
12 m ~78 g (81%) 
 
V1, POC, S1, 
FA, Ent 
Spread to laminae 
VI-VI, BG and Th 
Spread to laminae 
VI-VI, BG and Th 
Neuronal and 
non-neuronal  
SVZ, cortical laminae 
II/III 
 
14 m       Overt/Neurological: 
Motor, cognitive and proprioceptive deficits, 
including ataxia, wide stance, reduced mentation, 
decreased acoustic startle 
15 m ~76 g V1, POC, S1, 
FA, Ent, M1 
Widespread 
through cortex, 
less in subcortex 
Widespread 
through cortex, 
less in subcortex 
ND ND Advanced: 
Progressive disease +/- induced tetanic seizures 
Inefficient eating/drinking, compulsive circling  
18 m ~71 g (73%) 
 
Few cortical 
neurons 
remain 
Widespread 
through brain 
Widespread 
through brain 
Mostly non-
neuronal/ brain 
macrophages 
Prominent in SVZ, 
cortical laminae II/III 
 
24 m ~62 g (58%) 
Very atrophied 
but CB normal 
Few cortical 
neurons 
remain 
Widespread 
through brain 
Widespread 
through brain 
Widespread 
through brain 
Much less 
prominent  
Terminal: 
Progressive disease +/- spontaneous seizures 
1
70
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Table 8.2    Summary of clinical and neuropathological changes in CLN6 South Hampshire sheep 
Age * Mean brain 
weight (g) † 
Neuropathological findings Clinical phenotype 
Neuronal loss Astrocytosis Microgliosis Storage Neurogenesis  
E60 ‡ ~2 g (2%) 
Smooth 
surface 
   Sparse   
E80 ‡ ~8 g    Sparse   
E100 ‡ ~20 g 
Gyri evident 
   Sparse   
E110 ‡ ~30 g  Cortical WM  Sparse   
E130 ‡ ~45 g  Foci in laminae II/ 
III of V1 and POC 
 Sparse   
E150 
Birth ‡ 
~50 g (50%) 
 
 Foci in laminae II/ 
III of V1  
Foci in laminae II/ 
III of V1  
Sparse, only 
neuronal cells 
SVZ, HC and CB Normal 
12 d ‡ ~60 g  Laminae II/ III of 
V1, S1 and POC 
Laminae II/ III of 
V1, S1 and POC 
Sparse, only 
neuronal cells 
ND Normal 
2 m ~70 g (95%) V1, POC Reduced  Reduced ND ND Normal 
4 m ~ 75 g (81%) 
Peak brain 
weight 
V1, POC Laminae II/ III of 
V1 and POC 
Laminae II/ III of 
V1 and POC 
ND ND Normal 
6 m ~70 g (79%) 
Cortical 
atrophy first 
evident  
V1, POC Laminae II/ III of 
V1 and POC 
Laminae II/ III of 
V1 and POC 
Widespread, 
mainly 
neuronal 
Prominent in SVZ, 
cortical laminae II/III  
Normal 
7m       Preclinical: 
Low head carriage 
Propensity to baulk, crouch, stumble 
9 m ~68 g (74%) V1, POC, S1 Laminae II/ III of 
V1, POC  
Laminae II/ III of 
V1, POC  
ND ND  
12 m ~68 g (69%) 
 
V1, POC, S1, 
Ent, FA 
Spread to laminae 
VI-VI, M1, BG and 
Th 
Spread to laminae 
VI-VI, M1, BG and 
Th 
Neuronal and 
non-neuronal 
Prominent in SVZ, 
cortical laminae II/III 
Blind: 
Visual deficits, head tilt/stargazing 
Decreased or lost menace response, depressed 
PLR, dazzle response and ERG  
Reduced herding 
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Age * Mean brain 
weight (g) † 
Neuropathological findings Clinical phenotype 
Neuronal loss Astrocytosis Microgliosis Storage Neurogenesis  
15 m       Overt/Neurological: 
Motor, cognitive and proprioceptive deficits, 
including ataxia, wide stance, reduced mentation, 
decreased acoustic startle 
Some spontaneous facial tics 
18 m ~66 g (67%) 
Very 
atrophied but 
CB normal 
V1, POC, S1, 
FA, Ent, M1 
 
Widespread 
through cortex, 
less in subcortex 
Widespread 
through cortex, 
less in subcortex 
Mostly non-
neuronal/ 
brain 
macrophages  
ND Advanced: 
Progressive disease +/- induced tetanic seizures 
Inefficient eating/drinking, compulsive circling 
Extinct ERG waveforms in most  
24 m ~58 g (54%) Few cortical 
neurons 
remain 
Widespread 
through brain 
Widespread 
through brain 
Widespread 
through brain 
Prominent in SVZ, 
cortical laminae II/III 
Terminal: 
Progressive disease +/- spontaneous seizures 
Figure legend for Tables 8.1 and 8.2: 
* Age in embryonic day (E), days (d) or months (m)  
† Percentage mean brain weight of normal 
‡ Results from previous studies (Oswald et al., 2005; Kay et al., 2006) 
Abbreviations: BG basal ganglia; CB cerebellum; Ent entorhinal cortex; ERG electroretinography; FA frontal association cortex; HC hippocampus; m months; M1 primary motor 
cortex; ND not determined; POC parieto-occipital cortex; PLR pupillary light reflex; S1 somatosensory cortex; SVZ subventricular zone; Th thalamus; V1 primary visual cortex; WM 
white matter 
 
 
  
1
72
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8.1.2 Gene transfer to the sheep brain 
In an initial proof of concept study, the efficacy and tropism of adeno-associated virus serotype 9 
(AAV9) as a gene transfer vector was tested in the normal sheep brain (Chapter 5). This vector has 
successfully mediated gene delivery to non-dividing or terminally differentiated post-mitotic cells in 
many animal models of LSDs, with broad long-term gene expression and minimal associated 
inflammation or toxicity (Liu et al., 2005a; Sondhi et al., 2005, 2012; Fu et al., 2011; Haurigot et al., 
2013). Only the use of AAV serotype 1 has been documented in the sheep brain in gene knockdown 
experiments (Dufourny et al., 2008). In the current study, naïve, juvenile sheep received injections of 
AAV9 expressing a reporter gene (green fluorescent protein; GFP) into either the brain parenchyma 
or the lateral cerebral ventricles and GFP expression through the CNS was analysed a month later. 
Stable neurotropic expression of the transgene was achieved by both delivery routes (Figure 5.5). 
However the spread was better after intracerebroventricular delivery (Figure 5.1- Figure 5.2), and 
there was no evidence of vector or procedural neuroinflammation or toxicity (Figure 5.6), indicating 
that this simpler route may be the one of greater translational benefit. 
Chapter 6 and Chapter 7 describe successful viral-mediated gene therapy in pre-clinical CLN5 and 
CLN6 affected sheep respectively. As described above, no specific treatment is available for NCL. 
Preclinical experiments in murine models of CLN1, CLN2 and CLN3 NCL have shown that gene 
therapy can significantly slow disease progression (Griffey et al., 2004, 2006; Hackett et al., 2005; 
Sondhi et al., 2005, 2007, 2012, 2014; Passini et al., 2006) and safety and efficacy clinical trials are 
underway for the CLN2 form (see Section 1.6.4). The current study provides the first evidence of 
therapeutic and functional efficacy in large animal models of NCL. CLN5 deficient sheep, treated pre-
symptomatically with a single administration of brain-directed gene therapy, showed protection from 
stereotypical disease onset and progression. Two viral vector platforms were tested: lentiviruses 
which have previously proven efficacious in sheep (Linterman et al., 2010) and AAV9 which showed 
promise in Chapter 5. Surprisingly, both vectors afforded similar therapeutic benefit. The only 
disease manifestation seen in the treated sheep was a delayed onset visual deficit. Monthly clinical 
assessment and maze testing revealed retention of neurological and cognitive function (Figure 6.3- 
Figure 6.5), whilst CNS imaging demonstrated sustained normalisation of brain structure and 
intracranial volume (Figure 6.7– Figure 6.8). Quality of life was profoundly improved for the treated 
sheep and this was evident in their extended lifespan. In fact, one AAV9-treated sheep is still alive at 
32 months of age in May 2016, well exceeding the typical humane endpoint for untreated CLN5 
deficient sheep of 22 months of age. CLN5 transgene expression and neuropathological attenuation 
of the lysosomal storage pathology, glial activation, and neuronal loss will be examined in the post 
mortem treated brains but the in vivo results look particularly encouraging for clinical translation of 
CLN5 gene therapy. 
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The efficacy of CLN5 gene transfer was not entirely unforeseen, given that the CLN5 disease results 
from a soluble lysosomal protein deficiency and thus was expected to be amenable to ‘cross-
correction’ if sufficient cells were corrected. However the fact that one CLN6 deficient animal treated 
pre-clinically with AAV9-CLN6 (1027/13) also demonstrated phenotypic correction was a surprising 
finding. As CLN6 is a membrane-bound protein, gene therapy approaches for this form were deemed 
not likely to benefit from ‘cross-correction’ (Sands & Davidson, 2006). Only cells directly transduced 
by the AAV vector were thought capable of correction, yet the lysosomal storage defect, disease-
associated neuropathology and behavioural dysfunction was prevented or reversed in this one AAV9-
treated animal. At 26 months of age, 1027/13 was clinically indistinguishable from age-matched 
control animals and exceeded the maximum life expectancy of 24 months for CLN6 deficient sheep. 
Unlike the similarly treated CLN5 deficient sheep, 1027/13 retained vision although the retina was 
not entirely normal in appearance (Figure 7.15). Neuroimaging confirmed the structural integrity of 
the brain (Figure 7.8) and this was corroborated in subsequent neuropathological analyses. 
Lysosomal storage was significantly diminished after AAV9-mediated CLN6 transfer to 1027/13 at the 
pre-clinical age of 3.7 months (Figure 7.13) and a partial correction of disease-associated atrophy and 
neurodegeneration was also noted (Figure 7.10; Table 7.4). Importantly, the treatment had a 
profound therapeutic effect on the already established glial activation in the brain (Figure 7.11-Figure 
7.12). Why one CLN6 deficient sheep benefitted from the treatment whilst the others did not is yet 
to be determined. However previous studies on chimeric sheep, produced by the aggregation of 
blastomeres from normal and CLN6 affected embryos, indicated that the CLN6 disease may not be 
cell-autonomous and that corrected cells may release factors which promote the survival of diseased 
cells (Barry, 2011). This may well be the case in the one successfully treated CLN6 deficient sheep 
and merits exploration of CLN6 gene transfer in children. 
In fact, a Phase I/II CLN6 clinical trial (ClinicalTrials.gov identifier: NCT02725580) was just announced 
in April 2016. Interest in establishing a human trial was sparked after personal communication with 
the Gray Foundation detailing the ovine CLN6 results presented in Chapter 7. Subsequent 
unpublished safety and efficacy studies were performed by Dr. Brian Kaspar and colleagues at the 
Nationwide Children’s Hospital (Columbus, Ohio, U.S.A) on a murine form of CLN6. Gene transfer has 
since been attempted in 2 CLN6 patients with a further 4 to enrol, using a one-time intrathecal 
delivery by lumbar puncture with a self-complementary AAV9 vector (see Section 8.3.1) carrying the 
human CLN6 gene. Efficacy will be assessed by MRI, cognitive testing, electroencephalography, and 
ERG or optical coherence tomography (OCT).  
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8.2 Clinical translation  
The results presented in this thesis provide a strong rationale for the clinical translation of viral-
mediated gene transfer to human patients with both soluble and membrane-bound forms of NCL. On 
the whole, treatment of pre-symptomatic lambs prevented stereotypical NCL disease onset and 
progression. The literature suggests that corrective gene therapies for human neurodegenerative 
diseases may be restorative if intervention is delivered early in the disease process, otherwise 
therapeutic benefit is more likely to be achieved by simply halting further disease progression 
(Waddington et al., 2005). Sheep with well-characterised naturally occurring NCLs are ideal models in 
which to test if recombinant viral vectors can revert the pathological phenotype and established 
behavioural dysfunction in clinically symptomatic animals. Gene transfer to affected sheep at 
different ages will be useful for testing different temporal windows of therapeutic intervention for 
translation to humans and future studies will focus on this. Delivery prior to disease onset will always 
be an important objective but optimising the method of delivery and using gene transfer vectors that 
diffuse through the CNS most effectively will likely optimise efficacy.  
8.2.1 Timing of therapeutic intervention in the NCL sheep model 
In the absence of newborn genetic screening for all forms of NCL, the majority of human patients are 
diagnosed after the onset of symptoms. Early diagnosis occurs only when an older sibling has already 
presented with the disease. However there is no doubt that in progressive neurodegenerative 
disorders in children, like NCL, that better therapeutic advantage is afforded if treatment is 
administered early in the disease progression. For example, several NCL murine studies have shown 
that administration of gene therapy earlier in life is more advantageous than when administered to 
older animals (Griffey et al., 2006; Cabrera-Salazar et al., 2007; Sondhi et al., 2008). The rationale is 
that early administration gives both higher density and more widespread distribution of the gene 
therapy vector into the smaller, less mature neonatal brain and aims to prevent disease development 
rather than trying to reverse established disease (Waddington et al., 2004; Bostick et al., 2007; 
Sondhi et al., 2008). 
Early intervention likely underlies the success of the treated sheep in the current study. Pre-clinical 
gene therapy was administered to the sheep between 2 and 4 months of age. Examination of the 
ovine CLN5 and CLN6 neuropathological cascades indicated that these treatments were administered 
prior to the onset of neurodegeneration and brain atrophy (Chapter 4). For both ovine models, 
despite the presence of localised glial activation from birth, neonatal brains appear normal and grow 
within the normal weight range to 4 months of age. Although focal gliosis and slight compression of 
the upper laminae of the visual and parieto-occipital cortices is evident in this early pre-clinical stage 
(Figure 4.5, Figure 4.8 and Figure 4.11), the pathological effects are regionally limited and it is quite 
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probable any damage is reversible if the therapy is targeted and fast-acting (Chapter 6 and Chapter 
7). 
Between 4 and 6 months of age, both the CLN5 and CLN6 affected brains cease to grow and regional 
atrophy begins. Significant neuronal loss and reactive gliosis are evident in the visual and parieto-
occipital cortices in both models by 6 months. Using brain weight as a measure of atrophy, the CLN5 
and CLN6 affected brains weigh 89% and 78% of normal respectively (Table 8.1, Table 8.2). At this 
stage, CLN6 affected sheep are phenotypically indistinguishable from normal sheep however CLN5 
affected sheep exhibit mild ‘pre-clinical’ signs of NCL, which include a low head carriage and a 
propensity to stumble, baulk or crouch when travelling through gates or races. Although the 
neuropathology is more advanced than at 4 months of age, it is still restricted to localised cortical 
regions and there is evidence of a strong neurogenic ‘self-repair’ response in affected sheep (Figure 
4.14), which suggests the diseased brain at this stage is likely to be amenable to corrective gene 
therapy. 
The disparity between the normal and affected sheep brains becomes increasingly apparent with 
age, as neuroinflammation and cortical atrophy are more established. By nine months of age, both 
CLN5 and CLN6 affected brains weigh significantly less than normal brains (Table 4.2). Cortical 
thinning has spread to further regions, particularly the frontal cortex of the CLN5 affected sheep 
brain and the somatosensory cortex of the CLN6. The CLN6 affected sheep demonstrate a pre-clinical 
phenotype (described above for CLN5) from 7 months of age, whilst CLN5 sheep begin to lose vision 
at 10 - 11 months of age. The visual impairment seen in NCL affected sheep has both a central 
(cerebral) and a peripheral (retinal) component (Mayhew et al., 1985). The former is likely to be 
responsible for the early loss of vision, given the CLN5 and CLN6 affected visual cortices are reduced 
to 51% and 60% of normal thickness respectively by 9 months of age (Figure 4.3), whilst obvious 
differences were not detected in ERG recordings of diseased and normal sheep (unpublished PhD 
findings, Katharina Russell). 
Affected sheep at 6 – 10 months of age represent an early-symptomatic stage in NCL disease, 
correlating well with those children who receive an early NCL diagnosis on presentation of 
symptoms. As such, testing whether treatment to early-symptomatic sheep would be efficacious 
warrants further investigation. To this end, during the course of the present studies, six CLN5 
affected sheep received bilateral intracerebroventricular delivery of 3.5 x 1014 vg (total dose) of 
AAV9-CLN5 at 9 months of age. These sheep have been assessed by the author, using the same in 
vivo monitoring regime detailed in Chapters 6 and 7, through to euthanasia on trial completion 
at/before 19 months of age. Post mortem neuropathological analyses are underway but the results 
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of this trial are not included in this thesis. A second cohort of sheep was similarly injected with ICV 
AAV9-CLN5 at 7 months of age in May 2016. 
Unfortunately, an NCL diagnosis in children can often take some time after presentation of 
symptoms (Batten Disease Family Association, UK). Although clinically relevant, the impact of 
intervention on well-established mid-stage disease remains unclear. Injections into affected sheep 
from 12 months of age may be informative for this. By this age, neuronal loss is pronounced across 
the cortical mantle. Sheep have established disease signs, namely loss of vision and the onset of 
proprioceptive, motor and cognitive deficits, which are more pronounced in the CLN5 Borderdales 
(Figure 6.3). Neuroimaging reveals overt cortical atrophy, enlargement of the ventricles and 
intracranial ossification in both NCL sheep models. It is likely that the damage to the brain at this 
stage would be irreversible and the best therapeutic outcome of treatment at this stage may be a 
halt in disease progression. Although this is not a ‘cure’ per se, this would be a considerable advance 
on the currently inevitable decline to premature death. 
A paradigm that is possible but that has not yet been explored in ovine NCL is prenatal gene therapy. 
This method offers several potential advantages: a smaller brain size thus a beneficial vector-to-cell 
ration, transduction of stem and progenitor cells during a time when neurogenesis and gliogenesis is 
still occurring, immune tolerance to the vector and expressed protein, and intervention before 
irreversible damage is done. Prenatal gene transfer studies in rodents and rabbits have 
demonstrated the feasibility of in utero gene therapy (Baumgartner et al., 1999; Rahim et al., 2012; 
Roybal et al., 2012). However, the small size of these animal models and substantial differences in 
their embryonic development compared with humans limit their utility. Large animal models, such as 
sheep, represent a more accurate model of human embryonic development and pregnancy, as well 
as being a less costly alternative to primates (Themis et al., 1999; Tran et al., 2001; David et al., 2003; 
Pebbles et al., 2004; Porada et al., 2004). Certain fecund sheep breeds have multiple births 
(SanCristobal et al., 2001), thus providing siblings as uninjected experimental controls for such 
studies. Intraperitoneal injection of AAV vectors into early and late gestation foetal sheep is possible 
and results in systemic spread of the vector through the foetal tissues (David et al., 2011), which may 
prove advantageous in the treatment of LSDs. Whilst in utero gene therapy in humans remains 
controversial (Coutelle, 2008), for recessive diseases like the NCLs, pre-natal treatment could be 
possible currently in a minority of cases where a family history has been established or neonatally in 
the future as newborn screening programmes for all NCL genes become more widely available. 
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8.2.2 Optimising CNS gene delivery routes in sheep for human translation  
CNS-directed gene therapy has already entered clinical testing for several LSDs. Intraparenchymal (IP) 
delivery of AAV vectors have been used in patients affected by Canavan disease (Janson et al., 2002; 
Leone et al., 2012), late infantile NCL (CLN2) (Crystal et al., 2004; Worgall et al., 2008), 
metachromatic leukodystrophy (Zerah et al., 2015) and mucopolysaccharidoses type IIIA and B 
(Tardieu et al., 2014). However one of the greatest limitations of this approach is the restricted 
diffusion of the vector, limiting transgene expression to the vicinity of the injection site. It has been 
estimated that 50 to 350 injection tracts would be required for complete transduction of the entire 
human infant brain, with each injection risking oedema or infection (Ojala et al., 2015). Alternative 
routes of vector administration need to be explored.  
Intracerebroventricular administration of AAV encoding therapeutic transgenes has recently proven 
efficacious in correcting LSD (neuro)pathology in diverse animal models (this study; Rafi et al., 2012; 
Haurigot et al., 2013; Katz et al., 2015; Ribera et al., 2015). ICV delivery is less invasive than multiple 
intraparenchymal injections, it avoids systemic vector dissemination and has been shown to 
transduce ependymal cells and/or the choroid plexi, which serve as a ‘biological reservoirs’ for the 
continual secretion of recombinant protein into the CSF for distribution across the brain parenchyma 
(Passini et al., 2003; Liu et al., 2005a, 2005b; Yamazaki et al., 2014; Katz et al., 2015; Hironaka et al., 
2015). Additionally the ICV route is considered safe in humans, with ventricular access to the CSF 
through the lateral cerebral ventricles a routine diagnostic and therapeutic neurosurgical procedure 
in humans (Rosenbaum et al., 2014). Plans for clinical translation of this approach are underway 
(Biffi, 2015). Whilst bilateral ICV delivery has been employed in most studies, Katz et al (2015) 
demonstrated therapeutic benefit in a canine model of CLN2 NCL after a single unilateral injection of 
AAV2 expressing the canine TPP1 enzyme. ICV delivery is relatively simple to perform in sheep. 
Accessing only one ventricle would be less invasive and even faster and should be attempted.  
Intrathecal delivery, into the lumbar cistern or cisterna magna, also provides a simple alternative 
approach and has proven efficacious in other disease models, particularly those with motoneuron 
loss (Wang et al., 2014; Duque et al., 2015; Meyer et al., 2015). However limited distribution was 
seen in the porcine CNS after delivery via the lumbar intrathecal route (Federici et al., 2012) and no 
transduction was observed after intracisternal (IC) lentiviral-mediated delivery of GFP in sheep 
(linterman et al., 2011). The latter may be related to the vector dosage used (1 x 109 TU) and further 
investigation of these delivery routes with AAV vectors is warranted in sheep. Nevertheless, 
intracisternal injections are uncommon in the clinic due to the risks of complications derived from 
the proximity of the cisterna magna to vital cardiac, respiratory and vasomotor centres of the 
medulla, especially in children. Also, as vector spread after intrathecal delivery is reportedly limited 
to the caudal regions of the brain, it is rarely used in humans in preference to the ICV route (Wolf et 
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al., 2015). Interestingly though, this was the delivery route chosen for the recent Phase I/II CLN6 
clinical trial (NCT02725580). 
For NCLs with transmembrane protein deficiencies, convection enhanced delivery (CED) via multiple 
intraparenchymal microcatheters may have potential for treating the global brain pathology. This 
technique has been employed for delivery of drugs to the brain in animal models of Alzheimer and 
Parkinson’s disease (Barua et al., 2012, 2014, 2015). It uses a pressure gradient at the tip of the 
infusion catheter to induce convective flow of the vector through the interstital fluid spaces of the 
brain, which results in a greater spread than diffusion alone (Bankiewicz et al., 2000; Nguyen et al., 
2001). The technique has already been attempted in sheep for AAV-GFP based therapeutics (van der 
Bom et al., 2013a, 2013b) however no reports of expression, tropism or neuropathological outcomes 
have been published from these studies. CED of the reporter (green fluorescent protein; GFP) and 
therapeutic proteins will be assessed in sheep, in collaboration with colleagues from the University of 
Manchester, using the cranial navigation software Brainlab (Munich, Germany), in October 2016. It is 
hoped that this technique will prove beneficial for widespread gene delivery to the brain for those 
LSDs with defective transmembrane proteins, like the NCL protein CLN6 or heparan sulfate acetyl-
CoA: α-glucosaminide N-acetyltransferase (HGSNAT), the missing enzyme in mucopolysaccharidosis 
type III C under study by the Manchester group. 
8.2.3 Optimising gene expression in the sheep brain for human translation 
The current study is one of the first to perform a side-by-side comparison of AAV and lentiviral-
mediated gene transfer. AAV vectors are currently considered the best platform for CNS-directed 
gene therapy, because of their broad spread and viral tropism, and are in advanced clinical 
development and testing (Fu et al., 2011; Bartus et al., 2013; Rafii et al., 2014; Ribera et al., 2015; 
Walia et al., 2015). However lentiviral-mediated gene transfer in LSD brains has shown promising 
results in terms of transgene biodistribution, safety and therapeutic efficacy in small (Consiglio et al., 
2001; Di Domenico et al., 2009; Lattanzi et al., 2010, 2014) and large animal models (Kordower et al., 
2000; Jarraya et al., 2009). Moreover, the first clinical trial using a lentivirus to deliver dopaminergic 
genes in Parkinson’s patients showed safety and indications of efficacy in all treated patients (Palfi et 
al., 2014).  
Surprisingly clinical outcomes were similar in CLN5 affected sheep with both viral vector platforms 
that were tested here (Chapter 6). Late-onset loss of vision was the only clinical sign presented by 
treated sheep from both vector treatment groups, with earlier deficits seen in the lentiviral cohort 
than in the AAV cohort. Studies are underway to compare CLN5 transgene expression, vector tropism 
and neuropathological assessment of treatment-dependent modulation of lysosomal storage 
pathology, glial activation, and neuronal loss. In comparison, AAV9 proved to be more efficacious in 
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the treatment of ovine CLN6 disease than a lentiviral vector (Chapter 7). Whilst there was strong 
evidence for transduction of the ependyma lining the lateral cerebral ventricles in the lentiviral-
treated CLN6 sheep brains, this did not show sufficient therapeutic benefit to prevent disease onset 
and progression. Lentiviral vectors transduce both astrocytes and neurons in the normal and CLN6 
affected sheep brain (Linterman et al., 2011, Figure 7.9), whilst AAV9 has a predominant 
neurotropism (Figure 5.5). Similar findings have been published recently for the cynomolgus monkey 
brain, although lentivirus shows a greater tropism for astrocytes over neurons (An et al., 2016). The 
cellular tropism of the two vectors in the affected sheep brain may prove enlightening and suggest 
which vector is better suited for delivery to neurons. 
One of the limitations of using lentiviral vectors for ovine gene therapy studies in New Zealand 
relates to the genetically-modified status of the treated sheep. During the therapy trials described in 
Chapters 6 and 7, a successful application was made to the New Zealand Environmental Protection 
Agency to reclassify AAV-treated sheep as not ‘genetically modified’ under the Hazardous Substances 
and New Organisms (HSNO) Act (1996). This was made on the premise that the genome of the host 
(sheep) was not sufficiently altered or modified by treatment with an AAV vector to constitute a risk. 
AAVs lack integrative capacity, remaining episomal in the host cell nucleus in vivo (see Section 
1.6.3.2). Unfortunately a similar case could not be established for sheep treated with lentiviruses as 
these vectors do integrate into the host genome (see Section 1.6.3.1). The outcome of this 
reclassification was that AAV-treated sheep were released from the indoor Physical Containment 2 
sheep facility and could be maintained under normal pastoral conditions at Lincoln University. Hence, 
due to their greater efficacy, and the problems associated with long-term indoor housing of sheep 
(see Section 8.2.4), AAV vectors are the preferred vector platform for future sheep studies. They are 
also the vectors of choice for human NCL gene therapy studies (Crystal et al., 2004; Worgall et al., 
2008; Crystal, 2014), thus making translation of this work to human medicine more straightforward. 
The current study used traditional single stranded (ss) AAV vectors. A rate-limiting step which can 
affect the efficiency of single stranded vectors is the speed and ability with which infected cells 
perform viral genome second strand synthesis before initiation of transgene expression. Faster gene 
expression can be achieved with self-complementary (sc) AAV vectors and a 10- to 100-fold increase 
in transduction efficiency has been reported compared with ssAAVs (McCarty et al., 2001, 2003; Yang 
et al., 2002; Gray et al., 2011). Upon infection, an scAAV vector is not reliant on cell mediated second 
strand synthesis but rather folds back on itself through intramolecular base pairing to create a 
duplex, which is immediately ready for transcription (McCarty et al., 2001, 2003). Caveats associated 
with scAAV constructs are their reduced packaging capacity of ~2.3 kB, compared with ~4.5 kB for 
ssAAV (Wu et al., 2007), and reports that scAAV elicit a more potent transgene-specific immune 
response than ssAAV (Wu et al., 2012). The former is not an issue for the CLN5 and CLN6 cDNAs 
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(1086 and 933 bp respectively). The robust gene expression of scAAV warranted their inclusion in 
ovine NCL gene therapy trials in an attempt to improve expression and efficacy. Codon-optimised 
scAAV9-CLN6 vector was sourced from the University of North Carolina Vector Core in collaboration 
with Dr. Steven Gray (Chapel Hill, North Carolina, U.S.A.) and injected into pre-clinical CLN6 South 
Hampshire sheep in December 2015. Therapeutic efficacy is being assessed using the in vivo 
parameters described in this thesis. Additionally the codon-optimisation will allow post mortem 
quantitative measures of transgene-specific expression.  
8.2.4 Detrimental effects of long-term indoor confinement of sheep 
An external factor which negatively impacted on this study was the long-term indoor confinement of 
the treated sheep. During the trial, two lentiviral-treated animals were euthanised due to acute 
haemolysis caused by chronic copper poisoning. Of the ruminants, sheep are particularly susceptible 
to this, and it is exacerbated in animals housed indoors on pelleted feeds (Hogan et al., 1968; Lewis 
et al., 1997), because of their reduced copper requirement (Bostwick, 1982). Generally, sheep 
require about 5 ppm of copper in their total diet however acute toxicity can occur at levels above 25 
ppm (Kahn & Line, 2014). Excess copper is stored in the lysosomes within hepatocytes (Kumaratilake 
& Howell, 1987) and when retained there it does not cause any tissue damage. However it can be 
released spontaneously or at times of stress (e.g. shearing, extreme weather, transportation, 
exertion) (Bostwick, 1982). Once released into the circulation, copper causes acute oxidative injury to 
haemoglobin, preventing the binding of oxygen and carbon dioxide. The red blood cell membrane is 
concomitantly disturbed, resulting in haemolysis (a haemolytic crisis) and anaemia. Hepatic necrosis 
and renal failure result from the massive release of haemoglobin and death usually occurs within 
four days (Bostwick, 1982). 
The onset of symptoms in both treated sheep in this trial correlated with or occurred in the days 
shortly after completion of their maze testing. The general literature suggests that sheep breeds of 
British origin are particularly stress-prone (e.g. Suffolk, Texel and the crossbred South Hampshires) 
and thus are especially vulnerable to copper poisoning. This may explain why the toxicity remained 
sub-clinical in the more docile Borderdale sheep that were similarly housed (Chapter 6). Although the 
concentrate feed was relatively low in copper content, excessive levels in the sheep tissues at post 
mortem suggested a cumulative effect of low level copper ingestion over the year. Serum 
concentrations of the enzymes aspartate transaminase (AST) and gamma glutamyl transpeptidase 
(gGT) have been reported as predictive indicators of hepatic copper accumulation (Lewis et al., 
1997). Routine haematological screening for these enzymes in the current study was insufficient to 
detect elevated levels prior to the haemolytic crisis and subsequent euthanasia of the two treated 
sheep. 
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Long-term indoor confinement of sheep can also be extremely detrimental to their wellbeing 
(Reinhardt & Reinhardt, 2002). Combined with a reduced feeding time per day and the inability to 
exercise or perform simple natural behaviours (e.g. graze on grass), classic stereotypical behaviours 
can manifest. These include repetitive actions or body movements, such as head butting or nosing, 
aggression, increased vocalisation, pacing, pawing, or oral stereotypies (e.g. wool pulling, teeth 
grinding or chewing bar fixtures) (Sambraus, 1985; Hinch & Lynch, 1997; Vasseur et al., 2006). Given 
their similarity to the clinical signs of NCL, it was necessary to eliminate/minimise any chance of 
stereotypy in this trial to assess neurological efficacy accurately. The experimental design included 
environmental enrichment - sensory (playing music), social interaction, exercise and new objects/ 
toys to explore - to counter boredom and stereotypy. The provision of a rich and stimulating 
environment has previously been shown to induce neuronal changes that have a protective role, 
ameliorating functional deficits associated with various degenerative disorders and brain trauma 
(Horner & Gage, 2000; van Dellen et al., 2000; Johnson et al., 2013). During the current study, the 
enrichment appeared to be successful with the only behavioural pathology exhibited being wool-
biting for a short period of time (~1 month). The provision of fibre, in the form of chaffed hay, 
redirected this oral stereotypy whilst also increasing the bulkiness of the feed, time spent feeding 
and rumination. 
8.3 Future directions 
8.3.1 In vivo monitoring of disease progression and therapeutic efficacy 
The current study demonstrated the value of sheep as an alternative neurotherapeutic translational 
model to non-human primates and other domestic animals, and the utility of longitudinal in vivo 
behavioural and neurological function testing and neuroimaging techniques in the assessment of 
efficacy. It is particularly encouraging to see that similar efficacy parameters currently used or 
planned in sheep (Chapters 6 and 7; Sections 8.3.1and 8.3.3; Katharina Russell (unpublished PhD 
findings, Lincoln University); Perentos et al., 2015) are also applicable in human clinical trials. 
However there is potential to improve many of the in vivo parameters used to assess therapeutic 
efficacy in ovine NCL. Firstly, the slow and insidious onset of clinical signs in ovine NCL under field 
conditions make clinical staging of disease progression, especially in the early disease stages, difficult. 
Neurological dysfunction was assessed subjectively in the current study by a sheep-specific clinical 
neurologic examination (Passler et al., 2012); components of which included open- and closed-field 
behavioural observation (mentation, gait, head carriage and postural traits, as well as manifest 
tremor or seizure onset) and cranial nerve (optic II, oculomotor III, trigeminal V and facial VII) 
evaluation. Sheep were subjectively assessed by two independent investigators on a basic clinical 
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rating scale in the current study however this scale could be honed for better assessment of 
therapeutic efficacy in future trials. 
The unified Batten disease rating scale (UBDRS) is used to measure physical impairment and severity 
of disease-associated symptoms in human NCL (Marshall et al., 2005). Patients are scored from 0 to 4 
(normal to abnormal) for each of 27 items, which include vision, speech, tone, bulbar and motor 
function and the presence of abnormal movements. Higher scores reflect greater dysfunction. Based 
on the current study, specific components could be singled out for categorical grading in a similar 
method to the UBDRS, permitting a more in-depth rating scale for future sheep therapy trials. 
Although the maze used to assess therapeutic efficacy in the current study was relatively basic, it was 
sensitive enough to detect neurologic impairment. Sheep perform well in maze tests (Peirce et al., 
2001; Lee et al., 2006; Shamir et al., 2010; Banin et al., 2015; Hunter et al., 2015; McBride et al., 
2015), which indicates that they have good cognition and spatial memory – traits that allow them to 
graze with optimum efficiency (Bailey et al., 1996; Howery et al., 1999). To improve the quality of the 
data collected from maze testing, a computerised global positioning system (GPS) tracking set-up 
could be developed in conjunction with computational methods to codify spatio-temporal data. 
Similar methodology has been used to measure the flocking behaviour of CLN5 Borderdale sheep in 
naturalistic settings (Furmston et al., 2015). 
In vivo neuroimaging procedures used to assess efficacy in ovine gene transfer trials are also 
continually improving. Due to the increasing popularity of ovine models in translational 
neuroscience, many reports detailing MR imaging of the sheep brain have been published recently 
(Amorim et al., 2015; Ella & Keller, 2015; Lee et al., 2015; Nitzsche et al., 2015; Sawiak et al., 2015) . 
Longitudinal MRI studies of treated sheep should be possible. To complement this, quantitative 
measures and three-dimensional modelling of intracranial and ventricular volumetric changes in the 
neurodegenerating sheep brain have been developed from CT images (unpublished PhD data, 
Katharina Russell, Lincoln University) and MRI studies have begun with Dr. Tracy Melzer at the New 
Zealand Brain Research Institute (Christchurch, New Zealand). 
8.3.2 Other considerations for human translation 
Neuropathological studies will provide an important efficacy endpoint for the pre-clinical CLN5 trial 
(Chapter 6). These are underway in collaboration with BARN colleagues at Kings College London 
(United Kingdom). If amelioration of NCL disease hallmarks is noted then dose reduction studies 
could be easily conducted in sheep. A major obstacle in translating therapies from pre-clinical animal 
trials to a human clinical application is the need to produce large titres of highly concentrated viral 
vectors (Clement et al., 2009). Determining the lowest dose in sheep that provides full therapeutic 
benefit would be important for clinical translation and would minimise the risk of immunotoxicity. 
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One of the greatest limitations to successful viral-mediated gene therapy relates to immunotoxicity. 
Despite the removal of the replicative and pathogenic ability of viral vectors, administration can lead 
to a harmful innate or adaptive host immune response to either the vector or the transgene product, 
resulting in decreased efficiency of gene transfer or elimination of the transduced cells over time. 
Lentiviruses possess an intrinsic low immunogenicity and a mild proinflammatory profile, being well 
tolerated by the host immune system (Abordo-Adesida et al., 2005; Annoni et al., 2007). Whilst the 
immunogenicity of AAV is also low, a high prevalence of neutralising antibodies (NAbs) against 
various AAV serotypes has been detected in human (Calcedo et al., 2009; Boutin et al., 2010) and 
sheep (Rapti et al., 2012; Tellez et al., 2013) populations. There was no clinical evidence of an 
immune response in any of the treated sheep through the current study. CSF and serum were 
routinely collected from the treated sheep through the therapeutic trials and can be used in 
neutralising titre studies to detect potential sub-clinical immune responses to the viral capsid and/or 
transgene product if these data are required. 
8.3.3 Intraocular gene therapy 
Despite its peripheral location, the retina is actually part of the CNS. However brain-directed CLN5 
and CLN6 delivery delayed, but did not prevent, the natural retinal dysfunction seen in ovine NCL 
(see Sections 6.3.3.2 and 7.3.3.2). Other retinal degenerative disorders, such as Leber’s congenital 
amaurosis type 2, have been successfully treated in intraocular gene therapy clinical trials 
(Bainbridge et al., 2008; Cideciyan et al., 2009). This approach may hold promise as an adjunct 
therapy to preserve vision in treated sheep and NCL patients. 
Retinopathy in NCL results from the degeneration of rod and cone photoreceptor cells (Figure 8.1B) 
(Goebel et al., 1977; Goebel 1992). These lie several hundred microns deep within the human (and 
sheep) retina and thus represent a challenging target cell type. Intravitreal injection offers a 
relatively non-invasive readily accessible delivery route to the eye (Figure 8.1A). However, when 
administered intravitreally, most viral vectors do not transduce the retina. Transduction by those 
that do, such as AAV2, is mainly restricted to retinal ganglion and Müller cells of the middle retina 
(Stieger et al., 2011; Trapani et al. 2015). This is unlikely to be sufficient to protect against 
degeneration in NCL. For example, intravitreal AAV2-mediated delivery of palmitoyl protein 
thioesterase (PPT1/CLN1) to a murine model of infantile NCL specifically transduced ganglion cells 
(Griffey et al., 2005). Enzyme levels in the eye were elevated to above normal but only a partial 
improvement in retinal architecture and function was reported. Also, despite evidence of inner 
retinal transduction after intravitreal AAV2 delivery to the macaque in one study (Yin et al., 2011), 
similar success was not achieved in rodents with AAV serotypes 2, 7, 8 or 9 (Dalkara et al., 2009; Pang 
et al., 2008).  
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Figure 8.1    Schematic representation of intraocular injection routes (A) and some retinal layers 
(B). Amended from Trapani et al., 2015 
 
By comparison, subretinal injection of various viral vectors (Figure 8.1A) has been shown to 
transduce both photoreceptors and retinal pigment epithelium of mice effectively (Pang et al., 2008; 
Puppo et al., 2014). AAV5 restored vision in canine and ovine models of congenital achromatopsia 
(Komáromy et al., 2010; Banin et al., 2015). Phenotypic rescue has also been achieved by subretinal 
AAV gene transfer in several lysosomal storage diseases, including a feline model of 
mucopolysaccharidosis (MPS) V (Ho et al., 2002) and MPS VII mice (Hennig et al., 2004). However 
delivery by this route can be technically challenging. Injection into the subretinal space results in a 
transient retinal detachment which can be detrimental to retinas already undergoing degeneration, 
therefore early intervention is likely to be important.  
Ethical approval has been granted to perform ocular gene therapy in NCL sheep, using a subretinal 
strategy already tested in sheep (Banin et al., 2015). A veterinary ophthalmologist will inject one eye 
with an AAV9 vector encoding the corrective CLN gene, with the other eye being an internal control. 
Therapeutic efficacy will be objectively examined over time using established techniques including 
ophthalmic observations, fundus photography and electroretinography (Katharina Russell, PhD 
student, Lincoln University). The sheep eye is an excellent ophthalmic candidate for human studies, 
sharing a similar axial length, and equatorial and vitreous cavity diameter to humans (Mohammadi et 
al., 2011). A novel technique, optical coherence tomography, which has proven successful in efficacy 
studies in human NCL (Angela Schulz, personal communication) will be trialled in sheep and 
histopathology will follow at post mortem.  
8.3.4 Combination therapy 
Despite a strong record of success, limitations still exist with gene therapies. These include gene 
silencing or phenotoxicity, immunotoxicity, insertional mutagenesis and commercial viability 
Subretinal 
Intravitreal 
Retinal pigment epithelium 
Photoreceptor cells 
Retinal ganglion cells 
Vitreous 
Inner nuclear layer 
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(Mingozzi & High, 2011), and it is likely that no single treatment for the NCLs will suffice in many 
cases but rather a combination of therapies will be required. Many clinical gene therapy protocols 
currently employ transient immunosuppressant drugs (Sack & Herzog, 2009) however there is no 
mention of these in the Phase I/II CLN2 or CLN6 clinical trials underway. The evidence presented in 
the current study and by others (Oswald et al., 2005; Pontikis et al., 2005; Kay et al., 2006; Kielar et 
al., 2007) of precocial activation of non-neuronal cells highlights the important mediatory role of glial 
cells in early-stage NCL pathogenesis. As a chronic inflammatory response can be detrimental to both 
neuronal survival and neurogenesis (Raivich et al., 1999; Stoll & Jander, 1999; Streit et al., 2004; 
Whitney et al., 2009; Lyman et al., 2014; Lee & MacLean, 2015), early suppression of inflammation 
may be a valuable adjunctive treatment to gene therapy. Macauley et al. (2014) investigated the 
therapeutic value of a small molecule anti-neuroinflammatory drug as co-therapy to CNS-directed, 
AAV5-mediated gene therapy in a CLN1/PPT1 mouse model. Whilst the drug (MW151) alone 
decreased seizure susceptibility, the combination therapy did not significantly improve therapeutic 
efficacy over AAV-mediated PPT1 gene transfer alone. However like the PPT-/- mice, the human 
CLN1 disease typically has a rapid clinical course, affecting the brain in its entirety (Haltia 2003). 
Clinical improvement with gene therapies, which target the primary genetic defect, complemented 
with pharmocological neuro-inflammatory agents, that target dysregulated glia, may be 
synergistically greater in NCL subtypes that have a more protracted disease course.  
8.4 Conclusion 
Together the neuronal ceroid lipofuscinoses (Batten disease) are the most common degenerative 
brain diseases in childhood (Schulz et al., 2013). On average, four New Zealand families receive an 
NCL diagnosis each year imposing a huge burden on family life and relationships at an estimated cost 
of $60,000-$100,000 per annum per patient (Lysosomal Diseases New Zealand). Presently there are 
no effective treatment options for any forms of NCL, other than palliative care.  
The results presented in this thesis provide a strong rationale for the clinical translation of viral-
mediated gene transfer to human patients with CLN5 and CLN6 disease. Delivery of viral vectors 
encoding therapeutic NCL genes to pre-symptomatic lambs protected against stereotypical disease 
onset and progression. Treated CLN5 deficient sheep retained cognitive function and a normal brain 
structure and intracranial volume, and demonstrated an extended lifespan. The only clinical sign of 
NCL was a delayed-onset loss of vision. Neuropathological analyses of efficacy are pending. One 
AAV9-treated CLN6 deficient sheep demonstrated sustained functional efficacy and vision, and the 
treatment reversed the established neuropathology. 
This study poses a number of questions. How efficacious will gene therapy be when administered 
later in the disease course?  At what stage is the neuropathology too advanced to reduce any 
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likelihood of therapeutic outcome? Whilst the successful gene transfer in CLN5 deficient sheep likely 
benefits from ‘cross-correction’, accounting for the amelioration of disease phenotype in one AAV9-
treated CLN6 deficient sheep is harder to explain. Is the CLN6 protein involved in the processing of 
some soluble factor, which itself is secreted and endocytosed to correct functionality of neighbouring 
cells? What can be done to increase the efficacy of CLN6 gene transfer to ensure therapeutic benefit 
for all treated animals? These questions warrant further investigation, but do not detract from the 
value of  studies presented in this thesis which demonstrate that viral-mediated gene therapy of the 
CLN5 and CLN6 forms of NCL is possible and that NCL sheep provide excellent large animal 
neurotherapeutic models to expedite the translation of these findings to the clinic. 
 
‘sometimes the best answer a scientist could want is more questions’ 
Richard Panek, 2000 
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Appendix A 
Sheep Neurological Test  
NEUROLOGICAL EXAMINATION OF SHEEP    
DATE:     ANIMAL NO:                       
AGE:     BREED:   
SEX:              RECORDED BY:    
-------------------------------------------------------------------------------------------------------------------------------------- 
GENERAL EXAMINATION: 
1. Body Weight                       kg 
2. Body Condition Score   1                  2    3   4   5 
3. Blood Sample taken:   Y / N 
 
4. Rectal temperature:   ° C    Normal range 38.3–39.9° C 
5. Heart rate:    beats/minute  Normal range 60-90 beats/minute 
6. Respiration rate:   breaths/minute  Normal range 12-20 breaths/minute 
7. Hydration level:        Normal to Dehydrated 
8. Ruminal contractions: Normal / Decreased / Absent 
9. Mucous membranes: Normal (pink/red) / Abnormal (white) 
 
GENERALISED BEHAVIOUR AND MOVEMENT: 
Describe in detail if abnormal 
10. Posture when approached Standing Sitting sternal Other 
 
11. Behaviour/mentation Resting: 
 
Approached: Handled: 
 
 
 
BEHAVIOUR / MOVEMENT Normal Abnormal Exaggerated 
12. Posture/ Head Carriage 
 
Head high Head low  
13. Gait 
 
 Ataxia  
14. Walking upstairs/ flat 
surface 
 Difficulty on stairs  
15. Abnormal behaviour 
 
Absent Circling  
16. Abnormal movements/  
tremors/ tics/ seizures 
Absent   
 
CRANIAL NERVE FUNCTION AND REFLEXES: 
1. FACE / NECK Normal Decreased Absent 
17. Menace response (medial) 
(Optic nerve) 
Eyelid blink/ 
head aversion 
 No response 
18. Menace response (lateral) 
(Optic nerve) 
Eyelid blink/ 
head aversion 
Absent (unilateral) Absent (bilateral) 
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CRANIAL NERVE FUNCTION AND REFLEXES: 
2. FACE / NECK Normal Decreased Absent 
19. Pupillary light reflex (direct) 
(Oculomotor nerve) 
Direct pupil 
constriction 
Absent (unilateral) Absent (bilateral) 
20. Pupillary light reflex 
(consensual) (Oculomotor nerve) 
Consensual pupil 
constriction 
Absent (unilateral) Absent (bilateral) 
21. Dazzle reflex (Oculomotor, 
optic, facial nerves) 
Blink/head aversion 
on bright light 
 No response 
22. Corneal reflex (Trigeminal, 
facial nerves) 
Blink on touching 
cornea 
Absent (unilateral) Absent (bilateral) 
23. Palpebral reflex (Trigeminal, 
facial nerves) 
Blink on touching 
canthi 
Absent (unilateral) Absent (bilateral) 
23. Visual tracking (Optic nerve) 
 
Follow visual 
stimulus 
 Not follow visual 
stimulus 
23. Startle response (Facial 
nerve, hearing) 
Startle on loud 
noise 
 No response to loud 
noise 
 
3. OTHER HEAD ABNORMALITIES Normal Abnormal Exaggerated 
24. Ears (position/touch)  Droop  
25. Lips (symmetry/touch)  Droop  
26. Nose (movement/touch)    
27. Mouth/jaw (salivation/tone)  Dribbling  
28. Eating/drinking  Sham  
 
29. Skin lesions:    Y / N   List areas and types/ draw below 
 
30. Any other abnormalities:  Y / N   List areas and types/ draw below 
 
                                      
 
Recording: 
Still photo taken: 
 
Y  
Describe 
N 
Video taken:   
 
Y  
Describe 
N 
 
 
 
  
L L  R 
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